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Abstract 
 
Discovering new approaches to replace lost neurons following brain damage, as for traumatic 
injury, is one of the major goals in the field of regenerative medicine. Direct neuronal 
conversion of glial cells into neurons is emerging as a powerful strategy to achieve neuronal 
replacement. Despite large progress in the field, major limitations still exist before bringing 
this approach toward clinical translation. Major hurdles encompass epigenetic, metabolic and 
environmental barriers, which impede the newly generated neurons to properly integrate into 
the injured brain parenchyma, to substitute the lost neuronal networks and to fully replace the 
endogenous neuronal counterpart. 
The pathological process includes a cascade of fast-occurring events, such as metabolic 
impairment, reactive oxygen species and inflammatory molecules production, cell death, 
reactive gliosis and recruitment of inflammatory cells, which can have devastating 
consequences for the survival of the endogenous and reprogrammed neurons. Thus, a deeper 
understanding of the interplay between these mechanisms and how key players in the injury 
environment regulate processes of cell fate decision is needed. 
An important aspect fundamental to functional glia-to-neuron conversion in the injured brain 
is the viral vector used, especially in regard to the inflammatory reaction elicited in the tissue. 
Indeed we could observe that different viral vectors, routinely used in neuronal 
reprogramming studies, could induce diverse responses in the environment, independently 
from the transgene expressed. In particular, we noticed that retrovirus and lentivirus-mediated 
reprogramming elicited a strong inflammatory reaction, characterized by microglia and 
astrocyte reactivity, and massive immune cells infiltration, still persisting at the time when 
neurons start appearing. Conversely, adeno-associated virus (AAV)-mediated neuronal 
conversion had much a milder impact on the activation of the glial cells, with minimal 
immune cells recruitment. As using AAV greatly improved the rate of neuronal conversion, 
specification, integration and survival, compared to retroviral approaches, the environment 
plays a critical role in this successful reprogramming. 
A secondary mechanism also associated with inflammation is reactive oxygen species (ROS) 
production. Indeed, astrocytes transitioning into neurons face a burst of ROS, which lead to 
drastic cell death by ferroptosis if not properly counteracted. Consequently, buffering ROS 
with scavengers and pro-survival genes could greatly ameliorate the conversion efficiency in 
vitro as well as in vivo. As ROS production is mostly related to functional metabolic changes, 
we investigated this so far neglected aspect of direct neuronal reprogramming. 
I first demonstrated that a metabolic switch from glycolysis to oxidative phosphorylation is an 
essential requirement for a successful conversion to occur, as inhibiting the function of the 
electron transport chain did not improve the process despite the decrease in ROS, but actually 
entirely blocked the conversion of glia into neurons.  
As we were further interested in understanding the roles played by the metabolism in the 
reprogramming paradigm, we decided to characterize the mitochondria proteome of astrocytes 
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and neurons, to identify differences in the mito-proteome between these cell types. We 
identified proteins enriched to each cell type, highlighting metabolic pathways relevant for 
their specific physiological functions. Interestingly, some of the specific mitochondrial 
proteins analyzed were correctly up-regulated or down-regulated during the transition from 
astrocytes to neurons, but at a relatively late stage in the reprogramming process. This finding 
further confirmed that a remodeling in mitochondrial proteins, and consequently metabolic 
pathways, occurs during the reprogramming process, even if partial and temporally delayed 
compared to the burst of ROS which converting neurons face. Early dCas9-mediated 
overexpression of anti-oxidant proteins in converting astrocytes, specific to the neuronal 
mitochondria proteome, could greatly improve the speed and efficiency of astrocyte-to-
neuron conversion.  
Thus, understanding how to properly modify converting glial cells into neurons, not only 
from an epigenetic, genetic and morphological point of view, is necessary. In fact evaluating 
the impact on direct neuronal reprogramming of extrinsic factors, such as viral vectors and the 
environmental inflammatory reaction, as well as intrinsic constraints, such as mitochondria 
remodeling, ROS production and metabolic switch, could greatly improve the quality of 
reprogrammed neurons.  
The aim of my thesis is thus to unravel mechanisms involving inflammation, mitochondria 
and metabolic remodeling, which could increase our understanding of the glia-to-neuron 
conversion process, overall improving direct neuronal reprogramming. 
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Introduction !
The Central Nervous System (CNS) is probably the most complex and delicate organ of our 
body, yet the least understood. How trillions of cells intricately connect to each other, creating 
neuronal networks which shape our identity, is definitely a miracle of evolution and has been 
a long topic of debate amongst scientists and philosophers for centuries. Nevertheless, the 
advances in technology allowed us in the last decades to unravel many unknown functions of 
the brain and of the cells that constitute it, in physiological as well as in pathological 
conditions. In particular, understanding the interplay between fundamental components of the 
brain, namely neurons and glial cells, and how they react in pathological environment, 
interacting with local and invading inflammatory cells, is essential to treat neurodegenerative 
conditions affecting more than 50 million people worldwide, with huge health costs for 
society (Chen et al., 2016; Winblad et al., 2016).  
As later discussed in detail, following an acute pathological insult an impairment in supply of 
oxygen and metabolic substrates leads to energy failure and cell death. The most sensitive 
cells are neurons, mostly due to their high energy demand usually met by ATP generated 
through oxidative phosphorylation (oxphos) (Harris et al., 2012). Glial cells, such as 
astrocytes and mature oligodendrocytes, further support neuronal metabolic needs, beyond 
performing a plethora of other functions in the CNS (Magistretti and Allaman, 2015; Saab et 
al., 2013). In this early phase of damage inflammatory signals, such as cytokines, chemokines 
and reactive oxygen species, spread, leading to recruitment of immune cells and proliferation 
of local cells (i.e. astrocytes, oligodendrocytes precursor cells (OPCs) and microglia). These 
activated cells in mammals form a glial scar that, despite debated function, limits the 
spreading of damage signals and contributes to clean up the cellular debris. The final phase of 
the process is mainly focused on tissue remodeling for functional restoration, encompassing 
blood-brain barrier (BBB) repair, scar reorganization and alternative neuronal connections 
rewiring and reinforcement (Burda and Sofroniew, 2014). Unfortunately, spontaneous 
restoration of lost neuronal functions has still very limited success, leading the patient to face 
severe disabilities or death (Grade and Götz, 2017). 
The biggest barrier in the field of treating diseases related to damage of the CNS is indeed the 
very limited capacity of the brain for self-repair, as neurons and consequently functional 
circuits are irreversibly lost once an injury has occurred. A revolution in the field was the 
discovery of ongoing neurogenesis in the brain (for historical review see Gage, 2002), leading 
to great hopes to replace endogenous lost neurons. Despite that, the expectations have been 
disappointed, as endogenous neurogenesis is restricted to few neurogenic niches (Grade and 
Götz, 2017), leading to very small degrees of self-repair. 
Another turn in the promises for neuronal replacement was the discovery that adult somatic 
cells can be forced to change fate through selective overexpression of master developmental-
derived transcription factors (TFs) (for historical review see Xu et al., 2015), which lead to 
the discovery that adult somatic fate can be turned back to pluripotent state (Takahashi and 
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Yamanaka, 2006), opening the field of induced pluripotent stem cells (see review Avior et al., 
2016; Shi et al., 2017).  
Even prior to this breakthrough discovery, several somatic cell types have been 
reprogrammed into neurons, starting from glial cells (Heins et al., 2002) and extending to 
cells derived from different germinal layers, leading to the field of direct neuronal 
reprogramming (see review Amamoto and Arlotta, 2014; Heinrich et al., 2015). Especially in 
the last decade, enormous advances in technology and in the molecular understanding of the 
reprogramming process have drastically improved the generation of neurons (Grath and Dai, 
2019; Masserdotti et al., 2016).  
Despite the progress, the generation of specific neuronal subtypes that properly integrate, 
survive long-term and restore lost neuronal function in a pathological environment has still to 
overcome many hurdles. Indeed, gaps in understanding molecular, epigenetic and metabolic 
constraints to the process of direct neuronal reprogramming are the biggest challenges for its 
translation into clinical application (Gascón et al., 2017). As the role of the metabolism and 
inflammation in direct neuronal reprogramming has been barely investigated, a deeper 
understanding of the molecular and cellular interplay of these key factors with the converting 
neurons is fundamental.  
With this aim, I will first discuss in details the delicate metabolic interplay between astrocytes 
and neurons in the brain, highlighting their response in physiological and pathological 
conditions. I will introduce the inflammatory response consequent to brain injury and how it 
can influence the metabolism of neuronal and glial cells. I will then move to the available 
strategies to induce neuronal replacement and repair. I will finish by evidencing the current 
state of the art of direct neuronal reprogramming, as a promising strategy for brain repair. I 
will at the end discuss the hurdles that direct neuronal reprogramming needs to overcome to 
improve the process, focusing on the metabolic, mitochondria and inflammatory interplay. 
Metabolism in the CNS: astrocyte and neuron interplay 
Despite representing only 2% of the total body mass, the brain is responsible for the 
consumption of 20% of the oxygen (O2) and 25% of the glucose daily absorbed in the human 
body (Bélanger et al., 2011). Glucose is indeed the main energy substrate for most of the 
cells, and in particular for the brain, which requires higher amounts to sustain the intense 
electrical activity. The metabolism of glucose within the brain comprises sophisticated and 
not yet fully understood reactions and interchanges amongst glial cells and neurons. 
Glucose is generally distributed throughout the body via blood vessels. Within the CNS, the 
expression of specific glucose transporters (GLUTs) on endothelial cells, glial cells and 
neurons allows its distribution (Benarroch, 2014). Glucose is mostly first processed within 
astrocytes and its intermediates are then distributed to other glial cells and neurons. 
Astrocytes, accounting for about 20-40% of the total glial cells in the mammalian brain 
(Liddelow and Barres, 2017; Verkhratsky and Nedergaard, 2018), perform a plethora of 
functions, encompassing regulation of ion and neurotransmitter concentrations in the 
extrasynaptic space, setting brain blood flow rate, orchestrating synaptic pruning, contributing 
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to neuronal information processing, mediating phagocytic and inflammatory functions 
(Poskanzer and Molofsky, 2018; Sofroniew and Vinters, 2010). Most importantly, astrocytes 
are key player in regulating brain energy supply and storage. Indeed these cells metabolize 
glucose mainly through glycolysis and alternatively store it in the form of glycogen. Storing 
glycogen is a unique feature for astrocytes within the brain, which is released in condition of 
brain energy shortage, like upon intense neuronal activation and neurotransmitters induction 
(Magistretti and Allaman, 2015). 
The preferred pathways for glucose utilization are glycolysis and subsequently oxidative 
phosphorylation. Glycolysis is the sequence of reactions catalyzed by 10 enzymes converting 
glucose in pyruvate, generating adenosine triphosphate (ATP) and important cofactors, as 
nicotinamide adenine dinucleotide reduced (NADH), flavin adenine dinucleotide reduced 
(FADH2), coenzyme A (CoA). Importantly, glycolysis also provides precursors for chemical 
constituents of amino acids, nucleotides and lipid synthesis. It is thus the preferred pathway 
for proliferating cells, with high requirements for metabolic intermediates to support 
biosynthesis (Lunt and Vander Heiden, 2011), and for glial cells, which require high lipid 
content (Montani and Suter, 2018). Glycolysis produces two molecules of pyruvate, which 
can take different metabolic routes depending on oxygen availability and cellular metabolic 
context.  
When oxygen is available, pyruvate is converted to acetyl-coenzyme A (acetyl-coA) by 
pyruvate dehydrogenase complex, which then can enter mitochondria to feed the tricarboxylic 
(TCA) cycle, also known as Kreb´s cycle or citric acid cycle. TCA cycle is fundamental for 
most of the anabolic and catabolic reactions within the cells, as central hub to produce many 
molecular intermediates, such as amino-acid and lipids (Akram, 2014). TCA cycle produces 
also highly energetic cofactors, as NADH and FADH2, to feed the oxidative phosphorylation. 
Oxphos encompasses a series of enzymatic reactions that take place within mitochondria, 
requiring O2 and high energetic releasing cofactors, as NADH and FADH2. These cofactors 
carry electrons to allow transfer redox reactions to occur and are produced from glycolysis, 
citric acid cycle and β-oxidation of fatty acid. The electrons deriving from these molecules are 
passed through a set of complex enzymes, present along the inner mitochondria membrane 
(IMM), forming the electron transport chain (ETC) (Wilson, 2017). 
Five different complexes, constituted of 90 nuclear- and mitochondrial-encoded proteins, are 
responsible for coupling cofactor-derived electrons to ion transfer of protons (H+) across the 
IMM (Letts and Sazanov, 2017). This creates an electrochemical proton gradient that drives 
the synthesis of ATP and water (H2O) in the final ETC complex, ATP synthase, subsequently 
released in the mitochondrial matrix and exported to the cytoplasm. The process of aerobic 
respiration burns O2 molecules, creating a proton gradient across the mitochondrial 
membrane, but also produces reactive oxygen species as a byproduct (Nath and Villadsen, 
2015). The fundamental role of ROS in astrocytes or neurons is discussed later. 
Importantly, ATP production from glucose catabolism is more efficient in oxphos than in 
glycolysis, as the net yield from each pathway is 30-36 versus 2 ATP molecules (Berg et al., 
2002). Despite that, the preferred pathway within a cell is not necessarily the most energy 
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producing one, as this comes with the cost of higher ROS production and faster metabolism. 
Each cell type specifically regulates the preferential pathway for energy derivation according 
to specific function and cellular stage (Folmes et al., 2011). For example, higher and faster 
glycolytic rate can compensate for lower ATP production (Pfeiffer et al., 2001; Valvona et al., 
2015), e.g. in dividing cells, which have high macromolecules demand, or stem cells, which 
require low ROS production (Zhang et al., 2012). ATP production also derives from 
alternative routes of acetyl-coA metabolism, such as fatty acid metabolism, amino-acids 
catabolism and lactate conversion (Berg et al., 2002). 
β-oxidation of fatty acid includes catabolic reactions leading to acetyl-coA and cofactor 
production, used as substrates for ATP generation. How much of the brain energy demand 
relies on this pathway is a matter of debate, but some data suggest that up to 20% of energy 
expenses might be dependent on oxidation of fatty acid, which almost exclusively occurs in 
mitochondria (Panov et al., 2014). Indeed the complete oxidation of one molecule of fatty 
acid, compared to one of glucose, can produce more than double the amount of ATP 
molecules, even if preferring this pathway over complete glycolysis may occur at the costs of 
higher oxygen requirements and presumably increased ROS production (Darvey, 1998; 
Perevoshchikova et al., 2013; Schönfeld and Reiser, 2013; Souza et al., 2019). In any case, a 
prominent role for fatty acid β-oxidation in brain homeostasis is undeniable. Indeed many 
studies underline high expression levels of key enzymes involved in this pathway within 
astrocytes (van Deijk et al., 2017; Hofmann et al., 2017).  
Nevertheless astrocytes, despite their ability to perform glycogenesis, glycolysis, oxidative 
phosphorylation and fatty acid oxidation, absorb a disproportionally high amount of glucose, 
compared to their energy demand (Chuquet et al., 2010). A simple reason for this paradox is 
the well-established function of astrocytes as energy feeders for neurons. 
Neurons indeed lack key enzymes involved in fundamental steps of glycolysis, such as the 
correct pyruvate kinase (PKM) isoform (Zhang et al., 2014) or the rate-limiting enzyme Pfk3b 
(Herrero-mendez et al., 2009), compared to astrocytes. Indeed, pioneer experiments where 
selective key components of the oxphos machinery were ablated in the brain further 
confirmed the low reliance of neurons, compared to other glial cells, on glycolysis, also when 
oxphos was impaired (Diaz et al., 2012; Fünfschilling et al., 2012; Supplie et al., 2017). Other 
reports suggest on the contrary that neurons, in particular conditions of stimulation, may 
perform glycolysis, even at higher rate compared to oxphos (Díaz-García and Yellen, 2018; 
Ivanov et al., 2014); indeed some GLUTs isoforms are also expressed on neuronal plasma 
membrane (Vannucci et al., 1998). Nevertheless, neuronal glucose uptake in physiological 
condition may happen, but likely has a different degradation pathway compared to astrocytes.  
Indeed glucose in neurons is known to detour, at least partially, to the Penta-Phosphate 
Pathway (PPP) (Bélanger et al., 2011). PPP, divided in an oxidative and not-oxidative branch, 
is fundamental for defense against oxidative stress, generating nicotinamide adenine 
dinucleotide phosphate reduced (NAPDH) to fuel redox reaction of glutathione (GSSG, 
oxidized, or GSH, reduced), mainly involved in detoxifying from ROS (Bolaños and 
Almeida, 2009). PPP is further involved in maintaining carbon homeostasis providing 
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precursors for nucleotide and amino acid biosynthesis, according to specific cellular context 
needs (Stincone et al., 2015) 
Even if glucose does not seem to be the main energetic source for neurons, the astrocyte-
neuron lactate shuttle hypothesis (ANLSH) (Pellerin and Magistretti, 1994; Pellerin et al., 
1998) seems to reasonably explain how this supply of substrate might happen. Indeed 
pyruvate, in lower oxygen availability or when it is needed for other purposes rather than 
TCA cycle, can be converted by lactate dehydrogenase (LDH) into lactate. Lactate is released 
in the extracellular matrix by astrocytes and taken up by specific neuronal transporters, then is 
converted back to pyruvate and utilized for aerobic respiration. This offers the selective 
advantage for neurons to have a ready-to-use substrate to meet their energetic requirements, 
while astrocytes perform the high energy producing steps of glycolysis (Amaral et al., 2013; 
Mächler et al., 2016). 
Interestingly, also glutamate and glutamine have been shown to be potential substrates for 
ATP production within neurons. Glutamate is physiologically released following excitatory 
activity and it accumulates in the extracellular space. Astrocytes, through glial-specific 
glutamate transporters (EAATs), take up glutamate and convert it into glutamine, further 
released by astrocytes through glutamine transporter. Neurons then take up and recycle 
glutamine, converting it into glutamate through glutaminase (Gls) and reuse it as 
neurotransmitter or also to fuel the TCA cycle. Concomitantly, glutamate accumulation 
within astrocytes also triggers increase in glycolysis and lactate production (Calvetti and 
Somersalo, 2012; Fendt and Verstreken, 2017). 
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Figure 1. Schematic overview of the metabolic interactions between neurons and glial cells (Amaral et 
al., 2013. This is an open-access article distributed under the terms of the Creative Commons 
Attribution License). 
It is worthwhile mentioning that despite more than a century of studies on the CNS 
metabolism, development of new technologies and techniques still surprise us with how few 
we actually know of what happens in the brain in vivo. Interestingly, deep proteomic studies 
are finding more and more proteins involved in mitochondrial homeostasis, whose effect in 
cellular context is still to be determined (Calvo et al., 2016). Mitochondrial composition 
varies hugely amongst different tissues and even cell types within the same tissue (Calvo and 
Mootha, 2010; Forner et al., 2006; Pagliarini et al., 2008). Excitingly also mitochondria and 
metabolic differences within different compartments of the same cell type have been 
determined (Graham et al., 2017; Völgyi et al., 2015). Development of new technologies, like 
CRISPR-Cas9, is helping us unraveling new molecular functions for well known 
mitochondrial proteins (Arroyo et al., 2016; Jo et al., 2015), fundamental to fully understand 
specific mitochondrial pathways within a cell (Johnson et al., 2007b, 2007a).  
The importance of mitochondria in regulating broader and uninvestigated branches of 
metabolism is now being increasingly recognized (Spinelli and Haigis, 2018). This can have a 
great impact on unraveling new specific metabolic functions of astrocytes and neurons (Fiebig 
et al., 2019; Hayakawa et al., 2016).  
To sum up, according to the cellular and environmental context, the metabolism of astrocytes 
and neurons within the brain is plastic and mitochondria play a pivotal role in this regulation. 
In particular, it seems that neurons have a limited capacity for glycolysis, while having an 
active TCA cycle and oxphos machinery. Oxphos requires the metabolic supply of substrates 
and cofactors, like lactate, glutamate, NADH and FADH2, from astrocytes and 
oligodendrocytes. On the contrary, astrocytes seem to have a more adaptable metabolism, 
relying mostly on glycolysis and glycogenesis for production and storage of energy. 
Furthermore, high reliance also on fatty acid metabolism and oxphos for ATP generation has 
been suggested to occur in this glial cell type. Notwithstanding, scarce knowledge still exists 
on how specific mitochondria composition of astrocytes and neurons might influence cell-
specific function in physiological and pathological conditions.  
Interestingly, in a pathological model of Huntington disease, astrocytes from different regions 
compensate for lack of glucose metabolizing different substrates (Polyzos et al., 2019). 
Indeed a further level of understanding of the metabolic reactions occurring within glial cells 
and neurons derives from evaluating these cell types in a pathological context. In fact, 
astrocytes and neurons have different abilities to survive upon damage and oxidative stress 
(Wang and Michaelis, 2010).  
CNS damage and neuronal-glia response 
The delicate architecture and balance of functions within the CNS can be easily perturbed by 
a variety of different pathological insults. These diverse stimuli trigger a multifaceted cellular 
and molecular response, involving endogenous neuronal and glial cells, but also blood-
derived immune cells, which cooperate for wound repair and tissue replacement. 
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Nevertheless, neurological damage often leads to severe cell death, causing disability and 
representing a major cause of death worldwide (Jassam et al., 2017; Winblad et al., 2016). 
CNS injuries can be broadly defined as acute and focal, such as the ones consequent to 
ischemic stroke or traumatic brain injury (TBI), or diffuse and chronic neurodegenerative 
diseases, like Alzheimer´s disease (AD), multiple sclerosis (MS), Parkinson´s diseases (PD) 
and many more (Chen et al., 2016). The pathologies induce different response mechanisms in 
the brain, triggering wound repair and tissue replacement when the insult is acute, or more 
drastic tissue remodeling mechanisms when slow neurodegenerative diseases occur (Burda 
and Sofroniew, 2014). The adverse output for the recovery of the patient, in all these 
conditions, triggers the necessity for a deeper understanding of the molecular mechanisms 
regulating the pathological process, where metabolic deregulation represents one of the major 
challenges. 
TBI, or stab-wound injury (SWI) when referring to animal models, can be considered as a 
typical model of acute and focal injury. It largely varies as output for the recovery of the 
patient according to the severity of the trauma, the injured area involved and how fast the 
medical treatment occurs. TBI contributes to 30% of all injury-related deaths, leading also to 
permanent disabilities in most of the millions of people yearly affected (Gyoneva and 
Ransohoff, 2015; Jassam et al., 2017). Overall, at molecular and cellular level, it can be 
divided into three temporal phases.  
It is first characterized by disruption of blood vessels, inducing a lack of oxygen and glucose 
for the affected area. In seconds to minute after the failure in energy supply neurons 
depolarize, not being able to actively sustain their membrane potential. This has as a first 
consequence the inability to remove the released neurotransmitters, like glutamate, from the 
extracellular space, activating endogenous glutamatergic receptors triggering excitotoxicity. 
As consequence of excessive neuronal activation, free radicals species are generated, further 
damaging membranes, mitochondria and DNA, triggering caspase-mediated cell death 
(apoptosis) (Arundine and Tymianski, 2004; Leker and Shohami, 2002). Moreover, the 
extracellular concentration of potassium (K+) rises, further propagating waves of 
depolarization. According to the severity of the injury, accumulation of extracellular ions can 
induce swelling and edema, while intracellular calcium (Ca2+) within neurons can activate 
enzyme systems, like lipases, endonucleases and proteases, which further promote early 
neuronal death. Furthermore, early release of damage associated molecular patterns (DAMPs) 
together with free radicals from the injured tissue elicit the second phase of the pathological 
cascade, involving activation of microglia and recruitment of blood-derived leukocytes.  
In this early phase, perturbed interactions among astrocytes and neurons play a key role in 
spreading the pathological insult. Particularly relevant is the reliance of neurons on astrocytes 
for anti-oxidants and substrates for survival. Thus, it is not surprising that when an energy 
failure occurs and basic astrocyte functions are impaired, neurons are the first cells to suffer, 
losing substrates as lactate and glutamate (Bélanger et al., 2011). It is rather surprising instead 
that neurons, despite being stronger users of oxphos, are the most sensitive cell to ROS-
mediated damage in the brain. 
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 Figure 2. Phases and time course of multicellular responses following acute injury to the central 
nervous system (Burda and Sofroniew, 2014. License Number: 4565530405973). 
The most represented ROS are mitochondrial-derived superoxide radical (O2_), reactive 
hydroxyl radical (.OH), and hydrogen peroxide (H2O2) (Murphy, 2009). Many antioxidant 
systems protect the cell from their action, such as superoxide dismutases (SOD), glutathione, 
thioredoxins (TRX), peroxiredoxins (PRX) and catalases (CAT) (Birben et al., 2012). 
Astrocytes possess higher amounts of these antioxidant molecules and couple their 
bioenergetics system to neurons also with defense against ROS. Indeed, in different models of 
injury, neurons rely on astrocytes to survive and cope with damage (Allaman et al., 2011; 
Anderson et al., 2016; Chen et al., 2009). For example, astrocytes mostly synthesize and 
provide GSH, through recycling of glutamate, which is then used within neurons as strong 
anti-oxidant molecule, together with NADPH produced through neuronal PPP (Fernandez-
Fernandez et al., 2012). Neurons can anyway cope with stress relying on some self-produced 
antioxidant molecules, such as PRX and SOD, up-regulated in situation of stress, or produced 
through the PPP pathway (Boulos et al., 2007; Quaegebeur et al., 2016). 
The second phase of events within the lesioned area occurs hours to days after the injury, and 
is mainly characterized by tissue remodeling processes, such as cell proliferation and 
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migration, ongoing inflammation and secondary cell death (Burda and Sofroniew, 2014). In 
particular, DAMPs and ROS lead to secretion of chemokines and pro-inflammatory cytokines 
from the brain resident microglia and astrocytes, leading to activation of chemokine receptors 
on endothelial cells, mediating recruitment and extravasation of leukocytes. Neutrophils and 
macrophages are the first subtypes of leukocytes infiltrating the tissue, modulating and 
decreasing the ongoing inflammation in the environment, actively secreting pro- and anti-
inflammatory cytokines. Cytokines further increase in a positive loop the recruitment of other 
inflammatory cells on one side, and on the other side modulate glial function, activating 
phagocytosis to remove cell debris and resolve the ongoing inflammation (Chen et al., 2016; 
Gyoneva and Ransohoff, 2015; Silver et al., 2014). Shortly after early macrophage 
infiltration, microglia and astrocytes further increase their reactivity, up-regulating Iba1 and 
GFAP expression respectively, and acquiring a further activated ameboid morphology. These 
glial cells start to proliferate, forming the so-called “reactive gliosis”, contributing to the 
resolution of ongoing inflammation and to the formation of a glial scar in the mammalian 
brain (Dimou and Götz, 2014).  
In particular, the ambiguous role of reactive astrocytes in the injury environment has been 
long debated (Liddelow and Barres, 2017; Pekny and Pekna, 2014). It is known that 
astrocytes following an injury do not migrate to the injury site, unlike microglia or OPCs, but 
rather proliferate locally, mostly at the peri-vascular location (Bardehle et al., 2013; Robel et 
al., 2011). The local proliferation of astrocytes has been long considered as negative for the 
neuronal regeneration, leading to the formation of a scar in mammals that hampers neuronal 
axonal regrowth (Silver et al., 2014). However, growing pieces of evidence support beneficial 
effects of reactive astrocytes in neuroprotection and neurorepair, rather than being detrimental 
(Anderson et al., 2016; Frik et al., 2018; Tang, 2016). 
In many paradigms of injury, innate immune infiltration characterized by macrophages and 
neutrophils is usually followed by active induction and recruitment of lymphocytes, 
characterizing the branch of the adaptive immunity. This feature is typical of insults where 
bacterial, virus or autoimmune reactivity occurs. T lymphocytes exert the function of actively 
recognizing specific antigens, which can belong to the invading pathogen, or in case of 
autoimmunity to the host. This specific recognition leads to activation of pathways inducing 
selective killing of the targeted cells. B lymphocytes, producing antigen-targeted antibodies, 
further contribute to the killing of compromised cells and support the survival of T cells 
(Koyuncu et al., 2013; Russo and McGavern, 2015). Usually in TBI lymphocyte infiltration is 
absent or minimal, as most of the immune functions are performed from the non-specific 
branch of innate immunity (Frik et al., 2018; Mattugini et al., 2018). Anyway, some degree of 
T cell infiltration has been described in animal models of TBI and in patients following 
injury, even if their role in the post-injury environment is not clear (McKee and Lukens, 
2016). 
The last phase of the recovery process occurs one week to months following injury, and is 
mainly characterized by scar injury formation, BBB closure and neuronal rewiring to 
compensate the lost network, according to the degree of damage (Burda and Sofroniew, 
2014). Astrocytes orchestrate the process of BBB closure together with OPCs, microglia and 
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macrophages, through the extensive remodeling of the extracellular matrix (ECM) and neo-
vasculogenesis (Dimou and Götz, 2014). By 2 weeks post-injury, the brain has almost no 
more infiltrating immune cells, however activated microglia and astrocytes, associated with 
high levels of inflammatory cytokines, may persist for months. Indeed, a well-organized 
compact glial scar usually surrounds the lesion core, physically limiting the inflammation and 
allowing recovery. This reactive gliosis scar is characterized by high glial fibrillary acidic 
protein (GFAP) and Vimentin reactivity, which partially reduce over time (Burda and 
Sofroniew, 2014). Macrophages play a pivotal role in modulating the glial scar formation, as 
a lack of their infiltration results in reduced scar formation, already one month after injury 
(Frik et al., 2018). Interestingly, the capacity of the CNS to form a permanent scar opposed to 
full scarless regeneration differs in evolution. Mammals have indeed the most complex but 
also less plastic, in term of regeneration, central nervous system (Alunni and Bally-Cuif, 
2016).  
In mammals, the viable neuronal tissue surrounding the scar also faces a remodeling phase, 
whose extent varies accordingly to the degree of damage. Depending on the neuronal network 
involved, compensatory mechanisms exist to restore, at least partially, the lost neuronal 
connections, for example by strengthening the contra-lateral ones or forming collateral fibers 
(Carron et al., 2016; Nudo, 2013).  
It is worthwhile mentioning that the delicate metabolic balance disrupted within the brain 
following an injury has important consequence for mitochondria stability, which clearly plays 
an essential role in physiology and pathology. Indeed following an injury, drastic alteration of 
mitochondria morphology have been observed in astrocytes (Motori et al., 2013) as well as 
neurons (Misgeld and Schwarz, 2017), with fundamental consequences for ROS homeostasis 
and pathological progression (Knott et al., 2008; Sena and Chandel, 2012). Mitochondria are 
indeed the primary functional regulators of cell survival and cell death, and are commonly 
deregulated in diseases involving the CNS, consequently mainly affecting neuronal survival 
(Kasahara and Scorrano, 2014). 
Despite the endogenous attempt of the brain to fully restore neuronal function following a 
brain injury, the outcome for the patient is often fatal. This is due to the fact that neurons 
cannot regenerate like other glial cell types. It is thus not surprising that restoring lost 
neuronal cells has always been the dream of regenerative medicine. 
CNS repair: strategies 
The attempts to repair the central nervous system have been long focused on rescuing the 
remaining neurons, by providing chemicals and growth factors to stimulate neuronal 
outgrowth and activity, or by directly pushing neural plasticity to create compensatory 
networks for lost connection. Thus most of these treatments, including drugs and 
rehabilitation techniques, aim at alleviating symptoms and promote brain functional plasticity 
(Grade and Götz, 2017). Despite that, the rate of success has been extremely low, mainly 
restricted to combinatorial drug treatments in the very early phase after injury (Rajkovic et al., 
2018). 
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The discovery that endogenous neurogenesis occurs also in mammals (Altman, 1962), even if 
at a lesser extent than in other vertebrates (Alunni and Bally-Cuif, 2016), opened the door for 
a new field of neuroregenerative medicine. The main limitation to the use of endogenous 
neural stem cells (NSCs), for neuronal replacement therapies, is the restriction of adult 
neurogenesis to only two neurogenic niches, the subventricular zone (SVZs) and the 
hippocampus (Gonçalves et al., 2016; Lim and Alvarez-Buylla, 2016), which give rise to a 
limited number of specific long-term surviving and integrating interneurons  (Bergami and 
Berninger, 2012). Intriguingly, neurogenesis is increased to some extent in the lesion sites of 
some pathologies (Hou et al., 2008; Kandasamy et al., 2015), even if proper integration of 
these new neurons has been very limited or even detrimental (Cho et al., 2015). Furthermore, 
the notion that in ageing, where most of the neurological diseases occur, NSCs decrease in 
number and functionality, further cooled down the enthusiasm to apply this treatment for 
brain disorders (Calzolari et al., 2015; Lazarov et al., 2010). 
Excitingly, injury seems to elicit plasticity in glial cells to replace degenerated neurons, to 
some extent. The discovery that reactive cortical astrocytes up-regulate some feature typical 
of NSCs, and have neurogenic potential in vitro (Sirko et al., 2013), suggest that a better 
understanding of the developmental origin and molecular cues regulating astrocyte fate may 
be the future to foster neurogenesis after injury (Götz et al., 2015). Interestingly, also other 
cells within different brain regions, such as ependymal cells and striatal glia (Carlén et al., 
2009; Magnusson et al., 2014), or tanycytes in the hypothalamus (Goodman and Hajihosseini, 
2015), have been proven to have some neurogenic potential.  
More promising as strategy for brain repair has been transplantation of exogenous neurons or 
neural stem cells, with broader applications in term of source and targeted area. Diverse 
sources exist for neuronal replacement, such as primary fetal neurons and embryonic stem 
cells (ESCs)-derived neurons, which have proven excellent degree of differentiation, 
integration and survival in different mouse models (Falkner et al., 2016; Southwell et al., 
2014), and also some degrees of success when tested in human clinical trials (Curtis et al., 
2018; Politis and Lindvall, 2012; Yasuhara et al., 2017). Interestingly, transplantation of 
NSCs supports recovery in some injury models remaining undifferentiated rather than by 
differentiating into neurons, secreting molecules fostering the recovery; the so-called 
bystander effect (Bacigaluppi et al., 2016; Martino and Pluchino, 2006).  
Another promising source for transplantation are induced pluripotent stem cells (IPSCs)-
derived neurons. These cells have the advantages of reduced ethical concerns compared to 
ESCs, of deriving from a source easy to obtain (e.g. fibroblasts) and of being genetically 
matched with the patient, reducing the risks for immune response and rejection. The 
discovery that murine and human adult somatic cells, through the expression of specific 
embryonically-derived TFs, can be converted back to pluripotency, similarly to ESCs 
(Takahashi and Yamanaka, 2006; Takahashi et al., 2007), opened a new approach for the field 
of disease modeling and drug discovery, reaching nowadays the previously unthinkable 
possibility of generating organs-like structures in vitro (e.g. organoids) (Rowe and Daley, 
2019). Indeed, IPSCs can be converted virtually into any kind of differentiated cell type and 
mature IPSCs-derived neurons were indeed amongst the first generated (Dimos et al., 2008). 
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Most importantly, IPSCs-derived neurons can be efficiently transplanted in murine and non-
human primates disease models, leading to some extent of functional recovery (Hallett et al., 
2015; Wernig et al., 2008). 
 
Figure 3. Overview of strategies for neuronal replacement following brain damage (Grade and Götz, 
2017. Open Access: This article is licensed under a Creative Commons Attribution 4.0 
International License). 
The discovery that adult somatic cells can be directly converted into functional neurons, both 
in vitro and in vivo, opened the door to an alternative strategy for neuronal regeneration: 
direct neuronal reprogramming. 
Direct neuronal reprogramming in vitro and in vivo  
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The concept that adult somatic cells can be directly converted into other somatic cells was 
first demonstrated when overexpression of MyoD in fibroblasts induced their conversion to 
myoblasts (Davis et al., 1987). The first conversion of adult somatic cells into neurons, 
without passing through an intermediate pluripotent or proliferative stage, was proved when 
astrocytes were converted into neuronal cells through overexpression of Pax6, many years 
later (Heins et al., 2002). These discoveries inaugurated direct reprogramming or 
transdifferentiation. 
Since then, the field has been boosted by the discovery that other cells, not necessarily 
deriving from the same germinal layer, can be converted into mature neurons, with different 
efficiencies and degrees of maturation (Masserdotti et al., 2016). Beyond astrocytes (Heins et 
al., 2002), fibroblasts (Vierbuchen et al., 2010), hepatocytes (Marro et al., 2011), pericytes 
(Karow et al., 2012), microglia (Matsuda et al., 2019) and even lymphocytes (Tanabe et al., 
2018) have been reprogrammed into neurons, both of murine and/or human origin.  
Overcoming the barrier of transitioning from one cell fate to another, even beyond germinal 
layer origin as for fibroblasts (Vierbuchen et al., 2010), proved how few we knew about the 
mechanisms regulating cell state, and how adult somatic cells can actually be plastic. 
Unraveling new molecular and epigenetic mechanisms involved in this process has also 
important applications for developmental neurogenesis (Masserdotti et al., 2016). Notably, 
most of these early reprogramming approaches have in common that TFs alone, involved in 
embryonic neurogenesis, were sufficient to generate mature neurons, like in the case of the 
master TFs Neurogenin 2 (Neurog2) or achaete-scute homolog 1 (Ascl1), inducing mostly 
glutamatergic or gabaergic neurons respectively (Heinrich et al., 2010; Masserdotti et al., 
2015). Interestingly, while astrocytes are relatively easy to reprogram, this is not the same for 
other cells, such as fibroblasts or hepatocytes, where a combination of several TFs and 
molecules are required to generate a decent number of reprogrammed neurons (Pang et al., 
2011). Intriguingly, recent reports also highlighted the direct generation of neurons from 
human and murine fibroblasts through microRNAs (miRNAs), alone or in combination with 
TFs (Victor et al., 2014; Yoo et al., 2011), or even through combination of small molecules 
alone (Hu et al., 2015; Li et al., 2015).  
The biggest step forward was the proof of principle that in vivo direct neuronal conversion 
was possible (Buffo et al., 2005), even if early studies generated rather neuroblast-like cells, 
with short survival and rather immature morphology (Heinrich et al., 2014; Niu et al., 2013).  
When translating to in vivo approaches, a fundamental consideration is the cell type we want 
to target and reprogram. This has indeed a profound impact on the environment, as we 
subtract functional cells from the brain. Thus, it is important we aim to target cells with 
proliferative and homeostatic capacity, as we do not want to generate neurons at the expenses 
of other important glial cell functions, as metabolic and trophic support.  
The main cells targeted indeed are reactive and non-reactive astrocytes (Brulet et al., 2017), 
OPCs (Torper et al., 2013, 2015) or a mixture of both (Grande et al., 2013). Interestingly, 
according to the targeted region, usually striatum or cortex, as well as the targeted cells, OPCs 
or astrocytes, different efficiencies of reprogramming and survival of induced neurons have 
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been observed (Grade and Götz, 2017). Recent advances in genetic studies, taking advantage 
of transgenic mouse lines to selectively express the viral vectors carrying the neuronal TFs in 
one glial cell or the other, further allowed us to elucidate which cell is more amenable to 
neuronal reprogramming (Liu et al., 2015; Torper et al., 2015). The recent discovery that also 
microglia and pericytes can be reprogrammed into neurons opens new possibilities for in vivo 
studies, targeting these two CNS cell types. It would be further important to considerate 
which delivery strategy could be optimal for direct neuronal reprogramming, as different viral 
vectors can be modified to target specifically different brain cell populations, and have also 
been shown to elicit diverse immune responses within the CNS, which are potentially harmful 
for the newly generated neurons (Chew et al., 2016; Drokhlyansky et al., 2016; Mancini and 
Horvath, 2018).  
Surprisingly, in fact, very few papers have tested the possibility of direct neuronal 
reprogramming in a pathological context, as most of the efforts so far focused on generating 
mature and long-term survival neurons. Anyway, pioneering studies in mouse models of PD 
and stroke showed first hints of improvement in motor functions, following in vivo neuronal 
direct reprogramming (Guo et al., 2014; Rivetti di Val Cervo et al., 2017). 
Even if we are now able to produce neurons that functionally integrate into the CNS, showing 
electrophysiological properties and morphological features similar to the endogenous ones 
(Liu et al., 2015; Rivetti di Val Cervo et al., 2017), we still miss fundamental pieces of 
information to aim for proper neuronal replacement. Indeed, we are still lacking a 
comprehensive understanding of how specific neuronal subtype can be generated, how to 
foster their grafting and correct wiring within the lesioned area and which delivery method is 
optimal. Thus, many hurdles still exist before an efficient in vivo translation is possible.  
A deeper understanding of the epigenetic, transcriptional and metabolic processes regulating 
reprogramming, and how the highly inflammatory and reactive pathological environment may 
impact the conversion, are essential aspects to fill this gap in knowledge and boost direct 
neuronal reprogramming to the next step (Gascón et al., 2017). 
Hurdles to direct neuronal reprogramming 
Understanding what defines a cell identity is a central question in the field of reprogramming, 
which faces a further challenge when considering a neuron. Indeed, the advent of single cell 
genomics added a further layer of complexity, revealing dozens of unpredicted neuronal 
subtypes within the human and mouse brain (Lake et al., 2016; Luo et al., 2017), whose 
molecular characterization is not yet completed. As the aim of reprogramming is to regenerate 
bona fide neurons, a deeper understanding of which transcriptional and epigenetic networks 
regulate them is necessary. Interestingly, also astrocytes heterogeneity has been recently 
recognized as important for brain development and specification (John Lin et al., 2017; 
Lanjakornsiripan et al., 2018; Morel et al., 2017). Indeed, neuron and astrocyte heterogeneity 
seem to be intrinsically related and further associated to basic and specific cellular functions 
(Morel et al., 2017; Polyzos et al., 2019). Interestingly, different astrocyte subtypes are 
amenable to reprogramming with the same TFs, although generating different subtypes of 
neurons (Chouchane et al., 2017; Hu et al., 2019). Changing the molecular program 
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characterizing the starter cell is one of the greater challenges for the neuronal factors. Thus, a 
better understanding of the molecular mechanisms regulating cell fate specification of each 
starter cell can become an advantage to generate the correct neuronal subtype. 
Indeed, recent papers highlighted how understanding and manipulating these genetic, 
epigenetic or even metabolic hurdles in a cell-specific context, not only offer the possibility to 
better understand the biology of the process, but can also greatly improve the neuronal 
conversion (Masserdotti et al., 2015; Zhou et al., 2018). 
General hurdles to reprogramming can be subdivided as cell-specific and general. The second 
group encases mechanisms protecting genome stability, senescence or cell cycle re-entry 
(Gascón et al., 2017). Genome stability can refer to cell-type-specific transcriptional 
repressors or epigenetic barriers, which need to be manipulated for efficient neuronal 
reprogramming. For example, ablation of the RE-1 transcription repressor complex (REST) in 
astrocytes potently improves the conversion efficiency into neurons, as it competes for 
binding to targets of Neurog2 (Masserdotti et al., 2015); while the transcription factor Myt1l 
regulates neuronal program activation from fibroblasts by repressing all others somatic 
lineage programs (Mall et al., 2017). Understanding the epigenetic regulation of the 
reprogramming process, like was recently done for microglia converting into neurons 
(Matsuda et al., 2019), is essential, as epigenetic modulation has been shown to improve 
neurogenesis (Albert et al., 2017) and can have important consequences to boost neuron 
generation (Stricker and Götz, 2018). The discovery of CRISPR-Cas9 technology and its huge 
application for genome editing may offer great advantages in this regard (Barrangou et al., 
2007). 
CRISPR-Cas9 technology offers indeed an amazing tool for fast and efficient manipulation of 
gene expression, which has just been started to be exploited also in direct neuronal 
reprogramming in vivo and in vitro (Black et al., 2016; Zhou et al., 2018). The applications of 
Cas9 technology range from modulation of endogenous expression of multiple genes through 
guide-RNAs (gRNAs) co-expression targeting promoter regions (Breunig et al., 2018a; 
Chavez et al., 2015), screening of important proteins for neuronal metabolism and survival 
(Arroyo et al., 2016; Rubio et al., 2016), regulation of proteins important for mitochondria 
function and metabolic adaptation during reprogramming (Calvo-Garrido et al., 2019; Jo et 
al., 2015). 
Also proteome regulation can be a barrier to reprogramming, as larger differences between 
the starter and induced cell type, in term of protein composition, may elicit metabolic and 
cellular stress. To sustain this hypothesis in IPSCs generation mitochondrial and protein 
autophagy is essential and beneficial for cell fate conversion (Ma et al., 2015; Wang et al., 
2013). If Cas9 can be the future of reprogramming, the appropriate delivery method to 
mediate its expression deserves some thoughtful revision. 
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 Figure 4. General hurdles common to direct neuronal reprogramming (Gascón et al., 2017).  
Indeed, we know that most of the in vivo and in vitro reprogramming approaches so far 
discussed overexpress the factors mostly through Lentivirus (LV), Retrovirus (RV) and 
Adeno-associated virus (AAV). Each of these delivery methods have different advantages, 
mostly linked to the properties of the viral vector from which they derive. 
Lentivirus and Retrovirus share most of their components, deriving both from Retroviridae 
and consisting of a linear positive-sense single-stranded RNA. The main difference amongst 
LV and RV consists in the fact that the first can infect and replicate within quiescent cells, as 
neurons, being able to cross the nuclear membrane and use the endogenous cell machinery for 
viral replication, while the second is duplicated only in replicating cells with open nuclear 
membrane. Both viruses have similar capacity in term of transgene, about 8kb, and can 
virtually transduce any cell types, when pseudo-typed with vesicular stomatitis virus G (VSV-
G) envelope glycoprotein (Mancini and Horvath, 2018). A potential side effect for these viral 
vectors is their ability to integrate into the host genome, with increased risk for insertional 
mutagenesis and oncogenicity, although they tend to integrate distant from cellular promoters 
(Naldini, 2011). LVs have been broadly used to target specific glial cells, as pseudo-typing 
their envelope can restrict their selectivity (Buffo et al., 2008; Niu et al., 2013; Torper et al., 
2013), but RVs offer fundamental advantages. Retroviral-mediated reprogramming reduces 
the risks for false positive neurons, as these post-mitotic cells do not express the transgene. 
Furthermore, RVs target proliferating glial cells that will not be depleted and have strong 
22 !
homeostatic drive (Dimou and Götz, 2014; Gascón et al., 2017). Anyway, some of the 
limitations of LV and RV, like low efficiency of transduction and immunogenicity of the 
construct itself, can be overcome by AAV. 
AAVs are small viruses of the Parvoviridae family, which require a co-helper virus to 
properly replicate. The DNA consists of a single-stranded DNA filament, which exists in the 
host nucleus in episomal state or selectively integrating in the chromosome 19. Limiting the 
risk for insertional mutagenesis. However, the size of the transgene that they can carry is 
relatively small, only 5kb. Interestingly, several AAV capsids have been generated allowing 
selective targeting of cells, with higher transduction efficiency than RV or LV (Mancini and 
Horvath, 2018). Furthermore, the overexpression of the transgene in AAV occurs slower than 
for RV or LV, reducing the risks for the converting neurons to cope with the early highly 
inflammatory injured environment (Burda and Sofroniew, 2014). 
Indeed, an important factor to consider is that viral vector spreading, as it happens for 
pathogens attack in the CNS, can induce a strong immune response, which can be elicited 
both from the original viral components, as well as the transgene. This immune response can 
be first innate and then adaptive, limiting the expression of the new transgene, inducing even 
selective recognition and killing of the transduced cells. This can even increase inflammation 
and worsen the outcome (Drokhlyansky et al., 2016; Lowenstein et al., 2007), even if in the 
case of AAV this induced immune response does not seem to elicit cell death (Chew et al., 
2016). New technologies in the field of gene therapy are aiming at reducing side effects of 
viral vectors, decreasing immunogenicity and increasing delivery rate (Ewer et al., 2016). All 
of these hallmarks would also be useful for direct neuronal reprogramming. Indeed broad 
immune reaction and selective killing of transduced cells, further increasing inflammatory 
reaction in the environment, would enhance the pathogenic process and are fundamental 
general hurdles to consider for efficient neuronal conversion.  
Other general hurdles can be for example cell proliferation and DNA damage consequent to 
ROS production (Gascón et al., 2017). It is known that cells need to exit the cell cycle to 
efficiently convert into neurons, as for fibroblasts in which pushing the proliferation hampers 
the conversion (Fishman et al., 2015). The metabolism is also emerging as a relevant and 
preponderant mechanism regulating neuronal fate, which can be considered as cell-type 
specific hurdle. 
Indeed, it was already shown in other fields of cell fate decision, like IPSCs generation and 
adult and developmental neurogenesis, that a switch from glycolytic to oxidative metabolism 
occurs and is essential for proper neuronal generation (Khacho et al., 2016; Llorens-bobadilla 
et al., 2015; Mlody and Prigione, 2016; Prigione et al., 2015). In fact down-regulation of key 
glycolytic enzymes, increased mitochondrial biogenesis and enhanced oxidative 
phosphorylation accompany the neuronal differentiation processes (Fang et al., 2016; Gascón 
et al., 2017). Also similar metabolic changes have been observed in IPSCs generation 
(Prigione et al., 2010; Zhu et al., 2010). Furthermore, direct blockage of oxphos pathway, or 
converse stimulation of glycolysis, further increased IPSCs generation from fibroblasts 
(Folmes et al., 2011; Panopoulos et al., 2011; Son et al., 2013). This suggests that acting 
directly on metabolic regulation might also improve neuronal generation, as modulation of 
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oxygen availability increases direct neuronal reprogramming from fibroblasts (Davila et al., 
2013). Furthermore, modulation of oxygen availability is linked to increased IPSCs 
generation through activation of the transcription factor HIF1α, which enhances the glycolytic 
rate (Papandreou et al., 2006; Prigione et al., 2014; Yoshida et al., 2009).  
Interestingly, metabolic changes observed in IPSCs generation and developmental 
neurogenesis are also associated to ROS production, with direct and indirect effects on the 
converting cells (Le Belle et al., 2011; Khacho et al., 2016; Wu et al., 2013; Zhou et al., 
2016), in most cases affecting their survival. As neurons are extremely sensitive cells to ROS-
mediated damage (Wang and Michaelis, 2010), a better understanding of the consequences of 
metabolic transition for converting neurons is required. The role of ROS in impairing the 
generation of neurons might also have a big impact on the in vivo integration and survival of 
these cells. Indeed, the highly inflammatory environment characterized by ROS and immune 
cell infiltration might create a further barrier to the conversion process (Burda and Sofroniew, 
2014). Furthermore, ROS might also interfere with other pathways and molecules required for 
neuronal differentiation, such as fatty acid generation (Knobloch et al., 2012), prone to suffer 
from ROS-mediated peroxidation. This leads to properly evaluate the best timing to apply 
direct reprogramming following the pathological insult. A delayed treatment might be 
beneficial, as ROS and inflammation are decreased, but the glial scar could interfere. Also the 
viral vector used can influence this choice, as different times for transgene expression are 
required (Gascón et al., 2017).  
Notwithstanding, in the field of direct neuronal reprogramming not much is known on the 
impact that metabolic changes might pose on the transitioning neurons. 
To sum up, direct neuronal reprogramming future lies in unraveling the mechanisms that 
burden its success application into pathological models first, and for clinical translation after. 
Indeed, generation of specific neuronal subtypes that successfully integrate and correctly 
project in the injured environment, replacing the lost ones from a functional, genetic and 
metabolic point of view, are the main goals of the field now.  
My thesis aims to investigate and unravel common hurdles to the process of direct neuronal 
reprogramming, focusing on cell intrinsic and cell extrinsic properties. In particular, I 
investigate potential roles that metabolism, mitochondria and inflammation might play in the 
process, with the aim to find potential strategies to improve the conversion efficiency. To do 
so, I investigated in vivo the suitability of different viral vectors to direct neuronal 
reprogramming after TBI, evaluating in particular the effect that they exert on the 
environment and on the inflammatory processes. I then explored the mechanisms of metabolic 
conversion of glial cells to neurons. To do so, I first examined to which extent conversion to 
oxphos is required in the reprogramming process of astrocytes to neurons. Next, I asked how 
mitochondria protein composition differs between the starting glial cells and the end product 
of neuronal reprogramming, the neurons. I then investigated if mitochondria composition 
changes during glia-to-neuron conversion and how its modulation might impact direct 
neuronal reprogramming. 
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Aim of the study I 
The aim of the study is to investigate: 
 
1. The effect that different viral vectors used to mediate in vivo direct neuronal 
reprogramming exert on the injured brain parenchyma. 
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SUMMARY  
 
Astrocytes are particularly promising candidates for reprogramming into neurons as they maintain 
the original patterning information from their radial glial ancestors. However, to which extent the 
position of astrocytes influences the fate of reprogrammed neurons remains unknown. To elucidate 
this, we performed stab wound injury covering an entire neocortical column, including the Grey 
Matter (GM) and White Matter (WM), and targeted local reactive astrocytes via injecting FLEx 
switch (Cre-On) adeno-associated viral vectors (AAV) into mGFAP-Cre mice. Single proneural 
factors were not sufficient for adequate reprogramming, while their combination with the nuclear 
receptor related 1 protein (Nurr1) potently improved reprogramming efficiency. Nurr1 and 
neurogenin 2 (Ngn2) in combination resulted in high efficiency reprogramming of targeted astrocytes 
into neurons that develop lamina-specific hallmarks including the appropriate long-distance axonal 
projections. Surprisingly, astrocytes in the WM entirely fail to become reprogrammed, thereby 
unveiling a crucial role of region- and layer-specific differences in astrocyte reprogramming.  
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INTRODUCTION 
 
The mammalian neocortex is a complex and highly organized structure containing many different 
types of neurons and glial cells. The intricate specificity of neuronal subtypes is established via a 
sequence of transcriptional regulators during development when neurons of different layer positions 
are generated in a sequential order from radial glial cells (Govindan and Jabaudon, 2017; Lodato and 
Arlotta, 2015; Greig et al., 2013). In the injured cerebral cortex, various combinations of transcription 
factors have been used to turn reactive glial cells (proliferating glia, NG2+ oligodendrocyte 
progenitors or GFAP+ cells; for review see (Gascón et al., 2017; Wang and Zhang, 2018)) into 
neurons. While much progress has been made since the first report describing in vivo glia-to-neuron 
reprogramming (Buffo et al., 2005), an efficient and reliable cocktail of regulators driving sustained 
and adequate reprogramming of cerebral cortex neurons is still to be revealed. Importantly, long 
distance axonal projections have never been reported for in vivo reprogrammed neurons and hence, 
little is known about the generation of adequate layer-specific neuronal subtypes achieved by such 
glia-to-neuron reprogramming in the cerebral cortex.  
Recent data has shown that astrocytes display an amazing diversity in terms of positional identity, 
partly inherited from their radial glia ancestors (John Lin et al., 2017; Bayraktar et al., 2014) or 
instructed by surrounding neurons (Farmer et al., 2016; Lanjakornsiripan et al., 2018). Indeed, 
astrocytes at different positions within the neocortical Grey Matter (GM) differ in their morphology 
and gene expression through processes acquired during development that are associated with their 
neuronal laminar organization (Lanjakornsiripan et al., 2018). This suggests that either surrounding 
neurons, or intrinsic hallmarks of astrocytes at different laminar positions, may also influence the 
neuronal identity in direct reprogramming.  
Indeed, laminar differences of excitatory projection neurons are key for cerebral cortex function. 
Pyramidal neurons differ in their identity according to their laminar position, molecular hallmarks, 
morphology and input-output connectivity (Molyneaux et al., 2007; Harris and Shepherd, 2015; 
Jabaudon, 2017). For instance, according to their laminar position, pyramidal projection neurons 
receive distinct inputs and project to different target regions in the brain, thereby exerting distinct 
roles in the cortical neuronal network (Tomassy et al., 2010; Lodato and Arlotta, 2015). For this 
reason, in order to functionally replace lost neurons upon injury, it is essential to obtain reprogrammed 
neurons recapitulating the original identity features. While this has been achieved with transplantation 
(Falkner et al., 2016), the characterization of specific neuronal subtype identities induced by 
reprogramming is still in its infancy, as only Gascon et al., 2016 reported expression of deep layer 
hallmarks in reprogrammed neurons. Thus, a comprehensive analysis of in vivo directly 
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reprogrammed neuron identity in the cerebral cortex is lacking. Moreover, we recently discovered 
profound differences in reactive gliosis between GM and White Matter (WM) in a stab wound injury 
lesion model covering the entire depth of the cortex without extending into the ventricle (Mattugini 
et al., 2018). Here, we use this model for direct reprogramming to determine if and how GM and WM 
astrocytes may differ in their reprogramming capacity. 
 
 
RESULTS 
Nurr1 supports proneural factors to achieve high efficiency direct reprogramming of cortical 
astrocyte into neurons 
Different vectors, such as lentivirus (LV), retrovirus (RV) and adeno-associated-virus (AAV) have 
been used for in vivo reprogramming, achieving a great range of reprogramming efficiencies and 
neuronal survival (Gascón et al., 2017; Wang and Zhang, 2018). However, no direct comparison of 
these vectors on long-term immunogenicity in the injured brain has been performed despite previous 
data describing substantial differences in this regard (Nayak and Herzog, 2010; Lentz et al., 2012). 
We therefore injected viral vectors commonly used in direct reprogramming into our stab wound 
injury model. The injured site was then analyzed for infiltration of leukocytes (CD45+/Iba1- cells), 
microgliosis (Iba1+ cells)  and astrogliosis (GFAP+ cells) at a time point when acute inflammation 
and reactive gliosis have normally already receded (13 days after injury; (Simon et al., 2011; Sirko et 
al., 2015)). When LV or RV were injected 3 days after stab wound and analyzed 10 days later (i.e. 
13 days after stab wound injury and 10 days post viral vector injection, dpi), CD45+ leukocytes were 
still abundant and reactive gliosis was very strong at the site of injection (Figure S1A). Conversely, 
AAVs injection shows very low levels of reactive gliosis and few immune cells in the brain 
parenchyma (Figure S1A). The low reactivity upon AAVs injection was independent of the number 
of vectors used (1 to 3) and whether or not they contained the reprogramming factors or only 
fluorescent proteins (data not shown).  
Based on these results, we used AAVs for reprogramming for cell-type specific targeting, 
independent of the proliferation status (Lentz et al., 2012). To specifically target astrocytes we used 
FLEx (flip-excision) switch AAVs which are Cre-recombinase-dependent (Cre-On) as they are in 
inverted orientation and flanked by two pairs of loxP (Figure 1A; (Atasoy et al., 2008)). These 
constructs were injected 3 days after stab wound injury as described above into transgenic mice  
(mGFAP-Cre mice) expressing the Cre recombinase under the murine promoter of GFAP (Figure 1B; 
(Gregorian et al., 2009)). This lead to Green Fluorescence Protein (GFP) expression selectively in 
astrocytes (Torper et al., 2013; Wang et al., 2016) starting at 8-10 dpi (Figure S1B). To allow 
 5 
sufficient time of gene expression we quantified GFP+ cells at 24 dpi and found that virtually all had 
astrocyte morphology (Figure 1C for GM, for WM see below) and expressed the sex-determining 
region Y-box 9 (SOX9; Figure S1C; (Sun et al., 2017)).  About 50% of these cells were also positive 
for GFAP (Figures 1D and 1E). Consistently, only a small fraction of cells (less than 10%) were 
positive for neuronal markers, such as RBFOX3 (NeuN; Figures 1D and 1E), suggesting a small 
degree of leakiness of the mGFAP-Cre expression. Importantly, this percentage did not increase at 
later time points (at 72 dpi) with mostly astrocytes and only less than 10% NeuN+ cells amongst the 
GFP population (Figures 1F and 1G). Since injections into wild type mice did not result in any GFP+ 
cells (data not shown), these controls confirm the tight Cre dependence and predominant astrocyte-
specificity of the FLEx-switch AAV constructs of this model. 
In order to directly reprogram the local reactive astrocytes into neurons, we used FLEx-switch AAVs 
containing either Neurogenin 2 (Ngn2) or Achaete-scute homolog 1 (Ascl1; Figure 1C). The 
proneural transcription factor Ngn2 is sufficient to convert astrocytes into glutamatergic neurons in 
vitro (Heinrich et al., 2010), but rather inefficient on its own in proliferating reactive glia using RVs 
(Gascón et al., 2016). Given the high leukocyte invasion and reactive gliosis elicited by the RV, we 
first tested if more neurons could be detected using the AAV-FLEx-Ngn2, injected 3 days after stab 
wound injury. However, only a small percentage of GFP+ cells was NeuN+ (Figure S2A). We then 
chose to combine AAV-FLEx-Ngn2 with AAV-FLEx-Nurr1 (nuclear receptor related 1, Nr4a2), 
given the role of the later in improving reprogramming (Gascón et al., 2016) and neuroprotection 
(Saijo et al., 2009; Sousa et al., 2007). Indeed, when AAV-FLEx vectors carrying GFP, Ngn2 and 
Nurr1 were injected simultaneously at 3 days after stab wound, a significant increase (about 53%) in 
the proportion of induced NeuN+ neurons (iNs) was observed 24 dpi, with the remainder being largely 
astrocytes (determined by morphology or GFAP; (Figures 1D and 1E). To determine whether Nurr1 
is also effective with other proneural factors, we tested this combination with GFP and Ascl1, 
previously used in other reprogramming cocktails (Masserdotti et al., 2016). AAV-FLEx-Ascl1 
injection with GFP resulted in only 20% NeuN+ iNs (Figures S2B), while its combination with GFP 
and Nurr1 doubled the proportion of iNs to about 40% (Figures 1D and 1E). Conversely, injection of 
AAV-FLEx-Nurr1 alone (Figure S2C) or the combination of AAV-FLEx-GFP, AAV-FLEx-RFP and 
AAV-FLEx-Ngn2 showed low efficiency in direct neuronal reprogramming (data not shown), 
indicating that the combination of a proneural factor with Nurr1 is necessary to achieve efficient 
reprogramming. Analysis of long-term survival at 72 dpi showed even higher proportions of neurons 
induced by Ngn2 and Nurr1 (80% NeuN+) or Ascl1 and Nurr1 (70% NeuN+; Figures 1F and 1G), 
indicating that the combination of proneural factors with Nurr1 provides a powerful and highly 
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efficient in vivo reprogramming protocol. Notably, Ngn2/Nurr1 iNs exhibited a very mature 
pyramidal cell morphology, prompting us to examine their identity in more detail.  
 
Neurons induced with Ngn2 and Nurr1 acquire mature pyramidal neuron hallmarks and 
molecular identities according to their laminar position 
To examine the identity of these Ngn2/Nurr1 iNs in more detail, we analyzed the origin, laminar 
identity, morphology and axonal projections using an AAV-FLEx expressing the fluorescent reporter 
mScarlet-I under the human synapsin (hSyn) promoter, to selectively visualize the converted neurons 
(Figure 1A).  To determine if and how iNs derive from proliferating astrocytes, EdU was provided 
directly after stab wound for 10 days, i.e. during the entire period of reactive astrocyte proliferation 
in this injury model (Mattugini et al., 2018; Buffo et al., 2008). At 24 dpi, about 1/5th (21%) of Syn-
Scarlet+ iNs were derived from proliferating EdU+ astrocytes (Figure S3A), consistent with the overall 
proliferation rate of reactive astrocytes (Buffo et al., 2008). Thus, the origin of iNs is not restricted or 
skewed to, but includes, the proliferating astrocyte population.  
As the lesion paradigm extended throughout all cortex layers, we next compared the distribution of 
iNs (labeled with a AAV-FLEx-hSyn-mScarlet-I) and endogenous neurons (labeled with a AAV-
hSyn-mScarlet-I) and found that reprogrammed neurons distribute within an entire cortical column 
(i.e. upper and lower layers), similarly to endogenous neurons (Figure S3B). In order to molecularly 
discriminate subtypes of pyramidal cells, we stained for CUX1, characteristic for upper layer neurons, 
and CTIP2 for lower layer neurons (Lodato et al., 2015). CUX1- and CTIP2-immunoreactivity was 
only weakly detected in few iNs at 24 dpi, while many more were strongly positive at 72 dpi (Figure 
S3C). Interestingly, most iNs expressing CUX1 were located in upper layers and virtually all CTIP2+ 
iNs were found at deeper positions, closely resembling the distribution of the endogenous neurons 
(Figure 2A). Remarkably, both CUX1+ and CTIP2+ iNs display a stereotypical pyramidal shaped cell 
soma, a large apical dendrite oriented radially towards the pial surface, and an elaborated basal 
dendritic arbor (Figure 2B) similar to endogenous neurons (Harris and Shepherd, 2015). This was not 
the case when combining Ascl1 and Nurr1, which instead generated iNs of more variable 
morphologies (Figure 1F) and marker expression (Figure S3D). Notably, Ngn2/Nurr1 iNs matured 
over time (Figure 2B). The number of Ngn2/Nurr1 iNs with an apical dendrite was significantly lower 
at 24 dpi compared to the endogenous neurons, while this difference was reduced at 72 dpi (Figure 
2C). Likewise, the thickness of the iN apical process grew between 24 and 72 dpi (Figure 2D), and 
the soma was initially significantly more circular at 24 when compared to both iNs at 72 dpi and 
endogenous neurons (Figure 2E), demonstrating that iNs had acquired a pyramidal neuron shape. 
Moreover, the number of primary basal dendrites was reduced between 24 and 72 dpi, indicating 
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pruning processes as observed in transplanted neurons (Falkner et al., 2016) reaching a mean number 
(Figure 2F) and orientation, highly reminiscent to the basal dendritic arbor of endogenous pyramidal 
cells (Figure 2G). Together these data show that iNs adopt over time the congruent assignment of 
laminar, molecular and morphological features of mature pyramidal neurons. 
 
Neurons induced with Ngn2 and Nurr1 develop mature spine numbers and axonal projections  
Given the morphological maturation of the iNs described above, we next examined parameters 
indicative of connectivity and synaptic integration. As spines act as postsynaptic sites, we assessed 
their number on secondary dendrites and found a significant increase from 24 to 72 dpi with 
Ngn2/Nurr1 iNs reaching numbers comparable to endogenous pyramidal neurons (Figure 3A). 
Importantly, pyramidal neurons located at different laminar positions project to distinct target regions 
(Harris and Shepherd, 2015; Molyneaux et al., 2007): neurons in lower layers predominantly send 
ipsilateral corticofugal projections, towards the striatum, thalamus, midbrain or corticospinal tract, 
while many upper layer 2/3 neurons and a subpopulation of layer 5 neurons send callosal projections 
to the contralateral cortex hemisphere (Figure 3B). Following the axonal projections from mScarlet-
I+ (Figure 3) and GFP+ (Figure S4) iNs at 72 dpi, we observed subcortical axons in the striatum (Figure 
3C), thalamus and midbrain (Figure S4A) as well as axons travelling through the corpus callosum 
and reaching the contralateral cortex (Figure 3D; Figure S4A). In order to investigate the neuronal 
subtype-specific origin of these projections, we performed retrograde labelling from the contralateral 
hemisphere by Fluorogold injection and stained for SATB2 that is characteristic of callosal projection 
neurons in layers 2/3 and 5. This confirmed that most Fluorogold+ iNs (were SATB2+ most often 
located in L2/3 but also in L5, while fewer were CTIP2+ cells in L5 (Figure 3E). Together these data 
reveal for the first time a consistent reassignment of axonal target selection by reprogrammed neurons 
after cortical injury in vivo. 
 
White Matter astrocytes fail to undergo neuronal reprogramming  
Given the amazing specificity of neuronal reprogramming seen in the GM, we turned our attention to 
cells in the WM. Surprisingly, we virtually never detected any iNs in the WM at both 24 and 72 dpi 
(Figure 4). Some animals did not even display a single GFP+ cell in the WM when using the 
neurogenic constructs (i.e. Ngn2/Nurr1 and Ascl1/Nurr1), despite GFP+ cells present in all animals 
injected with the control virus containing only GFP (Figure 4A). In the few animals, where GFP+ 
cells were detectable in the WM, the majority had maintained their astrocyte identity despite the 
expression of neurogenic factors Ngn2/Nurr1 (Figure 2B) or Ascl1/Nurr1 (Figure 4C). Thus, the 
injections and astrocyte targeting worked well also for WM astrocytes, but upon transduction with 
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neurogenic factors many seem to die rather than reprogram. Taken together, these data suggest that 
both neurogenic combinations were not sufficient to successfully convert WM astrocytes into 
neurons, while they were very efficient to reprogram GM astrocytes. 
 
DISCUSSION 
Direct neuronal reprogramming from local glial cells after injury represents a promising strategy for 
brain repair (Barker et al., 2018; Grade and Götz, 2017). However, acquisition of adequate neuronal 
subtype identity and target region innervation is key for functional repair. Here we describe a novel 
reprogramming protocol using Ngn2 and Nurr1 sufficient to turn astrocytes with high efficiency into 
mature pyramidal neurons with different laminar and axonal projection identities after stab wound 
injury. Strikingly, Nurr1 is necessary for proneural factors to achieve the high reprogramming 
efficiency and this is specific for GM astrocytes, with WM astrocytes failing to be efficiently 
reprogrammed with these factors in the same lesion paradigm. These data therefore unravel a great 
specificity for in vivo direct neuronal reprogramming that is beneficial in achieving correct neuronal 
subtypes at different layer positions, but deleterious as observed in the WM.  
 
Nurr1 is required for highly efficient astrocyte-to-neuron reprogramming  
In the cerebral neocortex, proliferating glial cells have been targeted for reprogramming into neurons 
(Gascón et al., 2017). In contrast to striatal glia that could be converted into neurons using only Sox2 
(Niu et al., 2013; Wang and Zhang, 2018) cortical glia require a combination of proneural factors 
with Sox2 or Bcl-2 to improve the reprogramming efficiency (Gascón et al., 2016; Heinrich et al., 
2014). While Sox2 resulted in immature young neurons (Heinrich et al., 2014), Ngn2 and Bcl2 
(Gascón et al., 2016) or NeuroD1 (Guo et al., 2014) achieved more mature neurons from proliferating 
GFAP- or NG2-expressing glia. However, none of these protocols have achieved adequate axonal 
projections and pyramidal neuronal hallmarks. Here, we tested several combinations of proneural 
factors and unveiled a relevant role of the orphan nuclear receptor Nurr1 in direct neuronal 
reprogramming. The combination of Nurr1 with the proneural factor Ngn2 achieved over 80% 
efficiency in converting reactive astrocytes into neurons. Notably, efficiency and maturity of the 
converted neurons was much higher when Nurr1 was combined with Ngn2, compared to the proneural 
factor Ascl1. Nurr1 has also been previously used in reprogramming cocktails in vivo and in vitro 
towards generating dopaminergic neurons (Torper et al., 2015; Rivetti di Val Cervo et al., 2017) and 
although it is a well-known factor in specifying dopaminergic neurons in the ventral midbrain, it is 
also expressed in cortical and olfactory bulb neurons (Perlmann and Wallén-Mackenzie, 2004; 
Watakabe et al., 2007; Saino-Saito et al., 2004). Moreover, Nurr1 belongs to the orphan NR4A family 
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exerting anti-inflammatory effects in different tissues (Rodríguez-Calvo et al., 2017). In the central 
nervous system Nurr1 is recruited by the NF-kB promoter to regulate inflammatory genes and inhibit 
inflammatory signals in microglia and astrocytes (Saijo et al., 2009). This may be crucial for 
reprogramming given the sensitivity of this process to reactive oxygen species (Gascón et al., 2016). 
Indeed, Nurr1 overexpression in neural stem cells upregulates trophic and survival signals to improve 
their response to oxidative stress, while downregulating cell cycle genes (Sousa et al., 2007). These 
multiple pathways controlled by Nurr1 may be key in its potent role in improving the efficiency and 
efficacy of cortical astrocyte-to-neuron reprogramming as uncovered here. 
 
Distinct reprogramming efficiencies of astrocytes from Gray and White Matter 
Astrocytes located in the GM and the WM are known to differ in many aspects and are generally 
discriminated as protoplasmic (GM) and fibrous (WM) astrocytes, respectively (Lundgaard et al., 
2014). While the former wrap synapses in the GM, the latter are more in contact with nodes of Ranvier 
in the WM. This functional difference is also reflected by many molecular differences. They express 
different levels of GFAP (Lundgaard et al., 2014) and Olig2 deletion decreases the number of WM, 
but not GM astrocytes (Cai et al., 2007). Glial cell heterogeneity significantly affects the outcome of 
brain injury (Adams and Gallo, 2018; Dimou and Götz, 2014). However, astrocyte proliferation is 
similar between WM and GM after stab wound injury during the course of the first week, after which 
it quickly declines (Mattugini et al., 2018).  
Surprisingly, WM astrocytes differ profoundly from GM astrocytes in their capability to be 
reprogrammed into neurons. One possible cause for the reprogramming failure could be an adverse 
environment as stab wound injury elicits a wave of monocyte invasion close to the WM (Mattugini 
et al., 2018). Additionally, activated microglia cells are still present in the WM 14 dpi (Mattugini et 
al., 2018), possibly contributing to render the WM environment less permissive for survival of iNs. 
In addition, the failure of iN survival in the WM may be due to the lack of neuronal input as there are 
fewer neurons surrounding the iNs in WM. Finally, given the profound differences in astrocyte gene 
expression in different brain regions (Boisvert et al., 2018; John Lin et al., 2017) WM astrocytes may 
exhibit expression profiles less amenable to neuronal reprogramming. Indeed, reactive astrocytes in 
GM increase the expression of some neurogenic transcription factors, such as Pax6, Sox4 and Sox11 
(Götz et al., 2015) that help in neuronal reprogramming (Buffo et al., 2005; Ninkovic et al., 2013). 
Thus, both intrinsic and extrinsic factors may contribute to the profoundly different outcome in the 
reprogramming capacity of GM and WM astrocytes. 
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The combination Ngn2/Nurr1 converts Gray Matter astrocytes into neurons acquiring 
neuronal subtype identities according to their laminar position  
The mammalian neocortex is a complex structure, radially organized in six layers populated by 
different subtypes of projection neurons. Each subtype exhibits unique pyramidal morphology, has a 
specific gene expression profile, and accordingly serves distinct functions (Harris and Shepherd, 
2015; Lodato and Arlotta, 2015). We report here that the combination of Ngn2 with Nurr1 not only 
achieved high efficiency in direct neuronal reprogramming, but also that the resulting iNs displayed 
mature molecular, morphological and axonal projections adequate for their laminar position. iNs 
expressed CTIP2 and CUX1 according to their laminar position. Both these iNs developed the typical 
morphology of pyramidal cells, with a prominent apical dendrite and an elaborated basal dendritic 
arbor which gradually developed to resemble that of endogenous neurons. Finally, iNs acquired spine 
density and long distance axonal projections to the striatum, midbrain and thalamus as well as the 
contralateral cerebral cortex hemisphere. Most strikingly, these projections were not random, but 
rather iNs expressing SATB2 were found to project through the callosum, as is the case normally. 
Thus, these data show for the first time adequate neuronal subtype specification by direct in vivo 
reprogramming. 
The precise identity reassignment according to the iN location raises concerns about possible viral 
labelling artefacts. However, neither GFP on its own (Figure 1), nor Ngn2 or Nurr1 combined with 
GFP (Figure S2), nor GFP and RFP combined with Ngn2 (control for use of 3 viral vectors) resulted 
in any substantial labelling of mature pyramidal neurons. Moreover, pyramidal neuron maturation 
was achieved gradually with e.g. initially more dendrites than at later mature stages, a phenotype 
difficult to explain by labelling artefactual a mature neuron. These data, together with the 20% of iNs 
achieved by Ngn2/Nurr1 transduction deriving from proliferating EdU-incorporating cells leads us to 
exclude the possibility of artefactual labelling of mature neurons and favor the conclusion that the 
targeted astrocytes convert into neurons. This then prompts the question the intriguing question of 
whether the region- and layer-specific reprogramming is driven by cell-intrinsic mechanisms or 
environmental cues. Interestingly, astrocytes located in upper versus lower layers differ not only in 
their morphology but also in gene expression (Lanjakornsiripan et al., 2018). Surrounding neurons 
may play a key role in this process, as demonstrated in the cerebellum where neuron-released Sonic 
hedgehog influenced local astrocyte transcriptional activity (Farmer et al., 2016). This supports the 
intriguing hypothesis that layer-dependent differences in cortical astrocytes might affect the outcome 
of reprogramming in terms of neuronal subtype identity. Together, these results highlight the potential 
of astrocytes as promising starting cell population for direct neuronal reprogramming upon brain 
 11 
injury and highlight the fundamental importance of astrocyte subtypes not only to determine the 
efficiency of direct neuronal reprogramming, but also the emerging neuronal subtype. 
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MAIN FIGURES TITLES AND LEGENDS 
 
Figure 1. Neurogenic factors reprogram cortical Grey Matter astrocytes into neurons after 
traumatic brain injury. 
(A) Scheme of the AAV-FLEx constructs. (B) Timeline of the experimental design. (C) 
Photomicrographs showing an overview with GFP+ cells at 24 dpi of AAV encoding for GFP, 
GFP/Ngn2/Nurr1 and GFP/Ascl1/Nurr1. (D) Photomicrographs showing GFP+/NeuN+ neurons 
(yellow arrowheads) and GFP+/GFAP+ astrocytes (white arrowheads) at 24 dpi of GFP, Ngn2/Nurr1 
and Ascl1/Nurr1. (E) Histograms showing the percentage of NeuN+ (top) and GFAP+ (middle) among 
the GFP+ cells at 24 dpi of the viral vectors indicated on the x-axis. The lower panel show a Z-
projection of NeuN and GFP colocalization at 24 dpi of GFP/Ngn2/Nurr1 neuron (dashed square). 
(F) Photomicrographs showing GFP+/NeuN+ neurons (yellow arrowheads) and GFP+/GFAP+ 
astrocytes (white arrowheads) at 72 dpi. (G) Histograms of NeuN+ (top) and GFAP+ (middle) 
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percentage and Z-projection as described above. Each dot represents one experimental animal; n = 3, 
4 and 4 for GFP, Ngn2/Nurr1 and Ascl1/Nurr1, respectively. Data are shown as median ± IQR. 
Significance between mean was tested using the t-test after testing for normal distribution with the 
Shapiro test, * p ≤ 0.05 ** p ≤ 0.01, **** p ≤ 0.0001. AAV: adeno-associated virus; dpi: days post 
injection. Scale bars: 100 µm (C left), 50 µm (C right), 10 µm (D, F). See also Figure S1 and S2. 
 
Figure 2. Neurons reprogrammed from astrocytes with Ngn2/Nurr1 acquire adequate laminar 
identity and pyramidal morphology. 
 (A) Photomicrographs of endogenous (top) and reprogrammed (bottom) neurons 72 dpi of AAV-
mScarlet-I and AAV-FLEx-mScarlet-I/Ngn2/Nurr1, respectively. CUX1 and CTIP2 intensity levels 
are layer specific. The vertical dashed line in the right panel represents the intensity threshold 
(intensity of 0.2) defining positive cells. High magnification shows the co-localization of mScarlet-
I+ with CUX1 in upper L2/3 neurons and with CTIP2 in lower L5/6 neurons outlining a mScarlet-I+ 
neuron. The heatmap shows the cell distribution in ten bins. The color-coded columns represent the 
percentage of mScarlet-I+/CUX1+ or mScarlet-I+/CTIP2+cells per bin, of the total number of 
mScarlet-I+/CUX1+ or mScarlet-I+/CTIP2+, respectively, in an entire column. Histograms illustrate 
the average of percentage for each bin; n = 5 animals. (B) Photomicrographs showing pyramidal 
morphology of mScarlet-I+ endogenous and reprogrammed neurons at 24 and 72 dpi. (C-F) 
Histograms depicting the morphological analyses of endogenous neurons, younger (24 dpi) and older 
(72 dpi) iNs for the parameters indicated in the panels, supporting the maturation process of 
reprogrammed neurons. Each dot represents one experimental animal; n = 4. Data are shown as 
median ± IQR. Significance between median was tested using the Kruskal-Wallis test followed by 
the Dunn's multiple comparisons test, * p ≤ 0.05, ** p ≤ 0.01. dpi: days post injection, L: layer. Scale 
bars: 100 µm (A and B; overview), 20 µm (A; close up), 5 µm (G). See also Figure S3. 
 
Figure 3. Neurons reprogrammed with Ngn2/Nurr1 develop spines and project to the 
appropriate brain regions.  
(A) Photomicrographs of secondary dendrite segments of endogenous (top) and reprogrammed 
(bottom) neurons at 24 and 72 dpi of mScarlet-I/Ngn2/Nurr1. Histogram on the right displays the 
number of spines per µm (spines density). Each dot represents one experimental animal; n = 4. (B) 
Cartoon summarizing examples of cerebral cortex efferent projections. (C-D) Photomicrographs 
illustrating axons of iNs at 72 dpi in the ipsilateral (C) and contralateral (D) cortical hemisphere. (E) 
Schematic drawing indicates the experimental schedule and positions of callosal neurons to the left 
with a low power overview photomicrograph depicting the Fluorogold injection site. Retrogradely 
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traced iNs at 72 dpi are mainly located in L2/3 and L5. Histograms illustrate the percentage of 
Fluorogold+ endogenous or reprogrammed neurons in L2/3 that are SATB2+/CTIP2- and in L5 that 
are SATB2+/CTIP2- or SATB2-/CTIP2+ neurons. Each dot represents one experimental animal; n = 
3. Data are shown as median ± IQR. Significance between median was tested using the Kruskal-
Wallis test followed by the Dunn's multiple comparisons test, * p ≤ 0.05. cc: corpus callosum, Crb: 
cerebellum, Ctx: cortex, dpi: days post injection, ic: internal capsule, OB: olfactory bulb, LV: lateral 
ventricle, SC: spinal cord, Str: striatum Th: thalamus. Scale bars: 100 µm (C left and D left), 50 µm 
(C right), 10 µm (D right). See also Figure S4. 
 
Figure 4. Neocortex White Matter astrocytes are not reprogrammed into neurons by Ngn2, 
Ascl1 and Nurr1 after traumatic brain injury. 
(A-C) Photomicrographs showing GFP+ cells at 24 and 72 dpi of GFP (A), GFP/Ngn2/Nurr1 (B) and 
GFP/Ascl1/Nurr1 (C). Histograms show the percentage of NeuN+, GFAP+ and NeuN-/GFAP- cells 
among the GFP+ cells for each experimental animal (3 or 4 per condition). Data are shown as median 
± IQR of different technical replicates, i.e. immunostainings of different sections. Note that in some 
animals (B and C) GFP+ cells were either not detectable or they were largely positive for GFAP 
(grey), but virtually none are NeuN+ (black) neurons. dpi: days post injection. Scale bars: 20 µm. 
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SUPPLEMENTAL FIGURES TITLES AND LEGENDS 
 
Supplementary Figure 1. Immune response to different viral vectors and identity of GFP+ 
cells after injection of only AAV-FLEx-GFP. 
(A) Photomicrographs comparing immune cells infiltration (CD45+); microglia (Iba1+) and 
astrocyte reactivity (GFAP+) in the GM of mice injected with three types of viral vectors at 3 
days after stab wound injury and analyzed 10 days post injection (dpi). Note that the high degree 
of reactive gliosis after MLV-based retrovirus (for virus see: Heinrich et al., 2014; Gascón et 
al., 2016) or differentially pseudotyped lentivirus (see Buffo et al., 2008; Heinrich et al., 2014) 
versus low reactive gliosis after rAAV2/5 injection was independent from the transgene carried 
by the viral vectors (Ngn2 or GFP control). (B-C) Photomicrographs showing GFP+ cells at 10 
(B) or 24 dpi of AAV-FLEx-GFP, double-stained for GFAP (or for SOX9) and NeuN. White 
arrowheads indicate GFP+/GFAP+ or GFP+/SOX9+ astrocytes, dashed white arrowheads 
indicate cells with an astrocytic morphology that is only GFP+ and yellow arrowhead indicate 
GFP+/NeuN+ neurons that are GFAP- or Sox9-. Histogram on the right in (C) shows the 
percentage of NeuN+, SOX9+ and NeuN-/SOX9- among the GFP+ cells. Note that most of GFP+ 
cells are GFAP+ or SOX9+ indicating their astrocyte identity. Each dot represents one 
experimental animal; n = 3. Data are shown as median ± IQR. dpi: days post injection. Scale 
bars: 50 µm (A; overview), 20 µm (B and C), and 10 µm (A; close up). 
 
Supplementary Figure 2. Identity of GFP+ cells at 24 dpi of AAVs containing GFP and 
single neurogenic reprogramming factors 
(A-C) Photomicrographs show GFP+ cells at 24 dpi of AAV-FLEx expressing single 
neurogenic factor: Ngn2 (A), Ascl1 (B) and Nurr1 (C). White arrowheads indicate 
GFP+/GFAP+/NeuN- astrocytes, yellow arrowheads indicate GFP+/NeuN+/GFAP- neurons. 
Histograms on the right show the percentage of NeuN+ neurons, GFAP+ astrocytes and NeuN-
/GFAP- cells (that are mostly astrocytes based on their morphology) among the GFP+ cells. 
Each dot represents one experimental animal; n = 3. Data are shown as median ± IQR. dpi: days 
post injection. Scale bars: 20 µm. 
 
Supplementary Figure 3. Neurons reprogrammed with Ngn2/Nurr1 distribute along the 
entire cortical column.  
(A) Photomicrographs of endogenous (left) and reprogrammed (middle) neurons 24 dpi of 
mScarlet-I and mScarlet-I/Ngn2/Nurr1 respectively, showing the co-localization with EdU. 
Quantification (right) of EdU+ cells among mScarlet-I+ neurons showing that after injury only 
reprogrammed, but not endogenous neurons incorporated EdU, confirming that some iNs derive 
from proliferating astrocytes. As the proportion of EdU+ iNs corresponds well with the overall 
proportion of proliferating astrocytes amongst reactive astrocytes, we conclude that 
proliferating astrocytes are not more likely to convert into neurons than non-proliferating 
astrocytes. Each dot represents one experimental animal; n = 3 and 5 for Endo. and Ngn2/Nurr1, 
respectively). (B) Photomicrographs and drawings show the laminar position of endogenous 
and reprogrammed neurons 72 dpi of AAVs-FLEx expressing mScarlet-I, Ngn2 and Nurr1. The 
heatmap shows the cell distribution at ten different bins. The color-coded columns represent 
the percentage of cells per bin (n = 5 animals). Histogram illustrates the average percentage of 
cells per bin. (C) Histograms show the percentage of CUX1+ (top) and CTIP2+ cells (bottom) 
among mScarlet-I+ endogenous neurons (grey) and mScarlet-I+ reprogrammed neurons (blue) 
at 24 (light blue) and 72 dpi (dark blue). Each dot represents one experimental animal; n = 4. 
Data are shown as median ± IQR. Significance between median was tested using the Kruskal-
Wallis test followed by the Dunn's multiple comparisons test (C) or the Mann-Whitney test (A), 
* p ≤ 0.05. (D) Photomicrographs showing GFP+ cells at 72 dpi of AAV encoding for GFP, 
Ascl1 and Nurr1 double-stained for various neuronal markers as indicated. Note that GFP+ cells 
are negative for interneuron markers. dpi: days post injection. Scale bars: 100 µm (B) and 20 
(A and D). 
 
Supplementary Figure 4. Neurons reprogrammed with Ngn2/Nurr1 project to the 
appropriate brain regions  
Photomicrographs showing axonal processes of reprogrammed neurons at 72 dpi in the 
ipsilateral and contralateral hemisphere. Overview sections are shown on the top left with 
squares indicating the high power magnifications shown in the bottom row. C: caudal, cc: 
corpus callosum, Crb: cerebellum, Ctx: cortex, dpi: days post injection, OB: olfactory bulb, R: 
rostral, VL: lateral ventricle, SC: spinal cord, Str: striatum Th: thalamus. Scale bars: 1 mm 
(overview), 20 µm (close up). 
 
 
 
 
 
 
STAR METHODS 
REAGENT or RESOURCE SOURCE IDENTIFIER 
Antibodies 
Rabbit anti-GFAP Dako Cat#Z0334 
Mouse IgG1 anti-NeuN Merk/Millipore Cat#MAB377 
Rabbit anti-CUX1 Santa Cruz Cat#Sc-13024 
Mouse anti-SATB2 Abcam Cat# Ab51502 
Rat anti- CTIP2 Abcam Cat#Ab18465 
Chicken anti-GFP Aves Labs Cat#GFP-1020 
Goat anti-Choline Acetyltransferase  Merk/Millipore Cat#AB 144P 
Rabbit anti-Calbindin  Merk/Millipore Cat#AB1778 
Rabbit anti-GABA Sigma Cat#A2052 
Mouse IgG1 anti-Parvalbumin Sigma Cat#P3088 
Mouse IgG1 anti-TH Merk/Millipore Cat#MAB318 
Rabbit anti-Iba1 BD/Bioscience Cat#550539 
Rat anti-CD45 Wako Cat#019-19741 
Guinea pig anti-SOX9  Professor Palle Serup 
NNF Center for Stem 
Cell Biology 
(DanStem), 
Copenhagen 
University,Denmark 
Goat anti-Chicken IgY (H+L) Secondary Antibody, Alexa 
Fluor 488 
Thermo Fischer scientific Cat#A11039 
Goat IgG anti-Rabbit IgG (H+L)-Cy3 Dianova Cat#11-165-144 
Goat anti-Mouse IgG1 Cross-Adsorbed Secondary 
Antibody, Alexa Fluor 647 
Thermo Fischer scientific Cat#A21121 
Donkey anti-Goat IgG (H+L)  Alexa Fluor 647 Jackson immunoresearch Cat#705-605-003 
DAPI Sigma Cat#28718-90-3 
Recombinant DNA 
Plasmid: pAAV-CAG-FLEx-EGFP (Torper et al., 2015)  
Plasmid: pAAV-hSyn-FLEx-pmScarletI-P2A-GCaMP6  
Tobias Rose 
Project Group Leader 
at Max Planck Institute 
of Neurobiology, 
Munich 
 
Plasmid: pAAV-hSyn-pmScarletH-P2A-GCaMP6s  
Tobias Rose 
Project Group Leader 
at Max Planck Institute 
of Neurobiology, 
Munich 
 
Plasmid: pAAV-CAG-FLEx-Ngn2  
Professor Malin 
Parmar at 
Developmental and 
Regenerative 
Neurobiology, Lund 
University 
Plasmid: pAAV-CAG-FLEx-Nurr1  (Torper et al., 2015) 
Plasmid: pAAV-CAG-FLEx-Ascl1  (Torper et al., 2015) 
Plasmid: pHelper Cell Biolabs Cat#gb AF369965.1 
Plasmid: pAAV-RC5 Cell Biolabs Cat#VPK-425 
Plasmid:LV- PRSVLTR-psi-CAG-GFP-WPRE-LTRSIN (Buffo et al., 2008)  
Plasmid: RV- CAG-Ngn2-IRES-Dsred (Heinrich et al., 2011)  
Bacterial and Virus Strains 
Stable Competent E. coli (High Efficiency) NEB Cat#C3040 
rAAV2/5 CAG-FLEx-EGFP 
SFB 870  
Viral Vector Facility 
 
N/A 
rAAV2/5 CAG-FLEx-Ngn2 
SFB 870  
Viral Vector Facility 
 
N/A 
rAAV2/5 CAG-FLEx-Nurr1 
SFB 870  
Viral Vector Facility 
 
N/A 
rAAV2/5 CAG-FLEx-Ascl1 
SFB 870  
Viral Vector Facility 
 
N/A 
rAAV2/1 hSyn-FLEx-pmScarletI-P2A-GCaMP6s 
SFB 870  
Viral Vector Facility 
 
N/A 
rAAV2/1 hSyn-pmScarletH-P2A-GCaMP6s 
SFB 870  
Viral Vector Facility 
 
N/A 
Chemicals, Peptides, and Recombinant Proteins 
OptiPrep Density Gradient Medium Sigma Cat#D1556 
SYBR Green Real-Time PCR Master Mixes Thermo Fisher scientific Cat#4385612 
Fluorogold dye (Hydroxystilbamidine) Sigma Cat#223769-64-0 
EdU (5-ethynyl-2’-deoxyuridine) Invitrogen Cat#E10187 
Click-iT™ EdU Alexa Fluor™ 647 Imaging Kit Invitrogen Cat#C10340 
Experimental Models: Cell Lines   
293T ATCC CRL-3216 
Experimental Models: Organisms/Strains  
Mouse: B6.Cg-Tg(Gfap-cre)77.6Mvs/2J also known as 
GFAP-cre line 77.6 
The jackson laboratory Stock No: 024098 
 
Mouse: C57BL/6J The jackson laboratory Stock No: 000664 
 
Oligonucleotides 
SV40 Forward primer 5′AGCAATAGCATCACAA
ATTTCACAA3′  
(D'Costa et al., 2016) 
SV40 reverse primer 5′CCAGACATGATAAGAT
ACATTGATGAGTT3′. 
(D'Costa et al., 2016) 
GFP Forward primer 5′GATGTTGTGGCGGATC
TTGA3′ 
(D'Costa et al., 2016) 
GFP reverse primer 5′CAACAGCCACAACGTC
TATATCATG3′ 
(D'Costa et al., 2016) 
Software and Algorithms 
Zen software 2.3 lite Carl Zeiss  
ImageJ 1.48v NIH https://imagej.nih.go 
 v/ij/ 
Photoshop Adobe https://www.adobe.c 
 om/en/products/phot 
 oshop.html 
Illustrator Adobe https://www.adobe.c 
 om/en/products/illust 
 rator.html 
GraphPad Prism 7.04 GraphPad Software  
Other 
FPLC GE healthcare ÄKTA prime plus 
HiTrap Q FF anion exchange chromatography column GE healthcare Cat#17505301 
 
Animals and surgery 
Animal handling and experimental procedures were performed in accordance with German and 
European Union guidelines and were approved by the State of upper Bavaria. All efforts were 
made to minimize suffering and number of animals. Mice were maintained in specific 
pathogen-free conditions in the animal facility, upon 12:12 hour light/dark cycles. 
Adult (2-3 months) heterozygous GFAP-cre mice from both genders were used for stab wound 
injury as described in Mattugini et al., 2018 with slight modifications. Briefly, animals were 
anesthetized and injured on one hemisphere from Bregma: RC: -0.4 to -1.4 mm; ML: -1.0 mm; 
DV: -1.2 mm. Three days after stab wound injury mice were injected with AAV virus in the 
site of the lesion using a microinjector at the speed of 40-50 nl/min. For control experiments 
we injected 200-300 nl of -AAV-FLEx-GFP. To label endogenous neurons we injected 200-
300 nl of AAV-mScarlet-I (non- FLEx). For reprogramming experiments, we injected 800-
1000 nl of the following mixes containing 1/2 or 1/3 of each virus: AAV- FLEx -GFP/ AAV- 
FLEx -Ngn2; AAV- FLEx -GFP/ AAV- FLEx -Ascl1; AAV- FLEx -GFP/ AAV- FLEx -Nurr1; 
AAV- FLEx -GFP/ AAV- FLEx -Ngn2/ AAV- FLEx -Nurr1; AAV- FLEx -GFP/ AAV- FLEx 
-Ascl1/ AAV- FLEx -Nurr1; AAV- FLEx -mScarlt-I/ AAV- FLEx -Ngn2/ AAV- FLEx -Nurr1. 
For retro- and lenti-viral vectors testing, wild type animals were injured at the following 
coordinates from Bregma: RC: -0.4 to -1.4 mm; ML: -1.0 mm; DV: -0.6 mm. Three days after 
stab wound injury mice were injected with 300nl of LV-GFP (VSV-G) or 800nl of RV-Ngn2-
ires-dsRed.  
Where indicated, EdU (0,2 mg/ml) was administrated in 1% sucrose drinking water for 10 
consecutives days following the stab wound lesion (between -3 and 7 dpi).  
 
Immunohistochemistry 
Mice were anesthetized and trans-cardially perfused with 4% paraformaldehyde (PFA). Brains 
were post-fixed for 24 hours in 4% PFA and then cryo-protected in 30% sucrose in Phosphate 
Buffered Saline (PBS). Fifty-micrometer-thick brain sections were cut at the vibratome and 
incubated with blocking solution composed of PBS, 2% bovine serum albumin (BSA Sigma 
Aldrich), 0,5 % Triton X-100 (Sigma Aldrich) for 20 minutes and overnight with primary 
antibodies diluted in blocking solution. The day after, free-floating sections were washed in 
PBS and incubated with appropriate secondary antibodies, diluted in the blocking solution for 
2 hours. Finally, sections were washed and stained with 4’, 6-diamidino-2-phenylindole (DAPI; 
Sigma Aldrich) for 5 minutes. EdU was detected using the Click-iT EdU imaging kit 
(Invitrogen) following the protocol from the kit.  
 
Viral vectors preparation 
High-titer preparations of rAAV2/5 were produced based on Zolotukhin and colleagues 
(Zolotukhin et al., 1999) protocol with minor modifications. In brief, HEK 293T cells were 
transfected with the CaPO4 precipitate method, pRC5, Ad helper and pAAV plasmid at a 1:1:1 
molar ratio. After 72 h, cell pellets were harvested with AAV release solution, 50 U/ml 
benzonase was added, then incubated for 2 h at 370C in a water bath. Cells were frozen and 
thawn in liquid nitrogen to allow rAAV release. Purification of rAAV vector was done with 
iodixanol densities gradient (consisting of 15, 25, 40 and 56% iodixanol), followed by gradient 
spinning at 50,000 rpm for 2 h 17 min at 220C in a Ti70 rotor (Beckman, Fullerton, CA, USA). 
rAAVs were colleted at 40% iodixanol with 5-ml-syringe. rAAVs were dialyzed (Slide-A-
Lyzer 10,000 MWCO 5ml) in buffer A overnight to remove iodixanol. Anion exchange 
chromatography column HiTrap Q FF sepharose column and superloop were connected with 
the ÄKTAprime plus chromatography system to collect the eluted fraction. To measure rAAV 
concentration, the eluted fraction was spun and washed once in PBS-MK Pluronic-F68 buffer 
with Millipore 30K MWCO 6ml filter unit. rAAVs were stored in glass vial tube in 40C. rAAVs 
were titered by SYBR Green qPCR with GFP or SV40 primer (D'Costa et al., 2016). Usual titer 
was 3 x1014 to 5x1015 gc/ml. Retrovirus and Lentivirus were prepared as already described in 
(Gascón et al., 2016; Hack et al., 2005; Heinrich et al., 2011). 
 
Retrograde labeling 
Anesthetized animals were placed in a stereotaxic apparatus and injected with Fluoro-Gold (300 
nl) into the contralateral homotypic somatosensory cortex 68 dpi, in order to retrogradely label 
callosal projection neurons. Animal were scarified 4 days later (72 dpi) and analysed. 
 
Quantification and data analysis 
All images (30-40 µm thick z-stacks) were acquired on a confocal laser scanning (Zeiss 
LSM710) microscope. At least three sections from each animal (at least 3) were analyzed for 
quantifications. All quantifications of were done using Zen or ImageJ software. The proportions 
of neurons and astrocytes were obtained by counting NeuN+, GFAP+, SOX9+, NeuN-/GFAP- 
and NeuN-/SOX9- cells among the transduced GFP+ population. For CUX1/CTIP2 analysis, the 
intensities of CUX1 and CTIP2 were measured on the cells soma of both endogenous and 
reprogrammed neurons (> 2000 mScarlet-I+ cells per condition were measured) and plotted on 
the Y axis according to their laminar position. The normalized intensity threshold defining 
positive cells for CUX1 or CTIP2 was arbitrary fixed at 0.2. The number of positive (CUX1+ 
or CTIP2+) cells was divided by the total number of m-Scarlet-I+ cells in each bin, 
representative of ten different cortical levels. For morphological analysis, 50 cells per 
conditions (endogenous and reprogrammed m-Scarlet-I+ neurons) were analyzed. The presence 
of the apical dendrite was defined by the presence of a prominent primary dendrite oriented to 
the pial surface. The thickness of the apical leading process was measured in its proximal part 
(5µm from the cell soma). The circularity was measured using an ImageJ plugin drawing the 
cell soma. The number of primary processes was calculated as the number of processes leaving 
the cell soma in each neuron. The polarization was analyzed by measuring angles between the 
apical dendrite (red dots in Figure 2) and all the others primary dendrites (gray or blue dots) 
and plotted into a circular diagram divided in 12 different bins corresponding to the 360° 
orientation angles.  For spine density, high power images were acquired and quantifications 
were done by counting only laterally emanating protrusions longer than 0.4 µm (Holtmaat et 
al., 2009). 
Statistical analyses of data were performed using the GraphPad Prism 7.0 software. All data are 
plotted as median ± IQR and each dot represent one animal. Normal distribution was tested 
using the Shapiro-Wilk test. If not rejected, we performed the t-test (unpaired two-tailed) for 
the group comparison. If rejected, significance between groups was analyzed using of Kruskal-
Wallis test followed by Dunn’s multiple comparisons test or Mann-Whitney U-test. 
Significance is based on the P-value indicated in the figures as * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 
0.001, **** p ≤ 0.0001.  
! 59 
Aim of the study II 
The aim of the study is to investigate: 
 
1. How modulating metabolism can affect direct neuronal reprogramming in 
vitro, acting on glycolysis or oxidative phosphorylation. 
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SUMMARY
Despite the widespread interest in direct neuronal
reprogramming, the mechanisms underpinning fate
conversion remain largely unknown. Our study re-
vealed a critical time point after which cells either
successfully convert into neurons or succumb to
cell death. Co-transduction with Bcl-2 greatly
improved negotiation of this critical point by faster
neuronal differentiation. Surprisingly, mutants with
reduced or no affinity for Bax demonstrated that
Bcl-2 exerts this effect by an apoptosis-inde-
pendent mechanism. Consistent with a caspase-
independent role, ferroptosis inhibitors potently
increased neuronal reprogramming by inhibiting
lipid peroxidation occurring during fate conversion.
Genome-wide expression analysis confirmed that
treatments promoting neuronal reprogramming
elicit an anti-oxidative stress response. Importantly,
co-expression of Bcl-2 and anti-oxidative treat-
ments leads to an unprecedented improvement in
glial-to-neuron conversion after traumatic brain
injury in vivo, underscoring the relevance of these
pathways in cellular reprograming irrespective of
cell type in vitro and in vivo.
INTRODUCTION
Direct reprogramming of somatic cells has proven to be an
extraordinary method to generate cell populations such as neu-
rons that are otherwise difficult to obtain for research purposes
(Amamoto and Arlotta, 2014). In addition, replenishing neuronal
populations in the injured brain using reprogramming-based ther-
apies is an exciting future prospect (Buffo et al., 2005; Hein-
rich et al., 2014). However, the cellular andmolecular basis under-
lying direct reprogramming remains poorly understood. Most
studies are restricted to the function of neurogenic repro-
gramming factors (Masserdotti et al., 2015; Ninkovic et al.,
2013; Wapinski et al., 2013), while little is known about other as-
pects, such asmetabolic changes or proliferation. As the function
of neurogenic factors is context dependent, this also prompts the
question to which extent there may be mechanisms common to
all cells types converting into neurons. For example, Neurogenin2
(Neurog2) efficiently induces neuronal conversion of mouse post-
natal astrocytes in culture (Berninger et al., 2007; Blum et al.,
2011; Heinrich et al., 2010) but is rather ineffective in mouse em-
bryonic fibroblasts (MEFs) (Chanda et al., 2014) or adult reactive
glial cells in vivo (Grande et al., 2013). While the starting cell type
may dictate conversion efficiency by providing transcriptional
accessibility of target genes (Wapinski et al., 2013), other cellular
processes shown to influence reprogramming into induced
pluripotent stem cells (iPSCs) such as cell death (Kawamura
et al., 2009), proliferation rate (Halley-Stott et al., 2014; Ruiz
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et al., 2011), or metabolic state (Zhang et al., 2012) may also be
important in direct neuronal reprogramming. Among them, the
metabolic state is particularly relevant for the conversion into neu-
rons, which rely on oxidative metabolism, while astroglia,
fibroblasts, and proliferative cells rather utilize anaerobic glyco-
lysis and b-oxidation (McKay et al., 1983; Tsacopoulos andMag-
istretti, 1996). Moreover, metabolic factors such as reactive
oxygen species (ROS) have been implicated in cell fate regulation
(Maryanovich and Gross, 2013). Here, we used continuous sin-
gle-cell live imaging to monitor direct reprogramming of fibro-
blasts and glia into neurons. We identify stage-specific barriers
and metabolic regulators increasing conversion efficiency both
in vitro and in vivo.
RESULTS
A Critical Checkpoint Eliciting Cell Death in Neuronal
Conversion
To target also postmitotic cells, we transfected astroglial cells
isolated from mouse cerebral cortex at postnatal day (P) 5–7
with a dual red fluorescent protein (RFP) and Ascl1-encoding
vector (Heinrich et al., 2010;Masserdotti et al., 2015) and tracked
RFP+ cells starting at 26–29 hr after transfection (Figure 1A). In
this model, neuronal conversion is achieved within 7 days and
can be monitored by continuous single-cell imaging. Images
were taken every 5 min in phase contrast and 5 hr in the fluores-
cence channel (RFP+; Figure 1B shows stills from such movies;
Movie S1). To follow the fate conversion we used three methods:
neuronal morphology (Figures 1B–1H and S1A; Movie S1), GFP
driven by the Doublecortin promoter (DCX-GFP; Figures S2A–
S2C; Movie S2), and immunostaining for neuron-specific
antigens (Figure 1B, lower panels; Figures S2D and S2E). The
first signs of neuronal conversion were visible by weak DCX-
GFP signals at around 24 hr of live imaging (i.e., about 2 days af-
ter transfection, see Figure 1A; Figure S2, blue line) and most
cells that became DCX-GFP+ did so within the first 2 days of im-
aging (Figures S2A1, S2B1, and S2C, blue line), i.e., about 3 days
after transfection (Figure 1A). Thus, the regulation of key
neuronal genes occurs rapidly and is implemented within few
days (see also Masserdotti et al., 2015). Within 50 hr of imaging,
i.e., about 3 days after transfection, the first Ascl1/RFP+ cells
changed from flat astrocyte to neuronal morphology (Figures
1B1 and 1C1). Noteworthy, more than 90% of cells classified
with a neuronal morphology were accordingly immuno-reactive
for b-III-tubulin and MAP2. The more mature neuronal marker
NeuNwas present only in 60%of cells with neuronal morphology
(Figures S1B and S1C). Among the cells with non-neuronal
morphology we found cells in fate transition immunoreactive
for both neuronal (b-III-tubulin) and astroglia (GFAP) markers
(Figure S1E, upper). Cells with a neuronal morphology were
never found to be double positive for GFAP and neuronal
markers (Figure S1E, lower), confirming the stringency of these
criteria.
By about 150 hr of imaging (7 days post-transfection [DPT])
most RFP+ cells had developed a neuronal morphology (Figures
1B1, 1C1, and 1D, left bars) or DCX-reporter activity (see
example in Figures S2A1, S2B1, and S2C, blue line). However,
at that time, the number of RFP+ cells had decreased dramati-
cally, with only about 18% of all RFP+ cells observed at the
beginning of the time lapse (see Movie S1) surviving to the end
(Figures 1B1, 1C1, and 1D, left bars). The peak of cell death
occurred between 50- and 100-hr imaging (Figures 1B1, 1C1,
and 1D, left bars), when fate conversion manifests by morpho-
logical changes (Figures 1B1 and 1C1). Most (94%) transfected
cells that did not acquire a neuronal morphology underwent cell
death at some point during the observation period (Figures 1D
and 1G, left bars), while only 48% of the cells with neuronal
morphology died (Figure 1H, left bar). Accordingly, most cells
surviving until the end of imaging were reprogrammed into neu-
rons (Figures 1B1, 1C1, and 1D, left bars; Figures S2A1, S2B1,
and S2C, blue line). Thus, cell death is a main limiting factor of
neuronal reprogramming and peaks at the time of fate conver-
sion. Conversely, proliferation is limited in this paradigm (Fig-
ure 1F, left bar), with most astrocytes directly converting into
neurons (Figure 1C1).
Bcl-2 Improves Fate Conversion and Survival
To improve survival during reprogramming, we first examined
the effect of the anti-apoptotic protein Bcl-2. Indeed, co-expres-
sion of Bcl-2with Ascl1/RFP in astrocytes not only increased the
total number of surviving cells, but also the number of induced
neurons (iNs), based on morphological analysis (Figures 1B–
1D), DCX-reporter activity (Figures S2A–S2C), and immunostain-
ing for b-III-tubulin and MAP2 at 5 DPT (Figures S2D and S2E).
Furthermore, continuous single cell imaging revealed a faster
conversion of Ascl1/Bcl-2 co-transfected astrocytes, with a sig-
nificant increase in the proportion of cells with neuronal
morphology in the initial phases (8-fold at 50 hr of tracking
time; Figures 1C–1E;Movie S1) and faster acquisition of DCX-re-
porter (Figures S2A–S2C; Movie S2) but no effect on cell prolifer-
ation (Figure 1F). Bcl-2 expression increased the proportion of
surviving cells in the whole transfected population (Figures 1B–
1D and S2A–S2C), while each class of cells, i.e., those with
neuronal and non-neuronal morphology, still died as much as
cells not co-expressing Bcl-2 (Figures 1G and 1H). Thus, the
main effect of Bcl-2 is to facilitate fate transition from astrocytes
to neurons, which then have a lower death rate (Figure 1I).
Continuous live imaging results were further corroborated
by immunostaining and electrophysiology. Indeed, neuronal
morphology faster acquired by Bcl-2 co-expression corre-
lated with lower resting membrane potential (RMP = !60
to !40 mV; Figures S2F and S2G) typical for immature ne-
urons (Pedroni et al., 2014), while astrocytes have a RMP
of !90 to !80 mV (Anderova´ et al., 2004) (Figures S2F and
S2G). Notably, at 5DPT, when most reprogrammed cells have
already acquired DCX-GFP, b-III-tubulin, MAP2, and NeuN
expression (Figures S1C and S1D), their electrophysiological
properties are still immature, and only 10% of Ascl1/Bcl-2
co-transfected cells exhibited some very immature action po-
tential-like features (Figure S2F3). However, iNs recorded at 15
DPT showed action potentials consistent with fully developed
neurons (Figure S2H). Taken together, these results demonstrate
that Bcl-2 improves reprogramming by faster fate conversion.
Bcl-2 Promotes the Efficiency of Neuronal Conversion
via a Non-canonical Pathway
As the Bcl-2 effect seems not only related to its anti-apoptotic
role, we examined the contribution of its canonical function via
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Figure 1. Time-Lapse Analysis of Astrocyte-to-Neuron Reprogramming
(A) Schematic of the experimental protocol used for time-lapse video analysis.
(B) Still images from video-time lapse movies (see Movie S1) showing cells classified as non-neuronal/astroglial (green arrows), neuronal (yellow arrows), and
dying (red arrows) at the time in vitro indicated transfected with the constructs indicated.
(C) Progeny-trees of single cells tracked from example in B showing astrocytes (green lines), dead cells (depicted with ‘‘x’’) and neurons (yellow lines).
(D–H) Histograms depicting cell survival and neuronal conversion from movies (n = 5 for control; 339 cells tracked; n = 4 with Bcl-2, 237 cells tracked) based on
morphological classification, as detailed and verified by immunostaining in Figures S1A–S1D. The percentage of neurons is normalized to the initial number of
transfected cells in (D) and (E).
(I) Schematic summary of reprogramming and cell death as indicated by gradients of the respective color.
Error bars indicate ± SD. **p < 0.01, ***p < 0.001, pR 0.05, no statistically significant difference (n.s.); ANOVA Tukey’s post hoc test in (D); t test in (E)–(G) and (H).
Scale bars represent 40 mm. See also Figure S1 and Movies S1 and S2.
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the interaction with the pro-apoptotic Bax/Bak. Bcl-2 inhibits
apoptosis by sequestering Bax/Bak when phosphorylated at
serine 69/70 (Deng et al., 2006) (Figure 2A). The replacement of
both Ser69/70 by glutamic acid (EE-Bcl-2) mimics the con-
stitutively phosphorylated form of Bcl-2 that sequesters Bax
(Figure 2A), while substitution of Ser70 by alanine (A(70)-Bcl-2;
Figure 2A) mimics the un-phosphorylated form of Bcl-2,
reducing the binding to Bax (Deng et al., 2006). Likewise,
A(145)-Bcl-2 is unable to bind Bax due to a Glycine145/alanine
substitution (Figure 2A; Yin et al., 1994).
Co-expression of EE-Bcl-2 increased survival of cells trans-
fected with Ascl1 (Figure 2B), but did not alter the proportion
of iNs (blue bars in Figure 2C). As expected, A(145)-Bcl-2 had
no significant effect in promoting cell survival during reprog-
ramming (Figure 2B), but surprisingly still increased the propor-
tion of Ascl1-transfected cells that turned into neurons (blue
bars in Figure 2C). Co-transduction with A(70)-Bcl-2 still re-
tained some effect on cell survival (comparable to WT-Bcl-2;
Figure 2B) and was most efficient in neuronal conversion, due
to the added effect of rescuing non-converted cells from death
and allowing them to convert more efficiently (Figure 2C, gray
and blue bars, respectively). Moreover, we also observed
increased length and complexity of the neuronal processes in
cultures co-transfected with WT-Bcl-2, A(70)-Bcl-2, or A(145)-
Bcl-2, but not with EE-Bcl-2 (Figure 2D), further supporting
an additional non-apoptotic role of Bcl-2 in neuronal
reprogramming.
Importantly, Bcl-2 also enhanced conversion efficiency ob-
tained from astrocytes transduced with Neurog2 (Figure 2E),
which inducedmature glutamatergic neurons (vGlut1+ cells, Fig-
ure 2F). Both WT-Bcl-2 and, to a greater extent, A(70)-Bcl-2
potently enhanced reprogramming of MEFs in combination
with a single neurogenic fate determinant (Ascl1, Figures 2H,
2I, S3A, and S3C; Neurog2, Figures S3B, S3E, and S3F), giving
rise to functional neurons able to fire action potentials (Fig-
ure S3D). Notably, Bcl-XL, a member of the Bcl-2 family, had a
similar effect on reprogramming as WT-Bcl-2 (data not shown).
However, in the absence of a neurogenic factor neither A(70)-
Bcl-2 nor any other Bcl-2 construct nor Bcl-XL alone were able
to induce neuronal conversion (Figures 2G and S3C; data not
shown). We thus conclude that Bcl-2-related proteins act as a
potent facilitators of direct neuronal reprogramming for different
transcription factors in different cell types and do so most
potently in the A(70)-Bcl-2 mutant form.
Mode of Cell Death in Neuronal Reprogramming
As EE-Bcl-2, the mutant that exhibits an improved anti-
apoptotic function, increases cell survival but does not improve
the proportion of iNs, we tested how different modes of cell
death affect neuron numbers. The pan-caspase/apoptosis
inhibitor Z-VAD-FMK (ZVAD, 20 mM) was added once at
day 2 to Ascl1-transfected astrocytes, resulting in a significant
increase in surviving cells (Figure 3A) without affecting the pro-
portion of iNs neither among the initially transfected cells (Fig-
ure 3B, gray bars) nor at the end point (Figure 3B, blue bars).
Thus, like EE-Bcl-2, blocking caspase activation does not
improve neuronal conversion. We then tested the effects of
RIP-K dependent necroptosis and the oxidative stress-depen-
dent ferroptosis (Dixon et al., 2012) by using their respective in-
hibitors Necrostatin-1 (Degterev et al., 2005) and Liproxstatin-1
(Friedmann Angeli et al., 2014). While Necrostatin-1 had similar
effects to ZVAD in rescuing some cells from death (Figure 3A),
but no effects on iNs (Figure 3B), Liproxstatin-1 had a potent
effect on conversion efficiency (Figure 3B). Thus, while
apoptosis and necroptosis inhibitors protect cells from death,
only the ferroptosis inhibitor liproxstatin-1 promotes both sur-
vival and neuronal conversion.
Increased Lipid Peroxidation during Neuronal
Reprogramming
Given the positive effects of Liproxstatin-1 treatment on re-
programming efficiency, we next examined lipid peroxidation
(Lip-Ox) as a hallmark of ferroptosis (Dixon et al., 2012) by us-
ing two different reporters: Click-iT lipid peroxidation kit based
on linoleamide alkyne (LAA) reagent (Life technologies) and
C11-Bodipy (Drummen et al., 2002). Astrocyte cultures treated
with cumene hydroperoxide as a positive control for Lip-Ox
had increased signal from the LAA-based reporter in almost
all cells (Figure 3C, upper row). Without any additional treat-
ment, 60% of Ascl1-transfected cells exhibited the signal for
Lip-Ox at 3 DPT, in contrast to 25% of cells transfected with
the control plasmid (Figures 3C and 3D), suggesting that
Lip-Ox occurs primarily during neuronal reprogramming.
Similar results were obtained with C11-Bodipy, which inte-
grates into phospholipid-containing membranes and shifts
from red to green fluorescence upon oxidation (Drummen
et al., 2002). We also tested a-Tocopherol (aToc, one of the
forms of vitamin E, 20mM), known to protect against Lip-Ox
(Buettner, 1993), and found that it strongly reduces Lip-Ox
LAA-signal in astrocytes undergoing neuronal conversion (Fig-
ures 3C and 3D).
Given the non-canonical effect of Bcl-2 on neuronal repro-
gramming, we examined its effect on Lip-Ox. Indeed, all forms
of Bcl-2 significantly reduced Lip-Ox, with EE-Bcl-2 being the
weakest and A(70)-Bcl-2 the strongest (Figure 3D). This result
was observed with both reporters (Figures 3D and 3E), demon-
strating a novel role of Bcl-2 in protecting from Lip-Ox most
potently in the A(70)-Bcl2mutant form.Consequently, we hypoth-
esized that any condition that reduces Lip-Ox should be benefi-
cial for direct neuronal reprogramming. Indeed, aToc treatment,
almost doubled the proportion of Ascl1/RFP reprogrammed neu-
rons obtained from astrocytes at 5DPT (Figures 4A–4C) and
improved conversion efficiency of cells co-treated with ZVAD or
co-expressing Ascl1/EE-Bcl-2 (Figures 4A and 4B). Thus, the
anti-oxidant vitamin E improves direct neuronal reprogramming.
Forskolin Promotes the Efficiency of Neuronal
Conversion and Reduces Lipid Peroxidation
We next tested whether other molecules known to improve re-
programming such as forskolin (Fk; Liu et al., 2013a) may also
alleviate Lip-Ox. First, we verified its positive effects on reprog-
ramming in astrocytes aiming to determine whether it would
act similarly from what we had observed with Bcl-2. Both in
continuous live imaging (Figures S4A–S4D) and after immuno-
staining at 5DPT (Figures 4D and 4E) we observed more cells
surviving and efficiently converting after addition of 20 mM Fk
to Ascl1-transfected astrocyte cultures. As for Bcl-2, we also
observed a faster conversion (Figures S4A–S4D) without any
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Figure 2. Non-canonical, BAX-Independent Effect of Bcl-2 on Neuronal Reprogramming
(A) Cartoon depicting previously described interactions of Bcl-2 and its mutant forms with several molecular partners as described in the text.
(B–D) Histograms (with corresponding micrographs showing immunostaining for b-III-tubulin, in D) depicting the survival and fate conversion rate at 5DPT (for
details, see Supplemental Information) in astroglial cultures transfected with the constructs indicated (n = 3; cells = 900–2,500 for each condition).
(E and I) Histograms showing the proportion of b-III-tubulin+ neurons at 7 days post infection (DPI) of astrocytes with a viral vector containing Neurog2 alone or
with Bcl-2 (E, n = 3; cells = 1,500–2,000 for each condition) or 15 DPI of MEFs with the vector indicated (I, n = 3; cells = 340–700 for each condition).
(F) Confocal micrographs showing that iNs from E are immunoreactive for vGluT1 at 15 DPI.
(G) Arrows indicate astrocytes co-transfected with Bcl-2 and RFP (Red cells) being immuno-positive for GFAP (green) and retaining astroglial morphology at
7 DPT.
(H) Micrographs of fibroblast conversion into neurons (b-III-tubulin+ cells; green) at 15 DPI upon transduction with retroviral vectors of the constructs indicated.
Error bars indicate ± SD. *p < 0.05, **p < 0.01, ***p < 0.001; ANOVA with Tukey’s post hoc test in (B), (C), and (I); t test in (E). Scale bars represent 50 mm in (D) and
(H) and 10 mm in (F). See also Figure S2.
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effect on proliferation (Figure S4E). This effect is both
transcription factor and cell type independent, as Fk also
improved reprogramming efficiency of MEFs and pericytes (Fig-
ure S5) mediated by different transcription factors (i.e., Ascl1,
Neurog2, Sox2) but did not induce neuronal conversion in
absence of any neurogenic fate determinant (Figures S4F and
S5C).
As expected, the proportion of Lip-Ox reporter-positive cells
among Ascl1-transduced astrocytes was significantly reduced
from about 60% to below 20% by Fk treatment (Figures 4F
and 4G). Likewise, CellRox Green reagent (Molecular Probes;
Figure 4H) showed high levels of nuclear green fluorescence in
Ascl1-transduced astrocytes at 3DPT, when many cells suc-
cumb to cell death, which was reduced after Fk treatment (Fig-
ure 4H). As further proof of oxidation-dependent processes
occurring during reprogramming, we monitored the oxidation
of peroxiredoxin-2, a protein involved in oxidative stress detox-
ification (Prx2; Godoy et al., 2011), by western blot. Prx2 was
predominantly detected in its dimeric (oxidized) form in astro-
cytes andMEFs 3 days after transduction with Ascl1, and dimer-
ization was reduced by Fk treatment (Figure 4I). Thus, reducing
Figure 3. Ferroptosis and Lipid Peroxidation
Are Key Limiting Factors during Neuronal Re-
programming
(A, B, and D) Histograms showing the percentage of
survival and iNs (A and B) or Lipid ROS+ cells (D,
n = 3, for RFP, Bcl-2, A(70)-Bcl-2, aToc; n = 4 for EE-
Bcl-2 and Ascl1; cells = 80–500 each condition) in
astroglial cultures treated as indicated on the x axis.
Treatment with ZVAD (20 mM), Necrostatin (10 mM),
or Liproxstatin-1 (200 nM) was performed at 1 DPT
(n = 4, A and B; cells = 1,500–2,000).
(C and E) Confocal micrographs of Lip-Ox (Life
Technologies, green reporter) staining (C, treatment
with cumene hydroperoxide 100 mM; positive control
for Lip-Ox, or aToc 10 mM; negative control for
Lip-Ox, at 1 DPT) or C11-Bodipy (E) in astrocytes
transfected as indicated at 3.5 DPT. Arrows indicate
transfected cells (red) with increased levels of Lip-Ox
(green); arrowheads show transfected cells without
green signal.
Error bars indicate ± SD. *p < 0.05, **p < 0.01, ***p <
0.001; ANOVA with Tukey’s post hoc test in (B) and
(D); ANOVA with Dunnett’s post hoc test in (A). Scale
bars represent 40 mm. See also Figure S3.
oxidative stress during reprogramming
facilitates neuronal conversion.
Genome-wide Expression Analysis
Reveals Anti-oxidative Stress
Response in Improved Neuronal
Reprogramming
To identify candidate genes regulated by
non-canonical Bcl-2 function and by Fk
treatment that may promote neuronal con-
version, we collected mRNA from different
batches of MEF cultures. These were
transduced with Ascl1/RFP- or RFP-en-
coding vectors and treated or untreated
with Fk for 24 hr (1DPT) or co-transduced with A(70)-Bcl-2-
GFP (Figure 5A). Upon Fk treatment, 507 probe sets were
significantly regulated (p < 0.01, fold changeR1.53, see Table
S1; for genes regulated after A(70)-Bcl-2 co-transduction, see
Table S2). Heat maps show the 60 strongest upregulated genes
upon Fk treatment of Ascl1-transduced cells (Figure 5B, left)
and the subset of transcriptional regulators (right). The reliability
of the transcriptome analysis was confirmed by quantitative
real-time PCR analysis (Figure 5C). As expected from the
known role of Fk, we found increased expression of genes
involved in the cAMP signaling pathway (Table S3) and many
targets of Creb, including those regulating neurite outgrowth
and cAMP-signaling mediators (Tables S1 and S3), as well as
genes promoting neuronal differentiation (e.g., Prox1, Eya2,
Sox11; Figure 5B). In addition, we found enrichment of several
signaling pathways (e.g., IL-10 and IL-1; Wnt, Bmp) and nuclear
receptors (Figure 5B; Table S3). Interestingly, some of these
genes, including Nrf-2 effectors and JAK/STAT (Tables S1
and S3), are known to regulate metabolism and the oxidative
stress response (Nguyen et al., 2009; Park et al., 2012). Gene
Ontology (GO) term analysis further supported anti-oxidative
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pathways activated by Fk, with Nrf2-mediated pathway at the
top (Table S3). Indeed, we confirmed increased Nrf2-respon-
sive luciferase activity 15 hr after Fk addition (Figure 5D).
Interestingly, Nrf2-mediated pathway was found activated by
both Fk treatment and A(70)-Bcl-2 co-expression (Table S4).
These data support the notion of excessive oxidation oc-
curring during reprogramming and Fk as well as A(70)-Bcl-2
alleviating this.
Figure 4. Increased Reprogramming Mediated by a Reduction of Lipid Peroxidation Levels Is Reproduced by Treatment with Forskolin
(A–C) Histograms show iNs (b-III-tubulin+; green inmicrographs in C) and survival rate at 5 DPT from astroglial cells transfected and treated as detailed in Figure 3
(n = 3; cells = 1,500–2,000).
(D and E) Micrographs (D) and histogram (E, n = 3; cells = 110–200) of survival rate/neuronal conversion of astroglia transfected with Ascl1/RFP (red cells) and
cultured 5 days in absence/presence of 10 mM Fk. Neuronal conversion was monitored by b-III-tubulin (green).
(F and H)Micrographs showing examples of theC11-Bodipy reporter (F) or CellROX reporter (green in H) in astrocyte cultures transfected and treated as indicated
at 3.5 DPT. Arrows depict transfected cells (red) with increased levels of ROS (green); empty arrows depict untransfected cells; arrowheads show transfected
cells with low ROS signal.
(G) Quantification of cells depicted in (F). The result with aToc treatment has been included to compare with the effect of Fk (n = 3 for Ascl1 + aToc; n = 4 for Ascl1
and Ascl1+Fk; cells = 80–250).
(I) Immunoblots showing that 24-hr treatment with Fk reduces the levels of oxidized Prx2 (dimer, upper band) in both astroglial (upper) and MEF (lower) cultures
infected with Ascl1/RFP-encoding vectors.
Error bars indicate ± SD. *p < 0.05, **p < 0.01, ***p < 0.001; ANOVA with Dunnett’s post hoc test in (A), (B), and (E); ANOVA with Tukey’s post hoc test in (G). Scale
bars represent 40 mm in (C) and (D), 20 mm in (F), and 80 mm in (H). See also Figure S4 and Movie S3.
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As vitamin D receptor (Vdr) was already implicated in the anti-
oxidative stress response (Bao et al., 2008; Dong et al., 2012), we
validated its upregulation at mRNA level in MEFs and astrocytes
(Figure 5E; see also confirmation of other nuclear receptors) and
protein level in astrocytes (Figure 5F).We then tested its effect on
Lip-Ox in astrocytes and found that co-expression of Vdr
reduced the percentage of cells positive for LAA-based reporter
to less than one-third in Ascl1-transfected astrocytes at 3.5 DPT
(Figure 5G). Accordingly, co-transfection with Vdr improved
neuronal reprogramming by Ascl1 or Neurog2 to a similar extent
as Fk (data not shown) or Bcl-2 co-transfection (Figures 5H–5K).
Co-transduction of Bcl-2 and Vdr further increased reprogram-
ming (Figures 5H–5K) reaching up to 80% neurons among
Ascl1-transduced astrocytes (Figures 5H and 5J). Taken
together, genome-wide expression analysis confirmed the key
role of oxidative stress response in regulating reprogramming,
with Vdr as the top transcriptional regulator.
The Role of Bcl-2 and Anti-oxidants in Neuronal
Reprogramming In Vivo
We next examined the relevance of the above-identified path-
ways after brain injury in vivo. Such lesions induce a highly in-
flammatory environment (Abdul-Muneer et al., 2015) that may
impose oxidative stress and other metabolic constrains to the
generation and survival of iNs. Indeed, in the intact striatum
and cerebral cortex, neuronal reprogramming was more effi-
cient (Guo et al., 2014; Niu et al., 2013; Torper et al., 2013)
than after large invasive brain injury (Buffo et al., 2005; Grande
et al., 2013; Heinrich et al., 2014). Among the previously tested
factors, we chose Neurog2, as it instructs glutamatergic neu-
rons in the developing cerebral cortex (Imayoshi and Ka-
geyama, 2014) and from astrocytes in vitro (Berninger et al.,
2007; Heinrich et al., 2010; Masserdotti et al., 2015), but ex-
hibits a limited efficiency in neuronal conversion after brain
injury in vivo (Grande et al., 2013).
Figure 5. Transcriptome and Functional
Analysis of Genes Activated by Fk and
Bcl-2
(A) Schematic drawing of the experimental pro-
tocol.
(B) Heatmaps of linear fold changes with the top
60 upregulated genes (left) or transcriptional
regulators (right) in microarrays of Ascl1+Fk
versus Ascl1 only transduced MEFs; p < 0.01,
fold-changeR 1.5.
(C) Histogram showing qRT-PCR for genes pre-
dicted to be regulated by the microarray analysis
(ratio paired t test, p < 0.01; FCR 1.5). Genes with
lower significance were also validated (p < 0.07;
shown in red).
(D) Bars represent fold change of luciferase
levels from a Nrf2-responsive construct co-trans-
fected with Ascl1 in astroglial cultures induced by
Fk (15, 24, and 48 hr) compared with untreated
cells.
(E) qRT-PCR analysis of mRNA levels from four
representative targets induced by Fk in MEFs and
astrocytes.
(F) Western blot depicting levels of Vdr protein
after 24-hr treatment with Fk in astroglia cultures
infected with RFP- or Ascl1/RFP-encoding retro-
viral vectors.
(G) Percentage of astrocytes positive for the
lipid reporter based on linoleic acid (Life
Technologies) among the Ascl1- or Ascl1+Vdr-
transfected population at 3.5 DPT. n = 3.
(H–K) Histograms and correspondingmicrographs
(J and K) depicting the neuronal conversion
efficiency of astroglial cultures transfected with
constructs indicated on x axis at 5 DPT (n = 3;
cells = 80–250).
*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001;
ratio paired t test in (C); two-way ANOVA with
Sidak’s post hoc test in (D); t test in (G);
ANOVA with Tukey’s post hoc test in (G) and (H);
ANOVA with Dunnett’s comparison test in (I).
Scale bars represent 45 mm. See also Figure S5
and Tables S1, S2, S3, and S4.
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Retroviral vectors encoding Neurog2-IRES-RFP alone or in
combination with Bcl-2-IRES-GFP were injected close to the
stab-wound injury site 3 days later (Figure 6A), as previously
described (Buffo et al., 2005; Heinrich et al., 2014), and
immunohistochemistry was performed at 10 days post-injec-
tion (DPI). GFP or Bcl-2 single (GFP+) infected cells were
NG2+ glia or S100b/GFAP+ astrocytes (Figures 6C and S6C).
Similarly, most of the cells transduced with Neurog-2 (RFP+
only) were glia and only rarely acquired the neuronal marker
NeuN (Figures 6B, 6C, and 6F; 2% in only Neurog2-infected
brains, Figure S6D). Conversely, many co-transduced cells
(GFP+/RFP+) exhibited elongated neuronal-like morphology
and were immuno reactive for DCX or NeuN (Figures 6C and
S6E). Indeed, around 75% of co-transduced cells had turned
into NeuN+ neurons with a clear neuronal morphology at 10
DPI (Figure 6F). Taken together, the addition of Bcl-2 not
only increased the number of NeuN+ iNs but also accelerated
neuronal maturation, as appearance of NeuN typically takes
about 14–21 DPI (Grande et al., 2013). Thus, as in vitro,
Figure 6. Conversion of Reactive Glia into
Neurons Is Improved by Bcl-2, Calcitriol,
and a-Tocotrienol In Vivo
(A) Scheme of the protocol used for stab-wound
injury and subsequent infection with retroviral vec-
tors for Neurog2-IRES-RFP and Bcl-2-IRES-GFP,
the respective treatments and analysis time points.
(B) High-power micrograph of cells infected by
Neurog2-IRES-RFP alone or with Bcl-2-IRES-GFP
stained for NeuN at 10 DPI, with orthogonal pro-
jections of the confocal stack. The RFP+ cell
maintains an astroglial morphology and is NeuN-
immunonegative (arrows, left), whereas the co-in-
fected cell displays a distinct neuronal-like
morphology and NeuN signal (right).
(C–E) Confocal micrographs of the injection site at
10 DPI upon the treatments indicated (C, none; D,
Calcitriol; E, aT3) stained for NeuN. Co-infected
cells immunopositive for NeuN (arrowheads) are
shown at higher magnification in single optical
sections (*, **, ***; right).
(F) Histogram with the proportion of induced,
NeuN+neuronsamongRFP+andRFP+/GFP+cells
at 10 DPI, without (n = 3) or with treatments (calci-
triol, n = 3; aT3, n = 4; 390-575 cells per condition).
(G and H) Micrographs of maximum intensity
projections of neuronal examples as indicated. In-
serts show single optical section of the NeuN+ nu-
cleus (*; white arrow). The blue and red boxes in H
(**, ***) display higher magnifications of a process
with spine-like structures.
Error bars indicate ±SD. *p < 0.05, **p < 0.01, ****p <
0.0001; two-way ANOVAwith Tukey’s post hoc test
in (F). Scale bars represent 10 mm, except 20 mm in
(B). See also Figure S6.
Bcl-2 potently improves reprogramming
speed and efficiency in vivo.
We next examined whether activating
the Vdr pathway by the ligand calcitriol
after Neurog2/RFP transduction with/
without Bcl-2/GFP would elicit a further
improvement in reprogramming. Strik-
ingly, a single calcitriol administration at 2 DPI more than
doubled the proportion of NeuN+ iNs in Neurog2-transduced
cells (Figures 6D and 6F; 3.5-fold increase in only Neurog2-in-
fected brains, see Figure S6D). Most importantly, calcitriol treat-
ment resulted in almost 90% conversion of all Neurog2/Bcl-2
co-transduced cells (GFP+/RFP+; Figures 6D and 6F), dramati-
cally increased levels of NeuN (see Figures S6F and S6G) and
improved morphology and complexity of iNs, resulting in the for-
mation of long neuronal processes (Figures 6G and S6G). More-
over, long-term analysis of iNs after calcitriol treatment often re-
vealed very elaborate neurites with bouton-like (20 DPI;
Figure 6G) and/or spine-like structures (60 DPI; Figure 6H).
Taken together, these data demonstrate that calcitriol has a
beneficial effect on the reprogramming efficiency but more
importantly on the maturation of iNs.
To confirm that the oxidative state directly affects reprogram-
ming in vivo, we administered a-Tocotrienol (aT3; Figure 6A),
the vitamin E analog described above. Similarly to calcitriol,
aT3 administration improved the conversion efficiency and
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the levels of NeuN (Figures 6E and 6F). Strikingly, cells co-
transduced with Neurog2/Bcl-2 displayed a very complex
neuronal morphology in animals treated with aT3 already at
10 DPI (Figures 6E and 7A) and had a soma size comparable
to the endogenous neurons in the same area (Figures 7A and
7B). Notably, iNs also reached this soma size after calcitriol
administration, but at a much later time points (60 DPI; see Fig-
ures 7A and S6H). Likewise, upon aT3 treatment, iNs exhibited
the first spine-like protrusions already at 10 DPI (Figure 7A, left),
further corroborating the faster iN differentiation and maturation
elicited by this anti-oxidant.
As Neurog2/Bcl-2 overexpression and aT3 administration
resulted in most developed iNs, we used this paradigm to
determine their subtype identity. Regardless of the localization
of the co-transduced cells, about 80% were immunopositive
for Ctip2 (Figures 7D and 7G), a marker for layer V subcortical
neurons (Arlotta et al., 2005; Molyneaux et al., 2007). Most
of the remainder (20%) was positive for the deep layer
Figure 7. Subtype Identity of iNs after Stab-
Wound Injury
(A and B) Confocal micrographs (maximum in-
tensity projection, A) and histogramof soma size (B)
of cells at 10 DPI by Neurog2/RFP and Bcl-2/GFP
retroviral vectors after stab-wound injury and aT3
treatment (see Figure 6A) with thick processes and
spine-like structures (box X, left). The soma size of
these cells (NeuN staining, magnified in boxes *, **,
***; arrowheads) is similar to the size of nearby
endogenous neurons (arrows), unlike for mice that
did not receive aT3 (right, magnified in ****).
(C–F) Confocal micrographs showing neuronal
subtype markers FoxP2 (C), Ctip2 (D), GABA (E),
Satb2, and Cux1 (F) at 10 DPI. Filled arrowheads
indicate immunopositive, empty arrowheads im-
munonegative cells in the squared box (*, **). Spe-
cific examples of cells located in upper or deep
layers are depicted in (F).
(G) Histogram of double infected cells expressing
the indicated markers.
Horizontal lines in (B) indicate the mean. n = 4 in
A and B (aT3); n = 3 in B (no treatment and calcitriol,
40-60 cells per condition), (C), (D), and (G) for Ctip2
and FoxP2 (80-180 cells per condition); n = 2 in (E),
(F), and (G) for Cux1 and Satb2 (40-60 cells per
condition). *p < 0.05; one-way ANOVAwith Tukey’s
post hoc test in (B). Scale bars represent 10 mm.
See also Figure S7.
marker FoxP2, albeit with lower intensity
than endogenous neurons (Figures 7C
and 7G; Molyneaux et al., 2007).
Consistent with a V pyramidal neuron
identity, iNs were negative for the
upper layer markers Satb2 (Figures 7F,
left, and 7G; Britanova et al., 2008) or
Cux1 (Figures 7F, right, and 7G; Moly-
neaux et al., 2007) and the interneuron
transmitter GABA (Figure 7E). Therefore,
we confirmed the identity of reprog-
rammed cells as deep layer glutamater-
gic pyramidal neurons, consistent with
the role of Neurog2 in cortical development (Schuurmans
et al., 2004).
DISCUSSION
Here we used continuous live imaging to unravel critical hurdles
in direct neuronal reprogramming. Neuronal conversion became
detectable around 2–4 days after transduction by live neuronal
(DCX-GFP) reporters, post-imaging immunostaining (b-III-
tubulin, MAP2, NeuN), and morphological analysis (small cell
soma and thin processes). At around the same time, most trans-
duced astrocytes succumbed to cell death, while fewer of the
successfully converted cells died, suggesting that high levels
of Ascl1may be incompatible with astrocyte survival under these
conditions. Importantly, few astrocytes proliferated—neither
prior to cell death nor prior to fate conversion. Thus, a major
limitation in reprogramming efficiency is cell death around the
time of fate conversion.
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DifferentModes of Cell Death andOxidative Stress Limit
Neuronal Reprogramming
While blocking apoptosis by caspase inhibitors and necroptosis
by RIPK1 inhibitors significantly increased cell survival, these cell
death pathways did not affect the proportion of iNs. This re-
vealed an additional block for neuronal conversion that could
be consistently relieved by ferroptosis inhibitors (Liproxstatin-1
or vitamin E). Ferroptosis is typically induced by ROS, resulting
in peroxidation of lipids due to impaired cysteine availability,
glutathione depletion and GPX4 inhibition (Dixon et al., 2012;
Friedmann Angeli et al., 2014; Yang et al., 2014). Hence, exces-
sive ROS may be generated as a consequence of instructing
reprogramming per se or specifically into neurons that use
oxidative phosphorylation. In favor of the former possibility are
the findings of an oxidative burst with deleterious consequences
during the generation of mouse iPSCs (Kida et al., 2015; Qi et al.,
2015), initiated when cells are instructed to divide fast during re-
programming (Kida et al., 2015). This is notably different from
direct neuronal reprogramming, where few cells divide and yet
increased ROS and Lip-Ox occur. We therefore favor the hypo-
thesis that this effect is due to transitioning too hastily to the
neuronal oxidative metabolism during reprogramming (see also
below).
Consistent with high oxidation levels limiting neuronal repro-
gramming efficiency, we show here that treatments beneficial
for reprogramming, such as Fk or A(70)-Bcl-2, reduce Lip-Ox
and mount an anti-oxidative response mediated by Nrf2 among
others. Various agents attenuating Lip-Ox, such as aToc, aT3,
or Calcitriol, also improve neuronal reprogramming. This is not
only of crucial importance to better understand the conversion
process into iNs but also for thewidespread application of gener-
ating neurons from different cell types (astrocytes, MEFs, peri-
cytes, etc.) with various neurogenic transcription factors (Ascl1,
NeuroD4, Neurog2, Sox2, etc.) at much increased efficiency.
An Unexpected Role for Bcl-2 In Direct Neuronal
Reprogramming
Interestingly, Bcl-2 affected both reprogramming efficiency and
speed of neuronal conversion in a manner uncoupled from its
function in apoptosis. The Bcl-2 mutant with increased affinity
for Bax/Bak and therefore improved anti-apoptotic function
(EE-Bcl-2) neither improved neuronal reprogramming nor
reduced Lip-Ox. In contrast, A(145)- and A(70)-Bcl-2 mutants,
unable to bind Bax/Bak andwith reduced anti-apoptotic function
(Deng et al., 2006; Yin et al., 1994), improved neuronal repro-
gramming, with the latter being the most effective in reducing
Lip-Ox and, consequently, enhancing reprogramming efficiency.
While this is the first time that specific Bcl-2 mutants have been
used to assess selective effects on Lip-Ox, Bcl-2 has formerly
been implicated in the regulation of both metabolic transition
and oxidative stress pathways by reducing oxidation in mito-
chondria (Krishna et al., 2011) or improvingmetabolic conversion
via interaction with, e.g., p53 or Myc (Deng et al., 2006; Jin et al.,
2006). As EE-Bcl-2 interacts strongly with Bax, its lack of effect
on reprogramming could be due to its reduced availability for
molecular partners acting in the nucleus. Conversely, A(70)-
Bcl-2 may be more efficient in improving neuronal reprogram-
ming as more of this protein may be available in the nucleus
for interaction with relevant partners.
Notably, we show that Fk and A(70)-Bcl-2 lead to common
transcriptional changes in pathways (e.g., LXR) that have been
previously implicated in neurogenesis (Theofilopoulos et al.,
2013), suggesting that nuclear interactions of Bcl-2 may explain
the particular efficiency of the A(70)-Bcl-2 mutant in direct
neuronal reprogramming. Although not precluding additional
roles of Bcl-2 at the mitochondria or other mechanisms, our
data demonstrate that the effect of Bcl-2 in reprogramming is
independent of its well-known anti-apoptotic function.
Metabolic Conversion as Critical Factor in Direct
Neuronal Reprogramming
Importantly, factors alleviating Lip-Ox also accelerate fate transi-
tion. We observed this in vivo and by continuous single-cell
tracking analysis in vitro, both upon Fk treatment and in cells
co-expressing Bcl-2 (Figures 1 and S3). Fk treatment regulates
several genes affecting the cellular redox potential, e.g., Nor-1
that promotes the endurance phenotype in oxidative muscle
fibers (Pearen et al., 2012) and Vdr that alleviates oxidative stress
in various organs (Dong et al., 2012; George et al., 2012). It has
been previously shown that ROS and redox-signaling mecha-
nisms play a key role in cell fate decisions, including neurogene-
sis (Maryanovich and Gross, 2013; Prozorovski et al., 2015),
although the molecular mechanisms mediating these effects
are not yet fully understood. In iPSC reprogramming, changes
to a more glycolytic metabolism have been shown to govern
fate conversion (Liu et al., 2013b), despite the initial oxidative
burst mentioned above (Kida et al., 2015). The faster neuronal
conversion when excessive oxidation products are successfully
controlled is consistent with (1) ROS affecting gene expression,
e.g., by altering SIRT activity, a key regulator of neurogenesis,
and (2) interfering with metabolic pathways acting upstream of
other aspects of fate conversion. If the metabolic transition is a
prerequisite for the conversion in cell fate, redox homeostasis
failure may ultimately reduce efficiency or speed of conversion.
Confirming this hypothesis, we observed that cells cultured in
a medium with oligomycin A, allowing anaerobic glycolysis as
the only metabolic pathway to generate ATP (see Supplemental
Information), preserved astroglial features and interferedwith the
conversion to a neuronal fate (Figures S7A–S7C, S7E, and S7F).
As the total cell number did not decrease much (Figures S7A and
S7F), fate conversion seems to be blocked when oxidative phos-
phorylation is hampered. Notably, cells grown in anaerobic
glycolysis-only medium were also protected from Lip-Ox (Fig-
ures S7C and S7D), demonstrating that the metabolic change
during neuronal reprogramming causes oxidative stress.
Conversely, boosting the metabolic shift with a medium contain-
ing 2-deoxy-glucose, which can only be metabolized at mito-
chondria (see Supplemental Information), caused extraordinarily
high levels of Lip-Ox (Figure S7C) in astrocytes and resulted in
cell death (Figures S7A and S7F). Overall, these experiments
demonstrate that the metabolic shift is not only necessary to
allow survival of the neurons during reprogramming but also con-
stitutes a prerequisite for cell fate transition.
Potent Improvement of Direct Reprogramming in the
Injured Brain In Vivo
Importantly, aT3 supplementation or activation of anti-oxidant
pathways by calcitriol was remarkably powerful in improving iN
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maturation from reactive glia after traumatic brain injury in vivo.
Interestingly, calcitriol treatment has been shown to reduce
glutamate-induced neuronal death in vitro and attenuate hypoxic
brain damage in vivo (Gianforcaro and Hamadeh, 2014), as well
as the fibrotic reaction upon injury in other organs (Ding et al.,
2013; Sherman et al., 2014). These data thus suggest that calci-
triol alleviates several negative effects after injury. While both
calcitriol and aT3 also improve efficiency of reprogramming
but predominantly affect maturation and neurite growth, Bcl-2
co-expression was themost efficient in increasing iNs. The com-
bined action of Bcl-2 and Calcitriol or aT3 allowed us for the first
time to achieve an in vivo reprogramming efficiency of more than
90% after stab wound injury. The neurons survived for several
months and acquired a remarkably advanced state of matura-
tion. These data demonstrate that the number of neurogenic
fate determinants was not the limiting factor in neuronal repro-
gramming after injury in vivo, as believed so far. In fact, while
applying various combinations of neurogenic transcription fac-
tors only marginally improved reprogramming in the same para-
digm (Buffo et al., 2005; Grande et al., 2013; Heinrich et al., 2014;
Kronenberg et al., 2010), co-expressing Bcl-2 and alleviating
excessive ROS had an astounding effect. Indeed, our protocol
allowed iNs to proceed largely to a specific neuronal subtype,
namely Ctip2+ pyramidal neurons even when they were located
at more superficial positions and surrounded by Cux1+ upper
layer neurons. Interestingly, Ctip2 is not a direct target of Neu-
rog2 (Masserdotti et al., 2015; Schuurmans et al., 2004) and
acts as the key effector of subcortical deep layer neuron fate
(Amamoto and Arlotta, 2014). Moreover, Neurog2 knockout
mice have selective defects in deep layer, but not upper-layer
neurons of the developing cerebral cortex (Fode et al., 2000),
supporting the concept that Neurog2 is largely involved in spec-
ifying deep-layer neuron fate in this region.
Taken together, our data on the mechanisms facilitating the
metabolic transition and redox homeostasis in neuronal reprog-
ramming have not only widespread relevance for brain injury and
repair, but also highlight the urgency of improving the timely and
coordinatedmetabolic conversion as well as protection from fer-
roptosis in aiming at neuronal repair.
EXPERIMENTAL PROCEDURES
Primary Cell Cultures
Astrocytes were cultured and transduced as described in Heinrich et al. (2010)
and MEFs as described in Vierbuchen et al. (2010).
Live-Imaging Microscopy
Time-lapse video microscopy was performed with a cell observer (Zeiss) at a
constant temperature of 37!C and 8% CO2. Phase-contrast images were ac-
quired every 5 min and fluorescence pictures every 4–6 hr for 6.5–7.5 days us-
ing a 103 phase contrast objective (Zeiss) and an AxioCam HRm camera with
a self-written VBA module remote controlling Zeiss AxioVision 4.7 software.
Movies were assembled and analyzed using ImageJ (NIH) software. For
description of the analysis, see Supplemental Information.
Analysis of Lipid Peroxidation
For the detection of lipid peroxidation, we used either the reagent Click-iT lipid
peroxidation kit based on linoleamide alkyne (LAA) reagent (Life Technologies)
or BODIPY 581/591 C11 (C11-Bodipy, Molecular Probes; Drummen et al.,
2002). Astroglial cells were first cultured and transfected as previously
described (Heinrich et al., 2010; see also Supplemental Information).
At 3.5 days later, the cells were labeled according to the specifications
described in the product data sheet and fixed with 4% paraformaldehyde
(PFA) for 5 min. Finally, the direct fluorescence of the reporters was detected
by epi-florescent microscopy.
Animal Surgery
Operations were performed in accordance with the policies of the state of
Bavaria under license number 55.2-1-54-2532-171-2011. Three days after
performing a stab-wound injury, 0.5–1.0 ml of retroviral suspension (Neu-
rog2-IRES-RFP alone or 1:1 with Bcl-2-IRES-GFP) was injected into the site
of the lesion as described by Heinrich et al. (2014). When indicated in the
text, 200 ml of Calcitriol (1 ng/ml, Tocris) or aT3 (100 mg/kg body weight; Sigma
Aldrich) diluted in corn oil was administered through oral gavage at 2 DPI. The
dosage was determined according with previous publications.
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Figure S1. Related to Figure 1 
Validation of the Morphological Criteria. 
(A) Description of the morphological criteria used to classify cells as “non-neuronal/astroglial” or “neuronal” in the 
time-lapse movies. Cells with at least one thin process (ф˂3 µm) 3x longer than the soma were classified as “neuronal”. 
The cell soma was designated as an ellipsoid located at the most prominent swelling part of the cell, at the level where 
the nucleus is located (visible by accumulation of RFP fluorescence). The largest diameter of the ellipsoid was 
measured and compared to the length of the longest thin process (see examples).  For the morphometric analysis and the 
video tracking of single cells we used the software ImageJ (FIJI version). 
(B) Examples of astrocytes transfected with Ascl1 and RFP-encoding plasmid at 5 DPT classified according to 
morphological criteria. Cells classified as neurons (lower panels) are immune-reactive for the neuronal markers β-III-
tubulin, MAP2 and NeuN, contrary to cells with an astrocyte morphology (upper panels). 
(C, D) Histograms show quantifications of the analysis from B in cultures transfected with Ascl1/RFP alone (C) or in 
combination with Bcl-2 (D).  
(E) Immunocytochemistry showing that some “non-neuronal/astroglial” cells (upper panels) transduced with Ascl1 co-
express both neuronal (β-III-tubulin, white) and astroglial (GFAP, green) markers at 5 DPT. Contrarily, cells with 
neuronal morphology (lower panels) only express neuronal markers (β-III-tubulin). 
Error bars indicate ±SD. Scale bars: 20 μm in (B, E) and 40 μm in (A). 
 
  
Figure S2. Related to Figure 2 
Analysis of Neuronal Conversion by DCX-GFP, Expression of Neuronal Markers and Electrophysiology. 
(A) Still images from time-lapse movies (Figure 1A and Movie S2) show astroglial cells (blue arrows), DCX-GFP+ 
neurons (purple arrows, GFP reporter column) and dying cells (red arrows) at different time points in cultures co-
transfected with only DCX-GFP and Ascl1 (left panels) or in combination with Bcl-2 (right panels). 
(B) Progeny-trees of single cells tracked from the examples in A showing that cells rarely proliferate during 
reprogramming. Most astroglial cells (blue lines) do not turn directly into DCX-GFP neurons (purple lines) and die 
(depicted with “x”) before converting.  
(C) Percent of transfected cells that newly acquire DCX-GFP signal at different time-points in the movies from A. 1095 
and 220 cells were counted in Ascl1 and Ascl1+Bcl-2, respectively. 
(D, E) Histograms showing the percent of cells immune-reactive for neuronal markers or having a neuronal shape, as 
indicated, among the transfected (RFP+) cells at 5 DPT (N=3). 
(F) Patch-clamp recordings from the cells transfected with only Ascl1/RFP (1-2) or in combination with Bcl-2 (3, 4) at 
5 DPT. The left panels show brightfield with a patch electrode attached (up) and red-fluorescence (down). On the right, 
the resting membrane potential and voltage-clamp is shown for all the examples. In the example 3, a current-clamp 
displays very immature action potential-like features elicited by co-transfection with Ascl1/RFP and Bcl-2. 
(G) Histogram shows quantification of resting membrane potential (RMP) in short/long cells transfected with only 
Ascl1 or in combination with Bcl-2. N=6 cells in Ascl1/long-short cells; N=10 cells in Ascl1+Bcl-2/long cells; N=8 
cells in Ascl1+Bcl-2/short cells. Note that a higher number of cells has a neuronal morphology upon Bcl-2 co-
transduction (E) and hence a higher number of cells has a more positive RMP. 
(H) Recordings from a cell transfected with Ascl1 and Bcl-2 at 15 DPT show a current-clamp trace elicited by 50 pA 
current injection with notable mature action potentials. 
Error bars indicate ±SD. *p 0.05, **p˂0.01, ***p˂0.001, ****p˂0.0001; unpaired t test in D, E, G. Scale bars 50 μm in 
A, 40 μm in F, H. 
See also Movie S2. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Figure S3. Related to Figure 3 
Bcl-2 and A(70)-Bcl-2 Enhance Neuronal Conversion of MEFs. 
(A, B) Epifluorescence images of MEF cultures co-infected with Ascl1/RFP- (A) or Neurog2/RFP- (B) encoding viral 
vectors in combination with the GFP control or Bcl-2/GFP-encoding viral vectors. Note that Bcl-2 increases the number 
of neurons immunoreactive for β-III-tubulin obtained at 14 DPI (lower panels; white cells). 
(C) Histogram showing the quantifications of experiments from A and B (N=4). 
(D) Electrophysiological recordings from the cell infected with Ascl1 and Bcl-2 and shown in brightfield in the lowest 
panel with a patch electrode attached. On the top panel, a current-clamp trace elicited by 50 pA current injection is 
shown revealing a train of action potentials, while the middle panel shows voltage-clamp traces with notable fast-
inactivating inward currents. 
(E) Epifluorescence images of MEF cultures transduced with the retroviral vector Neurog2-IRES-A(70)-Bcl-2. Note the 
high proportion of neurons immunoreactive for β-III-tubulin (green) among the transduced population (flag+; red). 
(F) Histogram showing the high increase in the conversion efficiency mediated by Neurog2- and A(70)-Bcl-2-co-
expression compared to the Neurog2-only transduced controls (N=3). 
Error bars indicate ±SD. **p˂0.01; unpaired t test in C, F. Scale bars: 40 μm. 
 Figure S4. Related to Figure 4 
Analysis of Astrocyte-to-Neuron Conversion upon Forskolin Treatment by Live Imaging. 
(A) Examples of still images from time-lapse movies (see Movie S3) show astroglial cells (green arrows), neurons 
(yellow arrows) and dying cells (red arrows) at different time points, in the presence or absence of Fk. Last image shows 
immunostaining of fixed cells confirming that all RFP+ cells are neurons (yellow arrows) expressing β-III-tubulin 
(green). Note that at the end of the movie, the number of neurons increased in Fk treated cultures (20 μM). 
(B) Progeny-trees of single cells tracked from example in A showing that cells rarely proliferate during reprogramming 
and most astroglial cells (green lines) die (dead cells depicted with “x”) before they could become neurons (yellow 
lines). Fk treatment (right diagram) resulted in faster acquisition of neuronal morphology, reduced cell death and 
increased reprogramming efficiency.  
(C) Analysis of neuronal conversion and cell survival during the observation period, in Fk treated and untreated cultures. 
The total number of astrocytes/neurons (white and black bars, respectively) is normalized to the initial number of 
transfected cells analysed at 1 DPT.  
(D) Histogram showing that neurons appear mostly in the first half of imaging time upon Fk treatment. 
(E) Histogram of the proportion of Ascl1-transfected cells proliferating during 150 h of observation with or without Fk 
treatment. Note that this value is low and not significantly increased upon Fk treatment.  
(F) Micrograph showing that Fk does not induce neuronal conversion of astrocytes (β-III-tubulin, Red) without the 
expression of neuronal fate determinants.  
N=5 in the control condition (339 initial tracked cells); N=4 in Fk treated condition (195 cells). 
Error bars indicate ±SD. *p˂0.05, **p˂0.01, ***p˂0.001, p≥0.05 no statistically significant difference (n.s.); ANOVA 
with Tukey’s post-hoc test in C; unpaired t test in D, E. Scale bars: 40 μm. 
See also Movie S3. 
 
 
 
 
 
 
 
 
 
 Figure S5. Related to Figure 5 
Widespread Effect of Forskolin in Enhancing Neuronal Reprogramming  
(A, B) Micrographs showing Ascl1- or Neurog2-transduced MEFs analysed for β-III-tubulin immunoreactivity (green) 
14 days after retroviral infection. MEF-derived neurons exhibit longer and more complex processes upon Fk treatment 
(boxed areas 1 and 2 magnified in the lower panels).  
(C) Histogram showing the proportion of β-III-tubulin+ neurons amongst control (white bars), Ascl1 (grey bars) or 
Neurog2 (black bars) transduced (RFP+) MEFs upon Fk treatment (N=3). 
(D) Micrograph showing highly complex β-III-tubulin+ processes (upper right panel) of Ascl1-infected MEFs (upper left 
panel, green cells) upon Fk addition at 25 DPI. Lower panel shows high magnification view of β-III-tubulin+ (red) 
neurites with high density of synaptobrevin (SV) puncta (green) indicating synaptic contacts. 
(E) Epifluorescence images of human pericyte-derived neurons showing β-III-tubulin-immunoreactivity (red) 4 weeks 
after infection with a viral vector co-expressing Ascl1, Sox2 and GFP (green) in cultures with (right panels) or without 
Fk addition. After Fk treatment neurons show more mature morphology, with more complex and extended neurites. 
(F) Histogram depicting the proportion of β-III-tubulin-immunoreactive cells from (E) amongst all GFP+ transduced 
cells (N=3). 
Error bars indicate ±SD. Statistical tests performed on treated and untreated cells transduced with the same transcription 
factor (Control, Ascl1, Neurog2, Dlx2). *p˂0.05, **p˂0.01, ***p˂0.001; unpaired t test. Scale bars: 40 μm. 
 
 
 
 
 
 
Figure S6. Related to Figure 6 
Calcitriol Enhances Neurog2-Mediated Reprogramming of MEFs In Vitro and Glial Cells After stab wound 
Injury In Vivo.  
(A) Epifluorescence micrographs of MEF cultures 10 days after co-transduction with Neurog2/RFP and Bcl-2/GFP in 
the absence (upper row) or presence (lower row) of calcitriol. Higher magnification (right column) of the insets shows 
the beneficial effects of calcitriol. 
(B) Histogram depicting the proportion of β-III-tubulin-immunoreactive cells amongst the MEFs co-infected with 
Neurog2/RFP and Bcl-2/GFP with or without calcitriol, at 10 days after retroviral transduction. 
(C) Confocal micrographs (maximum intensity projection) of cells infected by the retroviral vector encoding for GFP in 
vivo after stab-wound injury and immunostained for NG2, GFAP and Doublecortin (DCX) at 7 days post-injection 
(DPI). GFP+ cells are NG2+ (left panel, arrow) or GFAP+ (right panels, arrowheads). No DCX+ cells were detected 
around the lesion site. 
 (D) Quantifications of NeuN/RFP double-positive cells after stab-wound injury and subsequent injection with 
Neurog2/RFP in vivo. Mice were treated or not with calcitriol and analysed at 10 DPI as depicted in Figure 6A. 
(E) Confocal micrographs of the injection site (10 DPI, maximum intensity projection) and immunohistochemistry for 
DCX. The cells in the insets (*,**) are shown at higher magnification, with white arrowheads indicating the co-
localization of the processes with DCX. 
(F) Cells infected by Neurog2/RFP alone or with Bcl-2/GFP after stab-wound injury in vivo, analyzed at 10 DPI after 
treatment with calcitriol (Figure 6A), with magnified single optical sections (*,**) shown on the right. Some RFP+ cells 
(transduced with Neurog2 only) are NeuN-immunopositive (arrow), whereas GFP+ cells (transduced only with Bcl-2) 
never do (empty arrowheads). Co-infected cells are frequently NeuN+ (filled arrowheads).  
(G) Confocal micrographs (maximum intensity projection) showing neurons co-transduced in vivo (10 DPI) after 
treatment with calcitriol. Purple arrowheads indicate neurites emerging from adjacent neurons and growing towards the 
pial surface (above) and the white matter (below). High magnification panels on the right (*,**) show that both neurons 
have high levels of NeuN (white arrowheads), comparable to those found in native neurons around the same area (white 
arrows).   
(H) Confocal micrographs (maximum intensity projection) of cells co-infected by Neurog2/RFP and Bcl-2/GFP 
(magnified in boxes *, ** and ***; arrowheads) after treatment with calcitriol are immunoreactive for NeuN at 60 DPI. 
Note that their soma size is comparable to the one displayed by surrounding endogenous neurons (arrows). The picture at 
the bottom shows single infected cells (RFP+ or GFP+) still viable after 60 DPI and maintaining their glial nature. 
Error bars indicate ±SD. N=1 in C, E, H; N=3 in A, B, D, F, G **p˂0.01; unpaired t test in B, D. Scale bars: 40 μm in A 
and 10 μm in C, E, F-H. 
 Figure S7. Related to Figure 7 
Maintaining Glycolysis in Astroglial Cells Reduces Oxidative Stress but Blocks Reprogramming Into Neurons. 
(A) Quantification of experiments with examples of cells shown in B depicting the % of neuronal conversion normalized 
to the initial number of transfected cells (1 DPT; grey bars), at the end point (5 DPT; blue bars) and % of surviving cells 
(black bars) grown in anaerobic glycolysis-only, OxPhos-only or control medium. Note that all cells grown in OxPhos 
medium die, while cells grown in anaerobic glycolysis medium survive but fail to convert into neurons. 
(B) Micrographs of astroglial cultures transfected with Ascl1/RFP and maintained in culture for 5 days in normal 
differentiation medium (control medium) or anaerobic glycolysis medium. As previously, neuronal conversion was 
monitored by β-III-tubulin immunoreactivity (green) among the transfected population (RFP+, red). Note that cells in 
glycolysis only medium do not acquire β-III-tubulin. 
(C) Micrographs showing representative examples of Lip-Ox evaluated by C11-Bodipy reaction (green channel), of 
Ascl1/RFP transfected cells (RFP+, red) 24 hours after change with medium capable of inducing selective metabolisms 
(control medium, anaerobic glycolysis-only medium, OxPhos-only medium). Arrows indicate transfected cells (red) with 
increased levels of Lip-Ox (green); arrowheads transfected cells without green signal. Note that anaerobic glycolysis 
medium reduces Lip-Ox in transfected cells, while OxPhos medium potently increases it compared to Control medium. 
(D) Micrographs of astroglial culture at 24h in the anaerobic glycolysis-only medium already shows much reduced ROS 
signal detected by the superoxide indicator dye Dihydroethidium (DHE, 5μM, Life Technologies), which shifts from a 
blue fluorescence in the cytosol to a red fluorescence in the nucleus when oxidized.  
(E) Micrographs of astroglial cultures transduced with Neurog2/RFP and maintained 7 days in normal differentiation 
medium (control Medium, left), anaerobic glycolysis-only medium (middle) or OxPhos-only medium (right). Neuronal 
conversion was monitored by β-III-tubulin immunoreactivity (green) among the transfected cells (RFP+, red). Note that 
also Neurog2-induced reprogramming is impaired in anaerobic glycolysis medium, while cells do not survive in 
OxPhos-only metabolism. 
(F) Quantification of the experiment in E showing that the % of neuronal conversion normalized to the final number of 
transduced cells (β-III-tubulin/RFP at 7 DPI; grey bars) is drastically reduced when cells are grown in anaerobic 
glycolysis medium, while % of surviving cells (RFP/total DAPI at 7 DPI; black bars) is unaffected. 
Error bars indicate ±SD. *p<0.05, **p˂0.01; ****p<0.0001; ANOVA with Tukey’s post-hoc test in A; ANOVA with 
Holm-Sidak’s post-hoc test in F. Scale bars: 40 µm. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplemental tables 
Table S1 as Excel file. Related to Figure 5 
Genes Regulated by Forskolin. Microarray analysis of MEF cultures treated or not with Fk. All cells were transduced 
with an Ascl1/RFP- encoding vector. Shown are 507 probe sets regulated in Ascl1+Fk vs Ascl1 as defined by p<0.01, 
fold change>=1.5x, and average expression in at least one group in the dataset>20 arbitrary units. See Excel file. 
 
 
 
 
 
 
 
Table S2. Related to Figure 5 
Genes Regulated by A(70)-Bcl-2. Table shows heatmaps of the top 60 up-regulated genes based on microarray analysis 
(Ascl1+A(70)-Bcl-2 vs Ascl1; p<0.01, fold-change≥1.45). Linear fold-changes are indicated. 
 
 Table S3. Related to Figure 5 
Analysis of Pathways Regulated by Forskolin. Enrichment analysis of canonical pathways based on the set of 1321 
probe sets differentially regulated between MEF cultures treated or not with Fk (fold change>1.3x, p<0.05, Av>20). All 
cells were transduced with an Ascl1/RFP- encoding vector. Analysis was done separately for up- and down-regulated 
probes using Ingenuity Pathway Analysis software and selected significantly enriched terms (p<0.05) are shown. 
 
 Table S4. Related to Figure 5 
Analysis of Pathways Regulated by Forskolin and A(70)-Bcl-2. Enrichment analysis of canonical pathways based on 
a set of 205 probe sets upregulated in both, MEF cultures treated with forskolin and MEF cultures expressing A(70)-Bcl-
2 (each versus control cells, paired Limma test p<0.05). All cells were transduced with an Ascl1/RFP- encoding vector. 
Analysis was done using Ingenuity Pathway Analysis software and significantly enriched terms (p<0.05) are shown. 
 
 
 
Supplemental Movies Legends 
 
Movie S1. Related to Figure 1 
Time-Lapse of the Effect of Bcl-2 During Neuronal Reprogramming 
Video example showing 150 h of astroglia-to-neuron conversion of cultures transfected with plasmids encoding 
Ascl1/RFP (cells in white, left) or Ascl1/RFP+Bcl-2 (cells in white, right; see Figure 1A and 2F for more details).  
 
Movie S2. Related to Figure 1 
DCX-GFP Reporter Expression in Ascl1- and Ascl1/Bcl-2-Mediated Reprogramming.  
Video example showing 150 h of astroglia-to-neuron conversion of cultures co-transfected with the Ascl1/RFP- or 
Ascl1/RFP+Bcl-2-encoding plasmids (RFP is shown in white, right panels) and DCX-GFP (expression of GFP is shown 
in white, left panels).  
 
Movie S3. Related to Figure 4 
Time-Lapse of the Effect of Fk During Neuronal Reprogramming. 
Video example showing neuronal conversion of astroglial cultures transfected with the plasmid encoding for Ascl1/RFP 
(cells in white) and tracked for 150 h. On the right, cells were additionally treated with Fk (20 μM) 5 h before the tracking  
time started (See Figure 1A for more details). The last frames of the movie show immunostaining for RFP (red) and β-III-
tubulin (green).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplemental Experimental Procedures 
Transfection of Mouse Postnatal Astroglia Cultures 
For transfection DNA-liposome complexes were prepared in Optimem medium (Invitrogen) using the retroviral plasmids 
described below and Lipofectamine 2000 (Invitrogen). Astrocyte cultures were exposed to DNA-liposome complexes at a 
concentration of 0.5 µg DNA per 400 µl of Optimem medium for 4 hours and cultured after that in the differentiation 
medium as above. See (Heinrich et al., 2011) 
For survival analysis of transfected cells after immunostaining we counted the total number of RFP+ cells at 5 DPT and 
normalized by the total number of RFP+ cells counted at day 1. To quantify the ratio of neurons/initial transfected cells we 
counted the proportion of RFP+/β-III-tubulin+ cells at 5 DPT and normalized by the whole population of RFP+ cells at 1 
DPT.  
   
Cell Cultures of Pericyte-Like Cells from Adult Human Cerebral Cortex 
After removal of the meninges, tissue was dissected and dissociated mechanically. Subsequently, cells were centrifuged for 5 
min at 1000 rpm, re-suspended, and plated in a medium consisting of DMEM high glucose with GlutaMAX (Gibco), 20% 
fetal calf serum (Gibco), penicillin/streptomycin (Gibco). For reprogramming experiments cells were harvested and replated 
as described above after 2-3 weeks of expansion. See also (Karow et al., 2012) 
 
Cell Cultures of Mouse Embryonic Fibroblasts (MEFs) 
MEFs were obtained from mouse embryos at day 14 gestation. Head, spine and visceras were removed and discarded 
(Vierbuchen et al., 2010). The remaining tissue was dissociated with 0.15% of trypsin, centrifuged for 5 min at 1300 rpm, re-
suspended, and plated in a medium consisting of DMEM high glucose (3.5mM) with GlutaMAX (Gibco), 10% fetal calf 
serum (Gibco) and penicillin/streptomycin (Gibco) in 5% CO2 and normoxygenated conditions. Fibroblasts were used for 
experiments after minimum 3 passages. For reprogramming experiments cells were harvested and replated as described 
above for astrocytes. 
 
Glycolytic and Oxidative Media 
To force different metabolism during neuronal reprogramming, astrocytes were prepared and plated as previously described. 
At 24 hours after plating cells were either transfected with plasmid or infected with retroviral vectors and after further 24 
hours medium was replaced with one of the following. (1) Control medium, composed of DMEM without sodium pyruvate 
or glucose (Gibco), supplemented with penicillin/streptomycin, B27 supplement (Gibco), glucose (4,5gr/lt), sodium pyruvate 
(110mg/lt); (2) Glycolysis-only (Glyco) medium, composed of DMEM without sodium pyruvate or glucose (Gibco), 
supplemented with penicillin/streptomycin, B27 supplement (Gibco), glucose (4,5gr/lt), Oligomycin A (1µg/ml) (Gajewski et 
al., 2003). (3) Oxidative Phosporylation-only (OxPhos) medium, composed of DMEM without sodium pyruvate or glucose 
(Gibco), supplemented with penicillin/streptomycin, B27 supplement (Gibco), sodium pyruvate (110mg/lt), 2-Deoxy-D-
glucose (5mM) (Candelario et al., 2013; Gajewski et al., 2003) .  
 
Analysis of Redox State 
To evaluate general ROS we used the CellRox Green reagent from Molecular probes that acquires green fluorescence and 
nuclear localization via DNA binding upon oxidation. The procedure was accordingly with the manufacter’s specifications 
and the green reporter was finally detected by microscopy of living cells stained with DAPI.  
To detect ROS production from astrocytes in the different metabolic conditions, cells were loaded with the Dihydroethidium 
dye (DHE, life tech), a superoxide indicator that when oxidized intercalates within the cell´s DNA, staining its nucleus a 
bright fluorescent red. After 24 hours in the metabolic medium, cells were incubated for 15 minutes with DHE (30µM) at 
37°C, then washed 3 times in 1x phosphate-buffered saline (PBS), fixed with 4% PFA for 5 minutes and fluoresce was 
detected by microscopy (see below). 
For in vitro experiments the antioxidants αToc, Fk (Sigma) and/or calcitriol (Tocris) were supplemented once with the 
differentiation medium at 2 DPT/DPI in a final concentration of 0.5 µM, 20 µM and 70 µg/ µl, respectively. 
 
Plasmids and DNA Constructs 
For the expression of neurogenic transcription factors we used self-inactivating retroviral vectors containing the actin 
promoter with the cytomegalovirus early enhancer element and the splice acceptor of the rabbit beta-globin gene (pCAG) 
driving the expression of the gene of interest (flag/myc-Ascl1, flag-Neurog2, Bcl-2 or Dlx-2) linked to a fluorescent reporter 
by internal ribosomal entry site (IRES) as previously described (Heinrich et al., 2011). To follow the conversion process of 
astrocytes into neurons, we used a neuronal reporter plasmid with GFP driven by the doublecortin promoter (DCX-GFP) 
previously described (Franco et al., 2011). The mouse version of Bcl-2 cDNA was obtained from Source BioScience 
(IRAVp968H01145D; pCMV-SPORT6.1-Bcl-2) and the human cDNA version (h-Bcl-2) from addgene (Plasmid number 
8793; pMIG-Bcl-2-IRES-GFP) to generate RV-pCAG-flag/myc-Ascl1-IRES-Bcl-2, RV-pCAG-flag-Neurog2-IRES-Bcl-2 or 
RV-pCAG-Bcl-2-IRES-GFP, which encodes for both Bcl-2 and the reporter GFP. The Bcl-2 mutants A-Bcl-2 and EE-Bcl-2 
were produced by directed mutagenesis with the oligos 5’-ggctgccaggacggctcctctcaggcccctcgttg-3’ (and complemantary) and 
5’-gggacatggctgccagggaggagcctctcaggcccctcgttgcc-3’ (and complementary) respectively, to generate the vectors pCMV-
SPORT6.1-A-Bcl-2, RV-pCAG-Ascl1-IRES-A-Bcl-2 and RV-pCAG-Neurog2-IRES-A-Bcl-2 and the corresponding EE-Bcl-
2 versions. Mutations were verified by sequencing. The murine Vdr was obtained from Sino Biological (MG51106-G, Vector 
pGEM-T) and sub-cloned in the retroviral vector to generate RV-pCAG-Vdr-IRES-GFP. 
Viral vectors were produced with a vesicular stomatitis virus pseudotyping at titers of 106-9 and cells were infected about 24 
hours after splitting as described above. Cells were allowed to differentiate in 16% O2 and 9% CO2. 
 
Immunoblot Analysis 
The cultures were lysed in RIPA buffer (10 mM Na2HPO4, pH 7.2, 150 mM NaCl, 1% sodium deoxicolate, 1% Nonidet P-
40, 0.1% SDS) containing protease (Complete EDTA-free, Roche). Protein concentrations were determined with the BCA 
reagent from Interchim. Equal amounts of protein (50 μg) were diluted in Laemmli Sample buffer containing β-
mercaptoethanol (BioRad, 161-0747) and separated by polyacrylamide gel electrophoresis and transferred to polyvinylidene 
difluoride membranes (Pall; Life Sciences).  
For the detection of Prx1 the cells were previously incubated 15 min with PBS containing 100 mM N-ethylmaleimide (NEM, 
Sigma, E3876-5G) and collected in RIPA buffer also containing 100 mM NEM. In this case, samples were diluted in sample 
buffer without β-mercaptoethanol (Pierce, 84788). 
Immunodetection of proteins was performed by standard procedures (ECL Prime Western Blotting Detection Reagent, 
Amersham). 
 
Immunocytochemistry 
Cells were fixed in 4 % PFA in PBS for 10 min at room temperature (RT), washed in PBS and pretreated in 0.5% Triton X-
100 in PBS for 30 min, followed by incubation in 2% BSA and 0.5% Triton X-100 in PBS for 30 min. Primary antibodies 
were incubated on specimen overnight at 4°C in 2% BSA, 0.5% Triton X-100 in PBS. The following primary antibodies were 
used: polyclonal anti-Green Fluorescent Protein (GFP, chicken, 1:1000, Aves Labs, GFP-1020), polyclonal anti-Glial 
Fibrillary Acidic Protein (GFAP, rabbit, 1:4000, DakoCytomation, Z0334), polyclonal anti-Red Fluorescent Protein (RFP, 
rabbit, 1:500, Chemicon, AB3216, or 1:2000, Rockland 600-401-379), monoclonal anti β-III-tubulin (mouse IgG2b, 1:500, 
Sigma, T8660), monoclonal anti Map2 (mouse IgG1, 1:500, Sigma, M4403), monoclonal anti NeuN (mouse IgG, 1:300, 
Millipore, MAB377), polyclonal anti V-Glut1 (rabbit, 1:500, SYSY, 135302), polyclonal anti synaptobrevin (SV, rabbit, 
1:1000, SYSY). After washing in PBS, cells were incubated with appropriate species- or subclass-specific secondary 
antibodies conjugated to CyTM2, CyTM3, CyTM5 (1:500, Jackson ImmunoResearch), Alexa Fluor 488 (1:500, Invitrogen), 
FITC (fluorescein isothiocyanate, 1:500, Jackson ImmunoResearch), TRITC (tetramethyl rhodamine isothiocyanate, 1:500, 
Jackson ImmunoResearch) or biotin (1:500, Jackson ImmunoResearch or Vector Laboratories) for 2h in the dark at room 
temperature, followed by extensive washing in PBS. Following treatment with secondary antibodies conjugated to biotin, 
cells were subsequently incubated for 2h at room temperature with DAPI (1:1000, Sigma) and AMCA streptavidin (1:200, 
Vector Laboratories) or Alexa Fluor 647 streptavidin (1:500, Sigma, D9542) and mounted with Aqua Poly/Mount 
(Polysciences, Warrington, PA).  
 Luciferase assay 
To test the activity of the Nrf2 pathway, we used a Nrf2-responsive luciferase construct obtained from Qiagen (kit CCS-
5020). Accordingly with the described protocol, levels of Luciferase were normalized by the expression levels of a non-
responsive construct encoding Renilla.  
 
Immunohistochemistry 
Animals were anesthetized and transcardially perfused with PBS, followed by 4% PFA in PBS. Brains were post-fixed over-
night, washed twice with PBS and embedded in 4% agarose/water. Finally, 60μm-thick coronal sections were cut using a 
vibrating microtome (Leica). 
For immunohistology, sections were pre-incubated for 30 min in blocking solution (2% bovine serum albumin, 0.5% Triton 
X-100 in PBS). The following primary antibodies were diluted in blocking solution and incubated with the sections for 48 
hours at 4°C: chick anti-GFP (1:500, Aves Labs, GFP-1020), rabbit anti-RFP (1:500, Rockland, 600-401-379) or goat 
mCherry (1:250, Acris, AB0081-200), mouse anti-NeuN (1:250, Chemicon, MAB377), rat Ctip2 (1:250, Abcam, Ab18465), 
rabbit Cux1 (1:250, Santa Cruz, sc-13024), mouse Satb2 (1:250, Abcam, 51502), goat FoxP2 (1:250, Santa Cruz, sc-81069). 
After washing in PBS, secondary antibodies were diluted in blocking solution and incubated at room temperature for 2 hours. 
Such antibodies were chosen according to the primary ones and were coupled to Alexa Fluor 488 or FITC, Cy3, Alexa Fluor 
647 (Dianova). Sections were eventually counterstained with DAPI (1:500, Sigma) prior to mounting. 
 
RNA Extraction and Real Time Quantitative PCR (qRT-PCR) 
RNA was extracted using RNeasy Plus Micro Kit (Qiagen) according to manufacturer’s instructions, including removal of 
genomic DNA. RNA was retro-transcribed using SuperScriptIII Reverse Transcriptase and Random Primers (Roche). Each 
cDNA sample was diluted one to 5 and 1µl was used for each quantitative real time reaction. Real Time quantitative PCR 
(qPCR) was performed on a LightCycler480 instrument (Roche) using LightCycler Probe Master kit (Roche) and Monocolor 
Hydrolysis Probe (UPL) Probe (Roche) according to manufacturer’s instructions (20µl final volume). The expression of each 
gene was analyzed in triplicate. Data were processed with the ''Ct method (Livak and Schmittgen, 2001). Quantification 
was performed on 3 independent biological samples. 
 
Microarray Analysis Procedure. 
Total RNA (30 ng) was amplified using the Ovation Pico WTA System V2 in combination with the Encore Biotin Module 
(Nugen). Amplified cDNA was hybridized on Affymetrix Mouse Gene 2.0 ST arrays. Staining and scanning was done 
according to the Affymetrix expression protocol including minor modifications as suggested in the Encore Biotion protocol. 
Expression console was used for quality control and to obtain normalized RMA gene-level data. Statistical analyses were 
performed by utilizing the statistical programming environment R (Team, R. D. C., R: A language and environment for 
statistical computing. 2005) implemented in CARMAweb (Rainer et al., 2006). Genewise testing for differential expression 
was done employing the limma t-test. Sets of regulated genes were defined by p<0.01 (507 probe sets) or p<0.05 (1321 probe 
sets), including filters for fold change>=1.5x and average expression in at least one group in the dataset>20 arbitrary units. 
Heatmaps were generated with CARMAweb and pathway enrichment analyses were generated through the use of IPA 
(Ingenuity® Systems, www.ingenuity.com).  
Array data has been submitted to GEO under the accession number GEO: GSE70921 
 
Microscopy 
Immunostainings were analyzed with a LSM710 laser-scanning confocal or Axio Observer Z1 epifluorescence microscope 
(Carl Zeiss). Digital images were captured using the ZEN software (Carl Zeiss) and cell counts of all RFP/GFP 
immunoreactive cells performed with a 10X objective. 
 
Live Imaging Microscopy Analysis 
For quantifications, cells were tracked in every frame and proliferation, neuronal conversion or cell death was analyzed for 
every single cell in each movie. For quantification of proportion of dead neurons or astrocytes we counted cells dying as 
positive events and classified them as neurons or astrocytes according to their morphology described in Figure 1. Next we 
add to this value the number of surviving cells (astrocytes or neurons in each group) at the end of the tracking period. This 
result is the total population for each lineage (dead + surviving astrocytes or neurons). Finally we normalized the proportion 
of dead neurons (counted as described) to the total population of neurons (calculated as described) and the same process was 
done for astrocytes. 
 
Patch-Clamp Method 
Transfected GFP+ or RFP+ cells were recorded using the patch-clamp technique in the perforated-patch or whole-cell 
configurations.For the perforated-patch, fire-polished patch pipettes with 4-6 MΩ resistance were front-filled with 
intracellular solution containing Amphotericin B (0.33 μg /ul) and backfilled with Amphotericin-free intracellular solution (in 
mM: 4 KCl, 2 NaCl, 0.2 EGTA, 135 K-Gluc, 10 HEPES, 4 ATP, 0.5 Na-GTP; pH = 7.3, 290 mOsm). Experiments were 
performed at room temperature with constant flow (2 ml/min) of the extracellular solution (in mM: 3 KCl, 140 NaCl, 2 
CaCl2, 2 MgCl2, 10 HEPES, 5 Glucose; pH = 7.4, 305 mOsm). For the whole-cell configuration, the cells were kept in 
following extracellular solution (in mM: 125 NaCl, 3 KCl, 1.25 NaH2PO4, 25 NaHCO3, 25 D-Glucose, 0.4 Ascorbic acid, 2 
CaCl2, 2 MgCl2; pH = 7.4, 310-330 mOsm) oxygenated by 95% O2/5% CO2 with constant fluid flow (2ml/min) at room 
temperature. The cells were recorded at 5 days post-transfection in the whole-cell configuration (4-6 MΩ electrodes) with the 
following intracellular solution (in mM: 135 K-Gluconat, 4 KCl, 2 NaCl, 10 HEPES, 0.2 EGTA, 4 ATP, 0.5 NaGTP, 10 
Phospho-Kreatin; pH = 7.3, 290-300 mOsm). The passive membrane properties were recorded using the membrane test 
paradigm of the pClamp software (Molecular Devices, Sunnyvale, CA, USA). In the voltage-clamp mode, a series of 10 mV 
rectangular pulse increments (50 ms long) ranging from -120 mV to +100 mV was used. Data were sampled at 10-30-μs 
intervals and low-pass filtered at 2 kHz using the Axopatch 200B 4-pole Bessel filter (Molecular Devices). Leak currents 
were subtracted after the test pulse using five repeated 10 mV negative pulses from a holding potential of −120 mV. The 
current-voltage relation expressed the steady-state whole-cell current (at 40 ms of the rectangular pulse) as a function of the 
voltage command. In the current clamp, 1 second current injections of 10 pA increments were applied from 0 to 150 pA. All 
recorded cells were photographed both in the brightfield and the fluorescence using a CCD digital camera (Orca-D2, 
Hamamatsu, Herrsching, Germany). 
 
Quantifications and statistics 
All error bars in this work indicate ±SD. Statistical analyses were performed with GraphPad Prism 4 software by using t test 
or ANOVA with different post-hoc tests (Tukey’s, Holm-Sidak’s or Dunnett’s). All the transfected cells from 3 coverslips 
were counted for each experiment with at least 3 independent experimental batches. Retroviral vector-transduced cells were 
quantified from five randomly chosen 10x fields in 3 different wells for each experiment in at least 3 independent 
experiments.  
For in vivo experiments, pictures of the injected area were acquired with a confocal microscope (Zeiss) using 40x 
magnification. Cells infected by either one virus or both were quantified according to NeuN immunoreactivity, in animals 
treated and untreated with calcitriol or α-Tocotrienol, with the open-source software Fiji (http://fiji.sc/Fiji). For the volume 
estimation, we applied the plugin Volumest on NeuN immunostaining of co-infected cells. The data were tested for 
significance using t test and one- or two-way ANOVA analysis (no repeated measurements) with Tukey’s correction for 
multiple comparisons (Prism 6, GraphPad). Asterisks in the plot represent multiplicity adjusted P-values. 
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Aim of the study III 
The aim of the study is to investigate: 
 
1. How astrocytes and neurons differ in term of metabolic properties and 
mitochondria composition, evaluating if mitochondria reorganization occurs 
during direct neuronal reprogramming and how manipulating mitochondrial 
proteome can affect neuronal conversion. 
 
 
 
Mitochondrial reprogramming using dCas9 boosts 
glia-to-neuron conversion 
Gianluca Luigi Russo, Giovanna Sonsalla, Christopher Thomas Breunig, 
Juliane Merl-Pham, Sabine Schmitt, Martin Jastroch, Hans Zischka, Stefan 
Stricker, Stefanie M. Hauck, Giacomo Masserdotti and Magdalena Götz 
 
 
For this paper I performed most of the experiments and analysed all the data, 
with the exception of the proteomic analysis done by Merl-Pham Juliane and 
Hauck M. Stephanie. I wrote and revised the first draft of the manuscript with 
Magdalena Götz, which was further reviewed and edited by us and all other 
authors. 
 
The project is finalized in a manuscript that will be submitted in the next 
month to Cell Stem Cell. 
 
 
 
 
 
 
 
 
Note that due to elevated number of pages Table 1, Supplementary Table 1 and 
Supplementary Table 2 are not included in the PDF version of the thesis, but are available 
as separated excel files. 
1"
"
Mitochondrial reprogramming using dCas9 boosts glia-to-neuron conversion 
Gianluca Luigi Russo1,2,3, Giovanna Sonsalla1,2,3, Christopher Thomas Breunig4,5, Juliane Merl-Pham6, 
Sabine Schmitt7, Martin Jastroch9,+, Hans Zischka7,8, Stefan Stricker4,5, Stefanie M. Hauck6,#, Giacomo 
Masserdotti1,2 and Magdalena Götz1,2,10,#,* 
1 Physiological Genomics, Biomedical Center, Ludwig Maximilians Universitaet Munich, Germany.  
2 Institute for Stem Cell Research, Helmholtz Center Munich, Neuherberg, Germany.  
3 Graduate School of Systemic Neurosciences, Biomedical Center, Ludwig Maximilians Universitaet Munich, 
Germany.  
4 MCN Junior Research Group, Munich Center for Neurosciences, Biomedical Center, Ludwig Maximilians 
Universitaet Munich, Germany.  
5 Epigenetic Engineering, Institute of Stem Cell Research, Helmholtz Zentrum, German Research Center for 
Environmental Health, Planegg-Martinsried, Germany.  
6 Research Unit Protein Science, Helmholtz Zentrum Munich, German Research Center for Environmental 
Health (GmbH), Munich, Germany.  
7 Institute of Molecular Toxicology and Pharmacology, Helmholtz Center Munich, Neuherberg; Institute of 
Toxicology and Environmental Hygiene, Technical University Munich, Munich, Germany.  
7 Institute of Toxicology and Environmental Hygiene, Technical University Munich, School of Medicine, 80802 
Munich, Germany. 
8 Institute of Molecular Toxicology and Pharmacology, Helmholtz Center Munich, German Research Center for 
Environmental Health, 85764 Neuherberg, Germany. 
9 Helmholtz Diabetes Center & German Diabetes Center (DZD), Helmholtz Center Munich, Neuherberg; 
Division of Metabolic Diseases, Technical University, Munich, Germany. 
10 Excellence Cluster of Systems Neurology (SYNERGY), Munich, Germany.  
 
+Present address: Department of Molecular Biosciences, The Wenner-Gren Institute, The Arrhenius Laboratories 
F3, Stockholm University, SE-106 91 Stockholm, Sweden. 
# Co-Last authors 
*Corresponding author: Magdalena.goetz@helmholtz-muenchen.de 
 
Abstract 
Astrocyte to neuron conversion has developed into a promising avenue for neuronal replacement 
therapy. However, during the reprogramming process excessive ROS production causes death by 
ferroptosis. To ease the metabolic conversion process, we set out to determine the differences in the 
mitochondrial proteome of cortical neurons and astrocytes to then ask if inducing the expression of 
neuron-specific mitochondrial proteins may help the conversion. Proteome analysis of isolated intact 
and functional mitochondria revealed profound differences in the mitochondrial proteome of cortical 
astrocytes and neurons. During Neurogenin2- or Ascl1-induced reprogramming, neuron-specific 
mitochondrial proteins are typically induced 5-7 days post transduction, while astrocyte-specific 
mitochondrial proteins are only partly down-regulated at this stage. Thus, conversion of the 
mitochondrial proteome is incomplete and occurs late during the process. To improve the acquisition 
of neuron-specific mitochondrial hallmarks, we used dCas9 technology to induce e.g. Prdx2 and Sod1, 
enriched in neuronal mitochondria. This resulted not only in seven fold increased conversion into 
neurons, but also speeded up the process, as shown by continuous live imaging in vitro. Taken 
together, reprogramming mitochondria in a cell type-specific manner has powerful effects on astrocyte 
to neuron conversion, suggesting mitochondria to be a driving force for this conversion process.   
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Introduction 
The ability to regenerate lost neurons, after an injury or degenerative disease, is still a key challenge in 
the field of regenerative medicine. Several approaches to replace degenerated neurons are pursued, 
ranging from recruitment of endogenous cells or transplantation of neurons to the use of direct 
conversion of local glial cells for neuronal replacement (Barker et al., 2018; Grade and Götz, 2017). 
Indeed, direct glia-to-neuron reprogramming, first demonstrated after traumatic brain injury (Buffo et 
al., 2005), has become a viable option to replace functional neurons in different brain regions (Gascón 
et al., 2017; Heinrich et al., 2015; Li and Chen, 2016). However, the long-term survival of the induced 
neurons is still a major obstacle, and little is known about how adequate their metabolic conversion 
actually is. We have previously described the increased production of reactive oxygen species (ROS) 
during the conversion process reduces the efficiency of neuronal generation in vitro and in vivo 
(Gascón et al., 2016). The co-expression of Bcl2, or pharmacological application of ROS scavengers 
drastically improved the conversion and survival of induced neurons, but long-term survival of these 
neurons was still compromised.   
Reactive oxygen species (ROS), highly reactive reduced forms of molecular oxygen, are physiological 
byproducts of the mitochondrial electron transport chain (ETC), possessing important signaling 
function but also harmful effects (Ito and Suda, 2014). For this reason, cells with strong reliance on 
oxidative phosphorylation (OxPhos), such as neurons (Harris et al., 2012), are likely to produce a 
higher amount of ROS, and hence require antioxidant scavengers to prevent excessive ROS-mediated 
damage. Surprisingly, neurons are extremely sensitive to oxidative stress, expressing antioxidative 
proteins at lower concentration and activity than astrocytes (Wang and Michaelis, 2010). The tight 
interplay of neurons with the surrounding astrocytes, which mostly rely on glycolysis, fatty acid 
oxidation and gluconeogenesis for cellular energy production (Bélanger et al., 2011; Panov et al., 
2014), provides them with the substrates to survive in situations of intense metabolic activity 
(Fernandez-Fernandez et al., 2012). As such, in situation of stress, neurons are the first cells to die, 
while metabolically versatile astrocytes provide a first barrier to oxidative-damage (Burda and 
Sofroniew, 2014; Chen et al., 2009).  
In direct neuronal reprogramming neurons are generated from different somatic cells. This involves 
for most cells a transition to higher ATP demand, thus an increase in Oxphos and mitochondrial 
activity, with the potential side effect of increased oxidative stress, previously observed during the 
process (Gascón et al., 2016). However, beyond regulating ROS levels and redox homeostasis, 
mitochondria perform a plethora of functions within the cell. As primary hub for metabolic regulation, 
mitochondria catabolize nutrients for energy production, generate precursors for macromolecule 
biosynthesis and manage metabolic waste (Spinelli and Haigis, 2018). All these functions have great 
impact on cell fate regulation. For example, amino acid metabolism and mitochondria-derived co-
factors, or intermediates, such as NAD+ and acetyl-CoA, together with redox-mediated signaling 
cascades, act as master regulators of transcriptional and epigenetic regulation of gene expression 
(Gascón et al., 2017; Janke et al., 2015; Lu and Thompson, 2012; Ryall et al., 2015). As metabolic 
functions differ amongst cell types (Folmes et al., 2012), specific mitochondrial proteins are likely to 
implement some of these cell type-specific functions (Calvo and Mootha, 2010; Pagliarini et al., 
2008). It is thus surprising that the mitochondrial protein composition has hardly been explored at 
comprehensive level in different CNS cell types (Graham et al., 2017; Völgyi et al., 2015), with no 
mitochondrial proteome of astrocytes or any information about changes in mitochondrial proteins in 
direct neuronal reprogramming. While interesting results have been achieved by determining the 
mitochondrial proteome of different muscle cells (Murgia et al., 2015), most often mitochondria are 
examined in whole tissue or a mixture of cell types (Forner et al., 2006). Thus, the proteome of 
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mitochondria from cortical astrocytes and neurons has not yet been examined by unbiased, 
comprehensive proteome analysis.  
Therefore, we set out here to determine the mitochondrial proteome of cortical neurons and astrocytes 
in vitro, to then explore the extent to which activating neuron-specific mitochondrial proteins may 
help the conversion process. This is achieved by employing dCas9-mediated transcriptional 
engineering, which allow targeting and regulating several genes simultaneously (Breunig et al., 2018a; 
Zhou et al., 2018).  
 
Results 
Changes in mitochondria morphology in astrocyte to neuron reprogramming in vitro  
To better understand if astrocytes undergoing neuronal conversion not only change morphological, 
electrophysiological and transcriptional features, as previously described (Heinrich et al., 2010; 
Masserdotti et al., 2015), but also adapt their mitochondria and metabolism, we first monitored 
morphological changes of mitochondria during astrocyte-to-neuron reprogramming. Astrocytes 
isolated from postnatal day 5 murine cerebral cortex (Heinrich et al., 2011) were transduced with 
retroviral vectors containing the proneural factors Ascl1 or Neurog2 cDNA (Heinrich et al., 2010) and 
GFP targeted to mitochondria (Ascl1-IRES- mitoGFP, Figure 1A). Interestingly, the conversion from 
astrocytes to neurons was associated with profound remodeling of mitochondria. Astrocytes that fail to 
convert maintain their mitochondria in a tubular morphology, forming an elongated and ramified 
mitochondrial network (Figure 1A, left), indicative of higher rates of mitochondrial fusion, as also 
seen in astrocytes in vivo under physiological conditions (Motori et al., 2013). On the contrary, when 
astrocytes successfully convert into neurons, as indicated by morphological changes, acquisition of 
neuron-specific β-III-tubulin-immunoreactivity and downregulation of the astroglial protein glia-
fibrillary acidic protein (GFAP), the size of mitochondria notably decreased assuming mostly short 
and round morphology (Figure 1A, right). This is in line with in vivo data, showing smaller 
mitochondria and dynamic properties of higher fission in neurons, allowing them to reach and support 
the distant neuronal processes (Misgeld and Schwarz, 2017; Plucińska and Misgeld, 2016). Thus, 
direct neuronal reprogramming is accompanied by profound changes in mitochondrial morphology, 
most likely accompanying also profound functional changes (Gascón et al., 2016), prompting us to 
examine the mitochondrial proteome of astrocytes and neurons in an unbiased manner.  
 
Cultured astrocytes and neurons from cerebral cortex differ in mitochondrial structure and 
function  
To determine the mitochondrial proteome of neurons and astrocytes, we used high purity neuron 
cultures derived from embryonic day (E) 14 cerebral cortex, cultured for 7 days (Walcher et al., 2013) 
and primary astrocyte cultures, obtained from postnatal P5 cerebral cortex, the same starting 
population used in our direct neuronal reprogramming protocol. First, we measured the Oxygen 
Consumption Rate (OCR) and the extracellular acidification, converted to Proton Production Rate 
(PPR), as measure for OxPhos and indicator for glycolytic rates respectively, in both cell types. As 
expected, we found profound differences between primary astrocytes and primary neurons, as 
highlighted by the different metabolic responses to stimuli in real-time, in both OCR and PPR (Figure 
1B). Focusing on the basal metabolic rates, astrocytes showed higher basal OCR and PPR rates 
compared to neurons (Figure 1C, 1D). Of note, astrocytes can promptly compensate with glycolysis 
when mitochondrial ATP synthesis is blocked by oligomycin, while neuronal glycolytic capacity 
appears limited (Figure 1E). This conclusion is further corroborated by PPR rates when completely 
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blocking the ETC with rotenone and antimycin A, thus blocking TCA cycle acidification (Figure 1F). 
The OCR/PPR ratio reflects that neurons rely predominantly on OCR rather than on PPR for energy 
production, compared to astrocytes (Figure 1G).  
Having confirmed the metabolic differences of cultured cortical astrocytes and neurons, we isolated 
functional mitochondria for proteome analysis through a cell fractionation-based method, as 
previously described (Schmitt et al., 2013, 2015) (Figure S1A). Mitochondria enrichment in the 
fraction of interest (Figure 1H, 9000g) was confirmed by Western Blot for mitochondrial proteins 
(Complex I, II, III, IV, V, ANT, residing in the inner mitochondrial membrane; VDAC, residing in the 
outer mitochondrial membrane; CS, residing in the mitochondrial matrix). Analysis of cytosolic 
(GAPDH, tubulin), nuclear (H3), lysosomal (Lamp2), endoplasmic reticulum (Bip) or peroxisomal 
(Pmp70) proteins showed their enrichment in the first two fractions (Figure S1B, 800g and S.N.). To 
verify that isolated mitochondria were functional and not damaged, we used Rhodamine 123, a cell-
permeant, cationic green fluorescent dye that is sequestered in quench-mode by functional 
mitochondria. Indeed, the membrane potential of the mitochondria isolated from both neurons and 
astrocytes remained constant for at least 1 hour after the isolation (Figure S1C) and similar to 
previous data (Schmitt et al., 2013). Also the swelling parameter, measured by the absorbance at 
540nm, showed a linear trend over time, indicative of intact/functional mitochondria (Figure S1C). 
Finally, ultrastructural analysis of the isolates by electron microscopy (EM) also showed largely intact 
mitochondria (Figure 1I). Mitochondrial isolates showed a higher purity when obtained from 
astrocytes compared to neurons, with some other organelles and debris present in neuronal samples 
(Figure 1I). This is most likely due to the complexity of isolating smaller mitochondria, tightly joined 
to cytoskeleton molecules, inside the thin neuronal processes. However, EM analysis confirmed that 
mitochondria from astrocytes are longer than the small and roundish neuronal mitochondria, as we 
also observed by immunofluorescent staining in the reprogrammed neurons (Figure 1A). 
Interestingly, mitochondrial complexity, in terms of cristae and membrane invagination, was 
comparable between the two cell types, supporting our functional data on mitochondria activity 
(Figure 1B), indicative of their differentiated and mature phenotype.  
 
Astrocytes and neurons exhibit profound differences in the mitochondria proteome  
To determine the mitochondrial proteome we used liquid chromatography-tandem mass spectrometry 
(LC-MS/MS) of the isolates from 3 independent biological replicates (Table S1). This allowed the 
quantification of 798 of the 1158 proteins classified as mitochondrial by MitoCarta 2.0 (Calvo et al., 
2016). Of these, 294 proteins were more abundant in astrocytes and 60 more abundant in neurons (p-
value<0.05 and a two-fold enrichment, Figure 2B). The PCA analysis and the heatmap cluster 
analysis of the differentially enriched mitochondrial proteins show a high degree of similarity for the 
biological replicates (Figure 2A, 2C).  
Gene Onthology (GO) term analysis (Genomatix Generanker) of the mitochondrial proteins 
significantly enriched in one of the cell types (Figure 2D, S1D for top 35 GO terms from biological 
processes and molecular functions, Table S2 for complete list), revealed that the astrocyte-enriched 
mitochondrial proteome contains more proteins involved in fatty acid catabolic process, fatty acid β-
oxidation and lipid metabolic process, which are relevant pathways for astrocytes also in vivo (van 
Deijk et al., 2017). Indeed, some of the top proteins specifically enriched in astrocyte-isolated 
mitochondria were Acads (Astrocytes versus Neurons (A/N) ratio=14,97, p-value=0,0008), Cpt1a, 
(A/N Ratio=13,63, p-value=0,0000), Cpt2 (A/N Ratio =11,27, p-value=0,0002), Acsf2 (A/N Ratio 
=9,39, p-value=0,0004); key regulators of lipid metabolism and fatty acid β-oxidation (Table 1). 
Furthermore, GO terms significantly enriched for astrocyte mitochondrial proteins comprise cellular 
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respiration, mitochondrion organization and respiratory electron transport chain, consistent with their 
higher energetic demand and metabolic rate in vitro (see also above).  
Mitochondrial proteins enriched in neurons shared most of the GO terms with astrocytes, such as small 
molecule metabolic process, carboxylic acid metabolic process and small molecules biosynthetic 
process, indicative of functional and active mitochondria in both cell types. Interestingly cholesterol 
biosynthetic process was mostly characteristic for neuronal mitochondria. Important proteins highly 
abundant in neuronal mitochondria were glutaminase (Gls, A/N Ratio =0,04, p-value=0,0000), the 
primary enzyme for the production of glutamate from hydrolysis of glutamine and ammonia, as well 
as Acly (A/N Ratio =0,41, p-value=0,0003), involved in the production of cytosolic acetyl-CoA with a 
central role in regulating cell metabolism, signaling and epigenetic marks. These results support the 
different metabolic reliance of astrocytes and neurons, as also shown above by Seahorse analysis. The 
“molecular function” GO terms mirrored and explained the metabolic pathways of both cell types 
represented in the selectively enriched mitochondrial proteome (Figure S1D).  
Supporting our observation that astrocytes have elongated mitochondria compared to reprogrammed 
neurons (Figure 1A), the mitochondria fusion protein Mitofusin 1 (MFN1) was enriched in astrocytes 
(A/N Ratio =5,97, p-value=0,0123). Conversely, neurons are enriched for the fission master regulator 
Dynamin related protein Dnm1l (Drp1, A/N ratio=0,12, p-value=0,0000; see Table 1). Notably, the 
GO terms cellular oxidant detoxification, oxidation-reduction process and oxidoreductase activity are 
among the most commonly represented in the mitochondrial proteome of both cell types (Table S2). 
This highlights that astrocytes and neurons use different proteins to respond to exogenous and 
endogenous oxidative stress, whose molecular function does not necessarily overlap. For example, 
some of the top enriched anti-oxidant molecules in astrocytes are Gpx1 (A/N ratio=9,37, p-
value=0,0205) and Gpx4 (A/N ratio=3,23, p-value=0,0032), while neurons have much more Prdx2 
(A/N ratio=0,35, p-value=0,0021) and Sod1 (A/N ratio=0,38 p-value=0,0313; see Table 1).  
This raises the intriguing question whether the neuron-specific antioxidant proteins may be 
specifically required during the direct conversion process, as antioxidant defense has been identified as 
critical in direct neuronal reprogramming in vitro and in vivo (Gascón et al., 2016).  
 
Mitochondrial protein changes during astrocyte-to-neuron reprogramming  
As mitochondrial proteins have so far not been examined in direct neuronal reprogramming, we aimed 
to determine whether astrocytes down-regulate their characteristic mitochondrial proteins and induce 
the expression of neuron-specific ones during the process of fate conversion. We chose mitochondrial 
proteins that can be reliably detected by immunostaining and/or play crucial functional roles (Table 
1).  
For example, Sfxn5 is a mitochondrial transporter of citrate (Miyake et al., 2002), an essential 
intermediate of the TCA cycle derived from condensation of oxaloacetate and acetyl-CoA, and is 
enriched in mitochondria isolated from astrocytes. Accordingly, it was detected by 
immunocytochemistry in mitochondria of GFAP+ astrocytes that were not transduced or were still 
GFAP+ at 3 days post infection (DPI) with the proneural factor Neurogenin 2 (hereafter Neurog2, 
Figure 3A, arrowhead). Astrocytes that acquire neuronal β-III-tubulin and lose GFAP-
immunoreactivity instead show decreased Sfxn5-immunostaining over time (Figure 3A, arrow, 5 DPI, 
7 DPI). However, 60% of these converting astrocytes still retain Sfxn5 protein (Figure S4A, S4B), 
even though at lower levels than surrounding astrocytes (Figure 3A, arrow). Thus, down-regulation of 
Sfxn5 is incomplete, at least within 7 DPI, and reprogrammed neurons show some degree of 
heterogeneity in switching to the neuronal mitochondrial proteins.  
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Conversely, immunoreactivity for the astrocyte-enriched protein Cpox was down-regulated faster and 
more efficiently during the reprogramming process, as it was detectable only in 30% of GFAP-
negative cells (arrow) at 5 DPI (Figure S2A, S4C), and almost undetectable in converted neurons at 
7 DPI (Figure S2A, arrow; Figure S4C). Notably, also astrocytes that fail to convert to neurons, but 
still overexpress the transcription factor, largely lose expression of the astrocyte-specific Cpox protein 
(Figure S4C), while surrounding astrocytes do not (Figure S2A, arrowhead). Thus, astrocytes failing 
to reprogram appear to be in an intermediate metabolic state retaining some mitochondrial hallmarks 
of their original identity. Notwithstanding, these non-reprogrammed astrocytes do not up-regulate any 
of the neuronal mitochondrial marker proteins analyzed (Figure S4D, S4E, S4F).  
We also investigated if and when reprogrammed neurons express neuron-specific mitochondrial 
proteins. To this end, we analyzed the expression of Prdx2 and Gls. Prdx2, which catalyzes the 
reduction of peroxides and hence protects from oxidative stress (Boulos et al., 2007), was not 
expressed at detectable levels until 5 DPI in Neurog2-expressing cells undergoing reprogramming 
(Figure S2B, arrow). However, by 7 DPI up of 80% of reprogrammed neurons had acquired Prdx2 
immunoreactivity (Figure S4F). 
Instead glutaminase, the enzyme regulating glutamine metabolism and glutamate neurotransmitter 
levels (Márquez et al., 2009), was up-regulated at earlier stages in converting neurons. It was 
detectable already at 3 DPI (Figure 3B, arrow) in neurons induced either by Ascl1 or Neurog2 
induced cells (Figure 3B, S3B, S4D, S4E), and was present in virtually all transduced neurons by 
7 DPI (Figure S4D, S4E). Gls and Prdx2 were instead virtually absent in astrocytes that failed to 
reprogram, at all time-points analyzed (Figure S2B, arrowhead, Figure S4D, S4E, S4F).  
Notably, the down-regulation of Sfxn5 and up-regulation of Gls follow similar dynamics in the 
conversion process (starting at 3 DPI and further progressing at 5 DPI) independently on the 
neurogenic reprogramming factor used (Neurog2 or Ascl1, Figure 3, Figure S3, Figure S4). This is 
interesting as our proteome was performed with cortical neurons i.e. largely with glutamatergic 
neurons, but also induction of GABAergic neurons with Ascl1 (Masserdotti et al., 2015) shows 
increase in Gls. We further noticed that neuron-specific mitochondrial proteins are higher in 
reprogrammed neurons with more mature morphologies (Figure 3B, Figure S2B), suggesting that the 
acquisition of a proper neuronal mitochondrial proteome may continue with prolonged maturation 
(e.g. further down-regulation of astrocyte-specific proteins, such as Cpox or Sfxn5, Figure S4A, S4B, 
S4C). Importantly, however, our data show that changes in mitochondrial proteins occur in a relatively 
uncoordinated manner (astrocyte-specific often fail to be down-regulated despite up-regulation of 
neuron-specific ones) and at a late stage during the conversion process (5-7 DPI). Moreover, our data 
suggest that astrocytes undergoing conversion to neurons pass through an intermediate stage (around 
3-5 DPI), when some astrocyte-specific mitochondrial proteins are already down-regulated (Cpox), 
while neuron-specific mitochondrial proteins have not yet increased much (like Prdx2). This prompted 
us to examine whether inducing neuron-specific mitochondrial proteins along with the proneural 
factors, e.g. providing them from the beginning of the reprogramming process, may improve the 
conversion speed or efficiency. 
 
dCas9-mediated induction of neuron-specific mitochondrial proteins potently improves speed and 
efficiency of direct neuronal reprogramming 
To examine if the early expression of specific neuronal mitochondrial proteins in astrocytes 
undergoing reprogramming would improve the process, we took advantage of the recently developed 
STAgR technique that allows expressing a series of gRNAs targeting different genes in one vector 
(Breunig et al., 2018b). This approach combines deactivated Cas9 (dCas9) with the VPR 
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transcriptional activator, which targets promoter regions of selected genes through gRNAs sequences, 
to induce endogenous expression (Chavez et al., 2015). As astrocytes and neurons possess cell-specific 
mitochondrial proteins to respond to oxidative stress and coping with oxidative stress is a key factor in 
the neuronal reprogramming (Gascón et al., 2016), we first focused on neuron-specific antioxidant 
proteins as potential candidates to improve reprogramming. We therefore selected the neuronal 
specific proteins Sod1 and Prdx2, important regulators of oxidative stress in physiological and 
pathological conditions (Boulos et al., 2007) and most abundant anti-oxidant proteins in neuronal 
mitochondria (Table 1). We chose gRNAs targeting the promoter of these genes as previously 
described (Breunig et al., 2018a) and cloned the respective gRNAs in a newly developed construct 
with a GFP reporter, which is only activated in the presence of both the self-transcribed gRNAs (e.g. 
for Sod1) and dCas9-VPR, i.e. when cells are co-transduced (Figure 4A). The specificity of the 
reporter is based on a minimal CMV promoter and the target sequences of one of the gRNAs included 
in the vector (here Sod1 or scrambled gRNA target for control)(Figure 4A). 
We first examined the extent of Sod1 and Prdx2 mRNA induction after co-transfection of cortical 
astrocytes with dCas9-VPR and the respective gRNAs or control (scrambled gRNAs combined with 
inducible GFP). Sod1 and Prdx2 mRNA levels were increased 15x and 11x respectively compared to 
the control in astrocytes sorted by FACS for GFP, 48 hours after transfection (Figure 4B). 
Subsequently, we transfected dCas9-VPR and the inducible GFP construct carrying the gRNAs 
targeting Sod1 and Prdx2 promoters (STAgR P-S), or alternatively control gRNAs (STAgR Cntrl), 
together with the reprogramming vector Ascl1-RFP, and examined neuronal conversion 6 days after 
transfection (Figure 4C). Strikingly, we observed a seven-fold increase in the proportion of induced 
neurons; from 5% with only Ascl1-RFP and control gRNAs to over 35%, when Ascl1-RFP was 
combined with STAgR P-S (Figure 4C, 4E). These data suggest that neuron-specific anti-oxidant 
mitochondrial proteins are needed during the neuronal conversion process and their earlier and/or 
higher expression strongly improves reprogramming.  
This prompted the question whether neuronal conversion occurs faster or simply at the same speed but 
with more cells converting or more converted cells surviving (see Gascón et al., 2016). To test these 
possibilities, we took advantage on continuous single cell live imaging following the conversion 
process, as previously described (Costa et al., 2011). Images were taken in bright field every 10 
minutes, and in GFP/RFP every 3 hours, over a period of 6 days. Transfected cells acquiring a 
neuronal morphology (criteria as in Gascón et al., 2016: processes longer than 3x cell soma) could be 
observed around 60 hours after transduction (Figure 4D). However, astrocytes co-transfected with 
Ascl1-RFP and STAgR P-S speeded up the neuronal differentiation with significantly more neuronal 
cells present at 90 hours after transduction (Figure 4D). Examples illustrating the hugely different 
level of neuronal maturation in the two conditions are depicted in Figure 4E. Importantly, while the 
cells with upregulated neuron-specific anti-oxidant proteins linearly increased neuronal generation up 
to 110 hours, Ascl1-RFP control cells turning into neurons reached a plateau fast and often died 
shortly after (Figure 4D). Thus, the early expression of neuron-specific anti-oxidant mitochondrial 
proteins promotes the speed of astrocyte-to-neuron conversion and improves their survival, thereby 
significantly improving the conversion efficiency. Taken together, reprogramming the mitochondrial 
proteome along with respective fate determinants potently improves fate conversion.  
 
Discussion 
Mitochondrial performance is key for neuronal survival and function, as also evident from 
neurodegenerative disease often caused by mitochondrial defects (Fernandez-Fernandez et al., 2012; 
Willems et al., 2015). Furthermore, mitochondrial function affects epigenetic, transcriptional and 
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signaling cascades (Janke et al., 2015; Spinelli and Haigis, 2018), highlighting the importance of a 
investigating the cell-type-specific mitochondrial proteome (Johnson et al., 2007). Given the 
importance of mitochondria function, it is surprising how little is known about cell-type-specific 
mitochondrial composition and its changes in direct neuronal reprogramming. Our data demonstrate 
profound differences in the mito-proteome of cortical neurons and astrocytes and their uncoordinated 
and partial regulation during reprogramming. This is clearly different from gradual timely-regulated 
metabolic changes from neural stem cells via transit-amplifying progenitors to neurons in normal 
neurogenesis during development and in adulthood (Khacho et al., 2016). Accordingly, the use of 
dCas9-mediated transcriptional engineering to promote neuron-specific mitochondrial protein 
acquisition potently improved the conversion process. 
Cell-type-specific mitochondrial proteome reveals profound differences between astrocytes and 
neurons related to specific metabolic pathways  
Cultured astrocytes showed flexible metabolic profile, as they rely on OxPhos but are able to 
compensate with high glycolytic capacity when required, as also observed in vivo (Panov et al., 2014; 
Supplie et al., 2017). Conversely, neurons did not demonstrate this potential, but mostly relied on 
OxPhos for energy production, as observed evaluating the OCR/PPR ratio (Figure 1G). Supporting 
this, neurons express key enzymes necessary to activate glycolysis at lower levels (Herrero-mendez et 
al., 2009; Zheng et al., 2016), while astrocytes respond better to energy deprivation (Lovatt et al., 
2007). Notably, extracellular flux analysis using the Seahorse device revealed that both cultured cell 
types were close to the maximal rate of their metabolism under basal conditions, limiting spare 
respiratory capacity (Figure 1B). For astrocytes, this may be explained at least partially by  
proliferation (Heins et al., 2002), which is linked to energetically demanding catabolic and anabolic 
reactions, enhancing metabolic requirements (Ito and Suda, 2014; Lunt and Vander Heiden, 2011). In 
the case of the neurons, this could be attributed to the fact that they are cultured in the absence of other 
glial cells, especially astrocytes, that metabolically support neurons in vivo (Bélanger et al., 2011; 
Chen et al., 2009; Diaz et al., 2012; Weber and Barros, 2015) and assist to respond to higher oxidative 
stress (Schreiner et al., 2015). For our purpose this was useful, as it allowed to determine the proteome 
of mitochondria at full functional capacity with supposedly all proteins needed present.  
Indeed, the mitochondrial proteome of the cultured neurons and astrocytes revealed profound 
differences in several cell-type-specific pathways (see Table S2). For example, some of the top GO 
terms enriched in the mitochondrial proteome of cortical astrocytes are lipid metabolism and fatty acid 
β-oxidation, demonstrating distinct specialization of astrocytic mitochondria. Indeed, this is also 
consistent with expression analysis at the RNA level in adult astrocytes (van Deijk et al., 2017; 
Hofmann et al., 2017). Despite controversial reports, this pathway seems to provide astrocytes with 
higher amount of ATP and co-factors, when sustained oxygen availability occurs, compared to 
glycolysis (Panov et al., 2014; Perevoshchikova et al., 2013; Schönfeld and Reiser, 2013; Souza et al., 
2019). Yet, astrocytes seemingly derive 20% of brain energy supply by β-oxidation (Panov et al., 
2014) and our in vitro data suggest a contribution of 30% when blocking this pathway by β-etomoxir 
(data not shown). This raises the interesting question if it would be beneficial for derived neurons, e.g. 
in direct reprogramming, to maintain a high capacity of this pathway, even though they clearly need to 
activate other pathways for fast and efficient ATP generation. 
During endogenous neurogenesis key enzymes of the fatty acid metabolism, such as carnitine 
palmitoyltransferase 1a (Cpt1a), are not only highly expressed in astrocytes (Table 1) (Zhang et al., 
2014), but also in adult neural stem cells (NSCs) where they regulate quiescence (Knobloch et al., 
2017), and are down-regulated when neurons are generated. Thus, the conversion of the metabolism is 
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regulated gradually during neurogenesis, while it is largely unknown how these enzymes are regulated 
during transcription factor induced astrocyte to neuron reprogramming. For example, Cpt1a is not yet 
down-regulated by 48 hours in astrocytes converting into neurons (Gascón et al., 2016; Masserdotti et 
al., 2015, Masserdotti et al., unpublished data), suggesting a relatively slow metabolic conversion.  
Interestingly, however, the mitochondrial proteome isolated from astrocytes is also enriched in 
proteins linked to cellular respiration, mitochondrion organization and respiratory electron transport 
chain compared to neurons. This fits to the recent observation that reactive astrocytes require OxPhos 
and complex I-V (Fiebig et al., 2019), and in vitro cultured astrocytes resemble reactive astrocytes 
(Götz et al., 2015). In comparison to neurons that mostly rely only on OxPhos (Bélanger et al., 2011; 
Kasischke et al., 2004) (present data), this enrichment in astrocytes seems surprising. However, 
astrocytes, as feeder cells for neurons, require higher energy metabolism to function (Bélanger et al., 
2011; Bouzier-Sore and Pellerin, 2013; Chuquet et al., 2010), while neurons also express proteins 
reducing glycolysis in other conditions which further restrict their energetic sustainability (Herrero-
mendez et al., 2009; Khacho et al., 2016). 
Importantly, however, most of these differences are quantitative, meaning that e.g. the proteins 
involved in the ETC are more abundant in astrocytes, but also present in neurons (see Table 1). 
Indeed, when comparing the mitochondrial proteome composition of different cell types, between 50% 
and 70% of the mitochondrial proteins are common (51% of mitochondrial proteins within a 2-fold 
change between astrocytes and neurons in our analysis, see Table S1) and expressed at similar levels 
(Mootha et al., 2003; Pagliarini et al., 2008), with ETC subunits among the less variable proteins 
(Calvo and Mootha, 2010). However, also subtle differences in ETC subunit assembly, beyond their 
relative abundance, differentiate astrocytes and neurons functionally (Lopez-Fabuel et al., 2016). Most 
importantly, direct neuronal reprogramming provides a read-out to determine which of these 
differences matter. 
 
Promoting neuronal fate conversion by early reprogramming of the mitochondrial proteome 
When monitoring individual mitochondrial proteins that were differentially enriched in astrocytes 
versus neurons, we observed only partial down-regulation of astrocyte-enriched and relatively late up-
regulation of neuron-enriched proteins. One of the markers tested was glutaminase, which is also 
functionally relevant, as it catalyzes the hydrolysis of glutamine to glutamate and ammonia and is 
involved in generating neurotransmitters in neurons (Albrecht et al., 2010). Thus, the expression of 
this enzyme represents a further step towards the acquisition of specific neuronal metabolic function in 
induced neurons. Interestingly, these changes in metabolic and mitochondrial enzymes were only 
detected in astrocytes that actually convert to neurons, but not in those that fail to do so. This is also 
the reason why a comprehensive mitochondrial proteome analysis of reprogrammed cells is difficult to 
determine – not only due to the limited number of cells, but also due to the heterogeneity in 
reprogramming outcome. This heterogeneous response can also be observed in the transduced 
astrocytes that fail to convert, as some of them down-regulate astrocyte-specific mitochondrial 
proteins, while others maintain them. As they do not acquire neuronal mitochondrial markers, many 
are in a confused metabolic state that may hinder reprogramming. This could explain, why our 
converse strategy, i.e. the up-regulation of neuron-specific mitochondrial proteins, is more successful 
in neuron induction, thereby overcoming unsuccessful reprogramming. 
We analyzed the expression of cell-specific mitochondrial proteins (Sfxn-5, Cpox, Prdx2, Gls) and 
found that differences emerged earliest at 3 DPI with most neuron-specific mitochondrial proteins 
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being induced only at 5 DPI (Figure S4). Given the fast induction of neuronal genes within a few 
hours (Masserdotti et al., 2015) and the change to neuronal morphology and neuronal proteins already 
by 2-3 days, neuron-specific mitochondrial proteins appear to lag behind. For instance, Prdx2 is 
detectable in converting neurons only starting from 5 DPI. However, as Prdx2 is a neuron-specific 
anti-oxidant protein protecting neurons from oxidative stress (Boulos et al., 2007), its late expression 
may be one reason why increased ROS levels cause cell death during direct neuronal reprogramming 
(Gascón et al., 2016).  
As oxidation-reduction process and cellular oxidant detoxification are also highly significant GO 
terms in the cell-type-specific mitochondrial proteome analysis of neurons and astrocytes, we 
examined the effects of the early co-expression of neuronal mitochondrial proteins, with known 
antioxidant functions, in the reprogramming process. To achieve this, we exploited the recently 
developed STAgR and dCas9 technology (Chavez et al., 2015), allowing synchronous overexpression 
of multiple endogenous targets. We selected two known antioxidant neuronal proteins, Sod1 and 
Prdx2, mostly involved in detoxification of superoxide and hydrogen peroxide, that when mutated lead 
to severe neurodegenerative diseases (Bunton-Stasyshyn et al., 2015; Hu et al., 2011).  
Interestingly we could prove, through time-lapse experiments, that selective overexpression of these 
two proteins in astrocytes turning into neurons could greatly help the reprogramming process, most 
likely acting both on cell survival and neuronal maturation. This implies that modification of the 
mitochondrial proteome of astrocytes converting into neurons might not only be a phenotypic 
consequence of a cellular change, but directly a driving force for the conversion process. Cas9 
technology offers great advantages for direct neuronal reprogramming, as recently demonstrated by in 
vivo (Zhou et al., 2018) and in vitro (Black et al., 2016) studies. It will be important to understand 
whether the powerful increase in reprogramming speed and efficiency achieved here by activating 
only 2 neuron-specific mitochondrial proteins is specific or also true for others. Genome-wide 
screening of mitochondrial proteins via CRISPR technology, as demonstrated for the OxPhos genes 
(Arroyo et al., 2016), could help answering this question and determining the mitochondrial proteins 
that are most relevant for this fate conversion.  
Excitingly, our data further corroborate the concept that the metabolic conversion is a key driver, not 
only a consequence, of fate conversion. This is supported by the much faster conversion to a neuronal 
morphology when Sod1 and Prdx2 were up-regulated from the onset of proneural gene expression. 
Thus, when these neuron-specific antioxidant proteins are not yet up-regulated the conversion process 
stalls and possibly aborts, despite the expression of a multitude of anti-oxidant proteins in astrocytes. 
It will be fascinating to determine how Sod1 and Prdx2 may speed up the acquisition of neuronal 
morphology at a mechanistic level, but most important for now, they hugely improve the conversion 
process.  
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Materials and Method 
Primary Astrocytes cultures and neuronal reprogramming 
Astrocytes were isolated and cultured as described previously (Heins et al., 2002). After removal of 
the meninges, grey matter tissue from P5–P7 cerebral cortex of C57BL/6J mice was dissected and 
dissociated mechanically. Subsequently, cells were centrifuged for 5 min at 1,300 rpm, re-suspended, 
and plated in a T25 flask in medium consisting of DMEM/F12 (Gibco), 10% fetal bovine serum 
(Gibco), penicillin/streptomycin (Gibco), and supplemented with B27 (Gibco), 10 ng/mL epidermal 
growth factor (EGF, Roche), 10 ng/mL fibroblast growth factor 2 (FGF2, Roche). Cells were passaged 
when confluence was reached after 7-10 days using trypsin/EDTA (Gibco) and plated on poly-D-
lysine (Sigma-Aldrich, Munich, Germany) coated glass coverslips at a density of 80,000 cells per 
coverslip (in 24-well plates; BD Biosciences,) in the same medium. The vast majority of the cells 
(>90%) in these cultures were positive for glial fibrillary acidic protein (GFAP) as previously 
described. One day after transduction or transfection (see below), the medium was replaced with 
neuronal differentiation medium, containing B27, but lacking FBS, EGF and FGF. At 6 or 7 days after 
transfection or transduction cells were fixed and immunostained.  
Primary neuronal cultures 
Cerebral cortices were dissected from embryonic day (E) 14 mice as described before (Hartfuss et al., 
2001). Cortexes were isolated, meninges removed and the samples mechanically dissociated in HBSS 
medium containing 10mM Hepes, on ice. Subsequently cells were digested for 15 min in trypsin-
EDTA (0,05%), and subsequently centrifuged for 5 min at 1,000 rpm. The pellet was further 
mechanically dissociated and resuspended in Neurobasal Medium (Gibco, 21103-049), supplemented 
with Glutamax (100x), penicillin/streptomycin (Gibco), and B27 (Gibco). Cells were counted and 
plated at a density of 600,000 cells in 6-well plated (BD Biosciences) pre-coated with poly-D-lysine 
(Sigma-Aldrich). After one week in culture, cells had differentiated mostly into mature neurons, with 
high purity and little contamination by other cell types (data not shown). 
Transfection and Transduction 
For transfection DNA-liposome complexes were prepared in Optimem medium (Invitrogen) using the 
retroviral plasmids described below and Lipofectamine 2000 (Invitrogen). Astrocytes culture were 
exposed to DNA-liposome complexes at a concentration of 0.6 µg DNA per 400 µl of Optimem 
medium for 3 hours and cultured in differentiation medium, as described above. For STAGR 
experiments a ratio of 2 : 1 : 1 was used respectively for dCas9-VPR : STAGr (Cntrl or P-S): Ascl1 (or 
dsRed). For transduction of astrocytes, seeded astrocytes were infected with 1ul of virus one day after 
plating, before changing with fresh differentiation medium 24 hours after. 
Mitochondria isolation and characterization  
Mitochondria isolation from cultured astrocytes and neurons was performed as previously described 
(Schmitt et al., 2013) using the pump-controlled cell rupture method; a cell homogenizer (Isobiotec, 
Germany) combined with 1-ml Luer Lock Gas-Tight Syringes (4.608 mm i.d., SGE Supelco, USA) 
and a high-precision pump (Pump 11, Harvard Apparatus, USA). The homogenizer was precooled on 
ice to ensure cooling of the samples during the isolation, the tungsten carbide ball (6um diameter) was 
inserted and the homogenizer was equilibrated with isolation buffer (300 mM sucrose, 5 mM TES, and 
200 µM ethyleneglycoltetraacetic acid [EGTA], pH 7.2). The sample of dissociated astrocytes or 
neurons was added to 1 ml of isolation buffer and passed three (neurons) to six (astrocytes) times 
through the system at a constant rate (700 µl/min). To recover the homogenate, the system was rinsed 
once with 1 ml of isolation buffer. The sample preparation and the tunable parameters of the PCC, 
such as the clearance and the number of strokes, were optimized for each sample. Yield and 
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functionality (mitochondrial transmembrane potential, Δψm) of the isolated mitochondria were used to 
assess the optimal parameters. Around 1 million astrocytes and neurons respectively were used to 
obtain a sufficient amount of mitochondria for further processing. The pooled homogenate was cleared 
from cell debris and nuclei by centrifugation (800×g, 5 min at 4 °C), and mitochondria were pelleted 
at 9000×g (10 min at 4 °C). After the isolation, the syringes were rinsed three or four times with 
double distilled water (ddH2O). The tungsten carbide ball and the cell homogenizer were cleaned with 
isopropanol followed by ddH2O to allow processing of the next sample without contamination.  
Mitochondria characterization  
The functional analysis of isolated  mitochondria was performed by measuring Rhodamine 123 
(Rh123) fluorescence quenching to determine Δψm and measuring absorbance change at 540nm 
(Synergy 2, BioTek, USA) to determine mitochondrial swelling; as described previously (Schmitt et 
al., 2013). Protein concentrations were determined by the Bradford assay. For immunoblotting 
analysis, 10 µg of protein was subjected to sodium dodecyl sulfate-polyacrylamide gel electrophoresis 
(SDS-PAGE), and separated proteins were transferred onto a polyvinylidene fluoride (PVDF) 
membrane. Equal protein loading and proper transfer were controlled by Ponceau red staining. 
Primary and secondary antibodies for Western Blot analysis are listed below. 
Species Primary Antibodies Dilution Company, Cat. Number Mol. weight 
Rabbit Lamp2 1:2000 Invitrogen, 51-2200 100kDa 
Rabbit H3 1:1000 Cell Signaling, 96495 17kDa 
Mouse Bip 1:500 BD Pharmingen, 610978/9 78kDa 
Rabbit GAPDH 1:2000 Cell Signaling, 2118 42kDa 
Mouse α-tubulin 1:8000 Sigma–Aldrich, T5168 50kDa 
Rabbit Pmp70 1:500 Acris, SP5237P 70kDa 
Rabbit CS 1:5000 Novus Biologicals, NBP2-13878 50kDa 
Rabbit VDAC 1:1000 Cell Signaling, 4866 33kDa 
Goat ANT 1:250 Santa Cruz, sc.9299 30kDa 
Mouse Cytochrome I Complex 1:500 Abcam, ab110413 20kDa 
Mouse Cytochrome II Complex 1:500 Abcam, ab110413 30kDa 
Mouse Cytochrome III Complex 1:500 Abcam, ab110413 47kDa 
Mouse Cytochrome IV Complex 1:500 Abcam, ab110413 39kDa 
Mouse Cytochrome V Complex 1:500 Abcam, ab110413 53kDa 
Species Secondary Antibodies Dilution Company, Cat. Number 
Horse Anti mouse, HRP linked 1:1000 Cell Signaling, 7076 
Goat Anti rabbit, HRP linked 1:1000 Cell Signaling, 7074 
Donkey Anti goat, HRP linked 1:1000 Santa Cruz, sc-2020 
Electron microscopy analysis of the isolated mitochondria was done as described previously (Zischka 
et al., 2007). ZE-FFE-separated mitochondrial fractions were immediately pelleted, fixed in 2.5% 
glutaraldehyde, post-fixed with 1% osmium tetroxide, dehydrated with ethanol and embedded in 
Epon. Ultrathin sections were negative stained with uranyl acetate and lead citrate and then analyzed 
on a Zeiss EM 10 CR electron microscope.  
Seahorse experiments  
Primary cortical astrocytes or neurons were plated onto XF24 V3 PET cell culture microplates from 
Seahorse biosciences, pre-coated with PDL, and analyzed the day after plating. Cells were seeded at 
20000, 30000, 50000 for neurons; and 15000, 25000 or 40000 for astrocytes. The final cell number 
was assessed by counting DAPI+ nuclei and measuring DNA content to normalize the data to µg DNA 
or 1000 cells. Before measuring cellular respiration, cells were washed twice with assay medium (XF 
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DMEM + 25 mM glucose) and then incubated in 750 µL of assay medium for 10 min in an air 
incubator without CO2 at 37°C. The XF24 plate was then transferred to the XF24 Extracellular 
Fluxanalyzer (Seahorse Bioscience). Basal respiration was determined with 4-5 assay cycles (2 min 
mix, 2 min measuring) , and for each of the parameters obtained after respective drug application. For 
the measurement of different mitochondrial respiration states, oligomycin (5 µg/ml) was used to 
inhibit the ATP synthase, followed by FCCP (1µM) to induce maximal substrate oxidation capacity, 
and a cocktail containing rotenone (5 µM) and antimycin A (2 µM) to inhibit ETC activity and 
determine non-mitochondrial oxygen uptake.  Spare respiratory capacity was determined by 
subtracting maximum from basal respiration values). Finally, 2-deoxyglucose (2-DG, 100mM) was 
added to block glycolysis. Extracellular acidification rate (ECAR) was converted to proton production 
rate (PPR) based on machine algorithms and buffer capacity of the medium. Basal PPR was measured 
averaging 3 to 5 values prior to oligomycin treatment. Oligomycin-dependent PPR determines the 
peak values of PPR during mitochondrial Oxphos inhibition.  
Proteome analysis 
Per sample 10µg of isolated mitochondria were used. SDS was added to a final concentration of 2% 
for efficient solubilization, prior to tryptic protein digest using a modified FASP protocol (Wiśniewski 
et al., 2009). Proteomic measurements were performed on a Q-Exactive HF mass spectrometer 
(Thermo Scientific) online coupled to an Ultimate 3000 nano-RSLC (Dionex). Peptides were 
separated on a C18 nanoEase MZ HSS T3 column (100Å, 1.8 µm, 75 µm x 250 mm; Waters) in a 95 
min non-linear acetonitrile gradient. Precursor (scan range 300 – 1500 m/z) and TOP10 fragment 
spectra of charges 2-7 were acquired in the orbitrap mass detector of the mass spectrometer, at 
resolutions of 60000 and 15000 respectively with each a maximum injection time of 50 ms and a 
dynamic exclusion of 30 s. The individual raw-files were loaded to the Proteome discoverer 2.2 
software (Thermo scientific) allowing for peptide identification and label-free quantification using the 
Minora node. Searches were performed using Sequest HT as search engine in the Swissprot mouse 
database with the following search settings: 10 ppm precursor tolerance, 0.02 Da fragment tolerance, 
two missed cleavages allowed, carbamidomethyl on cysteine as fixed modification, deamidation of 
glutamine and asparagine allowed as variable modification, as well as oxidation of methionine and 
Met-loss combined with acetylation at the N-terminus of the protein. Proteins were quantified by 
summing up abundances of allocated unique and razor peptides; resulting protein abundances are 
given in supplementary table 1. Mitochondrial proteins were classified using the mitoCARTA 2.0 
database (Calvo et al., 2016). Fold-change values were obtained from protein abundances across three 
independent biological replicates for each cell type, subsequently dividing astrocytes over neuronal 
values. Identified proteins were considered as enriched in neurons if fold-change value was < 0.5, and 
enriched in astrocytes if fold-change value was > 2. All selected proteins were considered as 
significantly different considering the three biological replicates showing a p-value <0.05 (unpaired t-
test on individual proteins after imputation of missing values). 
Principal components analysis was done in Perseus software (Tyanova et al., 2016) on the log2 ratios 
of mitochondrial protein abundances in the individual samples to the median protein abundance across 
all samples. Heatmap analysis of the same ratios was performed using Cluster 3.0 software (Eisen et 
al., 1998). The distance matrix was calculated using the ‘Euclidean distance’ setting. Hierarchical 
clustering was completed using the ‘complete linkage’ algorithm. The resultant tree and heatmap were 
visualized with Java Treeview (http://www.eisenlab.org/eisen/?page_id=42). Pathway enrichment 
analysis on significantly differentially abundant mitochondrial proteins per cell type was conducted 
applying Generanker (Genomatix). Significantly enriched molecular functions and biological 
processes (p<0.01) were exported and are given in supplementary table 2. 
Immunocytochemistry  
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Cells were fixed in 4% PFA in PBS for 10 min at room temperature (RT), washed in PBS twice for 5 
minutes, and stored up to a month at 4°C before staining. Specimen were incubated in primary 
antibodies (at the concetration listed below) in PBS containing 2% Bovine Serum Albumine (BSA) 
and 0.5% Triton X-100 overnight at 4°C. After washing in PBS, cells were incubated with appropriate 
species- or subclass-specific secondary antibodies, with or without DAPI diluted 1:10.000, for 1h in 
the dark at room temperature. Optionally, after washing twice for 5 minutes with PBS, biotin-labeled 
secondary antibodies were used at a dilution of 1:200 for 1hour, followed by streptavidin coupled 
fluorophores (1:500). Coverslip were then mounted with Aqua Poly/Mount (Polysciences, Warrington, 
PA) and samples were imaged at the LSM710 laser-scanning confocal or Axio observer Z1 
epifluorescence microscope (Carl Zeiss). Digital images were acquired using the ZEN software (Carl 
Zeiss) at 40X or 20x.  
The following primary and secondary antibodies were used: 
Species Primary Antibodies Dilution Company Catalog Number 
Mouse IgG2b β-III-Tubulin 1:100 Sigma T8660 
Rabbit GFAP 1:400 Dako Z0334 
Mouse IgG1 GFAP 1:400 Sigma G3893 
Rat RFP 1:300 Chromotek 5F8 
Chicken GFP 1:300 Aves Labs GFP-1020 
Rabbit CPOX 1:200 Abcam Ab169766 
Rabbit Prdx2 1:100 Provided by Sergio Gascon 
Rabbit Gls 1:100 Proteintech 20170-1-AP 
Rabbit Sfxn5 1:200 Abcam Ab172971 
Reactivity Secondary Antibodies Dilution Company Catalog Number 
Mouse IgG2b Alexa Fluor 488 1:1000 Invitrogen A21141 
Chicken Alexa Fluor 488 1:1000 ThermoFisher SA5-10026 
Rat Cy3 1:1000 Dianova 112-165-167 
Mouse IgG2b A 633 1:1000 Invitrogen A21146 
Mouse IgG1 A647 1:1000 Invitrogen A21240 
Rabbit Alexa Fluor 488 1:1000 Invitrogen A21206 
Mouse IgG1 Biotin 1:250 Biozol 1070-08 
Streptavidin A Fluor 405 1:500 Invitrogen S32351 
 
Fluorescence-activated cell sorting 
Astrocytes 48 hours after transfection with gRNAs and dCas9 were trypsinized and sorted for GFP 
positive cells, using the FACSAria III (BD Bioscience) system at high purity mode and a flow rate 
lower than 1200 cells per second. Forward and side scatter were adjusted to exclude cell debris and 
include only GFP positive cells, that were detected by 488nm laser-assisted excitation. 15.000 cells 
were sorted directly in RLT buffer (QIAGEN), to enhance RNA quality and efficiency, for subsequent 
extraction and qRT-PCR. 
RNA Extraction and Real Time Quantitative PCR (qRT-PCR) 
RNA was extracted using RNeasy Plus Micro Kit (Qiagen) according to manufacturer’s instructions, 
including removal of genomic DNA. RNA was retro-transcribed using SuperScriptIII Reverse 
Transcriptase and Random Primers (Roche). Each cDNA sample was diluted 1:5 and 1µl was used for 
each quantitative real time reaction. Real Time quantitative PCR (qPCR) was performed on a 
LightCycler480 instrument (Roche) using LightCycler Probe Master kit (Roche) and Monocolor 
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Hydrolysis Probe (UPL) Probe (Roche) according to manufacturer’s instructions (20µl final volume). 
The expression of each gene was analyzed in triplicate. Data were processed with the ΔΔCt method 
(Livak and Schmittgen, 2001). Quantification was performed on 3 independent biological samples. 
STAGr and gRNAs production 
gRNAs were designed to target in close proximity to the transcription start site of of Sod1 and Prdx2. 
All STAgR vectos were designed and produced as previously described (Breunig et al., 2018a)."
Live-Imaging Microscopy 
Time-lapse video microscopy was performed with a cell observer (Zeiss) at a constant temperature of 
37°C and 8% CO2. Phase-contrast images were acquired every 10 min and fluorescence pictures every 
3 hrs for 6 days using a 10× phase contrast objective (Zeiss) and an AxioCam HRm camera with a 
self-written VBA module remote controlling Zeiss AxioVision 4.7 software. Movies were assembled 
and analyzed using ImageJ (NIH) software.  
Quantification and Statistics  
To analyze reprogramming efficiency with dCas9 experiments, the proportion of GFP+/RFP+/β-III-
tubulin+ cells was assessed at 6 DPT and normalized to the entire population of transduced GFP+/RFP+ 
cells. For time lapse experiment quantification, cells were tracked in every frame of the movie. 
GFP+/RFP+ cells acquiring neuronal morphology, considered as appearance of processes longer than 
3x the cell soma, were quantified out of the total GFP+/RFP+ cells, as previously published (Gascón et 
al., 2016). When virus was used to induce neuronal conversion, astrocytes were fixed at day1, day3, 
day5 and day7 after transduction, corresponding to different stages of neuronal maturation and glial 
dedifferentiation, to verify cell-specific mitochondrial markers appearance and disappearance. 
Statistic analysis of data was performed using the GraphPad Prism 7.0 software. Data in Figure 1C, 
2B, 4C are plotted as median ± IQR; each dot represents one biological replicate. Data in Figure 1B, 
4B, 4D are plotted as mean ± SD as they are normally distribution according to the Shapiro-Wilk test. 
If not rejected, we performed unpaired two-tailed t-test analysis for group comparison. If normal 
distribution was rejected, significance between groups was analyzed using Kruskal Wallis test, 
followed by Mann-Whitney test. Significance is based on the P-value indicated on the figures as * 
p≤0.05, ** p≤0.01, ***p≤0.001. 
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Figure titles and legends 
Figure 1. Cultured astrocytes and neurons from cerebral cortex differ in mitochondrial structure and 
function  
(A) Immunofluorescence microscopy images showing the mitochondrial network morphology in not 
reprogrammed astrocytes (left) versus induced neurons (right), 7 days after transduction with Ascl1-mitoGFP 
(green), respectively co-labeled with GFAP (white) or β-III-tubulin (red).  Cells nuclei are labeled with DAPI 
(blue). Scale bar: 20µm. Inserts and magnification highlight the different mitochondrial structure. Scale bar: 
6µm. 
(B) Longitudinal traces of extracellular flux analysis measured by Seahorse XF analyzer, comparing the Oxygen 
Consumption Rate (left) and the Proton Production Rate (right), of astrocytes (green) versus neurons (red) over 
time, after challenging the cells with different electron transport chains or glycolysis inhibitors (Oligo = 
Oligomycin A; FCCP = Carbonyl cyanide-4-(trifluoromethoxy)phenylhydrazone; Rot = Rotenone; Ant = 
Antimycin A; 2-DG = 2-Deoxy-D-glucose). Values are normalized per 1000 cells. Each time point is shown as 
SD ± mean. (n=3 for each group). 
(C-H) Seahorse XF analyzer results comparing metabolism of astrocytes versus neuronal culture, showing basal 
OCR (C), basal PPR (D), oligomycin-dependent PPR (E), rotenone+antimycin-dependent PPR (F) and 
OCR/PPR ratio (G). Values are normalized per 1000 cells. Data are shown as median ± IQR. Significance 
between median was tested using upaired t-test, *p ≤ 0.05, **p ≤ 0.01, *** p ≤ 0.001. (n=3 for each group). 
(H) Immunoblot detection of several mitochondrial proteins, in different fractions (8000g - nuclear; S.N. - 
cytosolic; 9000g - mitochondria and other organelles), of astrocytes versus neurons. 
(I) Electron microscopy images showing the mitochondrial isolation composition at ultrastructural level. Scale 
bar: 5µm. Magnifications show single mitochondria morphology. Scale bar: 500nm. 
 
Figure 2. Astrocytes and neurons exhibit profound differences in the mitochondria proteome  
(A) Principal components analysis on all identified mitochondrial proteins shows a clear separation between 
neuron (red) and astrocyte (green) samples. 
(B) Volcano plot of the quantified mitochondrial proteins with the log2 ratio of abundances astrocytes/neurons, 
given on the x-axis, and the –log10 of the corresponding significance value, on the y-axis. Fold changes of 2-fold 
are indicated as vertical lines, the significance cut-off of p=0.05 is given as horizontal line. 2-fold significantly 
more abundant proteins in astrocytes are given in green, for neurons in red. Enlarged dots highlight relevant 
proteins. 
(C) Heatmap cluster analysis of significantly and at least 2-fold differentially abundant mitochondrial proteins 
(n=3 for each group). Log2 abundance ratios to the median abundance per protein were calculated across all 
samples, with positive values (higher than the median) given in yellow, and negative values (lower than the 
median) given in blue.  
 (D) GO terms have been elaborated with Genomatix generanker software. Top 35 biological processes are 
shown for neurons (red bars) and astrocytes (green bars). On the x-axis is shown the –log10 of the p-value. 
 
Figure 3. Mitochondrial protein changes during astrocyte-to-neuron reprogramming  
 (A) Immunofluorescence microscopy images showing mitochondrial astrocytic marker (green, Sfxn5) in 
astrocytes (arrowhead) not reprogrammed versus converting neuronal cells (arrow), respectively co-labeled with 
GFAP (white) or β-III-tubulin (white). Cells were transduced with Neurog2-mitoRFP (red) and analyzed at 1, 3, 
5 and 7 days post infection (DPI). Scale bar: 20µm.  
(B) Immunofluorescence microscopy images showing mitochondrial neuronal marker (green, Gls) in astrocytes 
(arrowhead) not reprogrammed versus converting neuronal cells (arrow), respectively co-labeled with GFAP 
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(white) or β-III-tubulin (white). Cells were transduced with Neurog2-mitoRFP (red) and analyzed at 1, 3, 5 and 7 
days post infection (DPI). Scale bar: 20µm 
 
Figure 4. dCas9-mediated induction of neuron-specific mitochondrial proteins potently improves speed and 
efficiency of direct neuronal reprogramming 
(A) Scheme illustrating the dCas9-VPR combined with STAGr technique used to upregulate neuronal 
mitochondrial target in astrocytes. 
(B) RNA PCR of sorted primary astrocytes, transduced with dCAS9-VPR and gRNAs, control or to upregulate 
Sod1 and Prdx2, 48 hours after transduction. Data are shown as SD±mean. 
(C) Reprogramming efficiency calculated as percentage of cells acquiring neuronal marker β-III-tubulin over 
total  RFP+/GFP+ only cells. Analysis was performed 6 days after transduction with Ascl1-RFP, dCas9-VPR and 
inducible GFP construct coding for control gRNAs (Stagr Cntrl) or for gRNAs to upregulate Sod1 and Prdx2 
(Stagr P-S). Data shown as median ± IQR. Significance between median was tested using upaired t-test, ***p ≤ 
0.001. (n=7 for experimental condition). 
(D) Time lapse graphs of cells undergoing reprogramming and acquiring neuronal morphology (y-axis) over 
time (x-axis), co-transduced with Stagr Cntrl (green line) or Stagr P-S (red line). Data are shown as mean ± SD. 
Significance between mean was tested using upaired t-test, *p ≤ 0.05, **p ≤ 0.01. (n=3 for each time point and 
experimental condition). 
(E) Immunofluorescence miscroscopy images showing cells co-transduced with Ascl1-RFP (red), dCas9-VPR 
and gRNAs (green), acquiring neuronal morphology, β-III-tubulin (white), over total population of cells (DAPI). 
Control (left) versus experimental condition upregulating Sod1 and Prdx2 (right) are compared. Arrowheads 
highlight neuronal cells. Scale bar: 200µm. Inserts and magnification highlight the different maturation of 
derived neurons in the two conditions. Scale bar: 20µm. 
 
Supplementary Figure 1. Cultured astrocytes and neurons from cerebral cortex differ in mitochondrial 
structure and function  
 (A) Schematic illustration of mitochondrial isolation procedure based on pump-controlled cell rupture method, 
modified and adapted from (Schmitt et al., 2013). 
(B) Immunoblot detection of contaminants proteins, in different fractions (8000g - nuclear; S.N. - cytosolic; 
9000g - mitochondrial and other organelles) of astrocytes versus neurons.  
(C) Graphs showing the vitality of isolated mitochondria for one hour upon isolation, measuring the membrane 
potential by Rhodamine 123 assay, and the swelling parameter by absorbance at 540nm, of astrocytes (green) 
versus neurons (red).   
(D) GO terms have been elaborated with Genomatix generanker software. Top 35 molecular function are shown 
for neurons (red bars) and astrocytes (green bars). On the x-axis is shown the –log10 of the p-value. 
 
Supplementary Figure 2. Mitochondrial protein exchange during astrocyte-to-neuron reprogramming  
 (A) Immunofluorescence microscopy images showing mitochondrial astrocytic marker (green, Cpox) in 
astrocytes (arrowhead) not reprogrammed versus converting neuronal cells (arrow), respectively co-labeled with 
GFAP (magenta) or β-III-tubulin (white). Cells were transduced with Neurog2-RFP (red) and analyzed at 1, 3, 5 
and 7 days post infection (DPI). Scale bar: 20µm.  
(B) Immunofluorescence microscopy images showing mitochondrial neuronal marker (green, Prdx2) in 
astrocytes (arrowhead) not reprogrammed versus converting neuronal cells (arrow), respectively co-labeled with 
GFAP (violet) or β-III-tubulin (white). Cells were transduced with Neurog2-RFP (red) and analyzed at 1, 3, 5 
and 7 days post infection (DPI). Scale bar: 20µm. 
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Supplementary Figure 3. Mitochondrial protein exchange during astrocyte-to-neuron reprogramming (Ascl1) 
 (A) Immunofluorescence microscopy images showing mitochondrial astrocytic marker (green, Sfxn5) in 
astrocytes (arrowhead) not reprogrammed versus converting neuronal cells (arrow), respectively co-labeled with 
GFAP (white) or β-III-tubulin (white). Cells were transduced with Ascl1-mitoRFP (red) and analyzed at 1, 3, 5 
and 7 days post infection (DPI). Scale bar: 20µm.  
(B) Immunofluorescence microscopy images showing mitochondrial neuronal marker (green, Gls) in astrocytes 
(arrowhead) not reprogrammed versus converting neuronal cells (arrow), respectively co-labeled with GFAP 
(white) or β-III-tubulin (white). Cells were transduced with Ascl1-mitoRFP (red) and analyzed at 1, 3, 5 and 7 
days post infection (DPI). Scale bar: 20µm 
 
Supplementary Figure 4. Time-course expression of mitochondrial marker during direct neuronal 
reprogramming 
(A-F) Time course analysis at 1, 3, 5 and 7 DPI showing percentage of cells retaining mitochondrial markers 
expression tested by immunofluorescence, comparing cells acquiring neuronal morphology (Neurons, red) or 
maintaining astrocytic one (Astrocytes, green). Quantification was performed at each time-point for cells 
transduced with Neurog2-mitoRFP (A, B), Ascl1-mitoRFP (C, D) and Neurog2-RFP (E, F). (10-30 cells 
analyzed for each time-point and condition, from 2/3 biological replicates). 
 
Table 1. List of the 354 mitochondrial proteins, according to MitoCarta 2.0 database, more abundant in 
astrocytes or neurons, selected for a statistical significance of <0.05, and a two-fold enrichment. Specific 
proteins mentioned in the text underlined in yellow. 
 
Supplementary Table 1. Full list of the 4755 proteins identified by LC-MS/MS analysis on isolated 
mitochondria of cortical astrocytes and neurons. 
 
Supplementary Table 2. List of GO term analysis, performed with Genomatix Generanker, of the 
mitochondrial proteins enriched in astrocytes or neurons, divided each for GO terms from biological 
processes and molecular function. 
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Discussion  !
In my Ph.D. projects I could identify key hurdles and novel modulators to direct neuronal 
reprogramming of astrocytes. In particular, following the discovery from Gascon et al., that 
converting neurons face a dramatic burst in ROS, detrimental for the neuronal conversion, I 
could prove that modulating the metabolism of the converting cell further hampers the 
neuronal generation. Indeed, reducing ROS by pushing the metabolism toward a glycolytic 
phenotype could not improve the process, as a proper metabolic shift toward oxphos, 
functionally relying on ATP generation from the ETC, is essential for neuronal generation. 
Furthermore, investigating mitochondria composition of astrocytes and neurons in Russo et 
al., beyond identifying novel proteins and specific pathways of these two cortical cells, could 
demonstrate that, even if at a later stage, a shift in composition from astrocytes to neurons 
occurs. We further showed that mitochondria proteome reprogramming occurs, even if partial, 
as not all the astrocytic proteins are properly regulated in converting neurons. This suggests, 
at least from those markers tested, also a partial functional metabolic reprogramming. 
Furthermore, pushing with cas9 technology the early expression of neuronal mitochondrial 
proteins in converting astrocytes can greatly improve the generation of neurons, suggesting 
that metabolism modulation can be also a direct driving force, rather than a mere 
consequence, to cell fate change. These data require further attention when thinking about 
translating these findings in vivo. Mitochondrial composition in vivo is barely known and still 
many hurdles need to be dismantled to fully characterize the functionality of the in vivo 
generated neurons. Mattugini et al. seems to move the field a further step forward, as long-
term surviving neurons and specific neuronal subtypes are generated. Interestingly, we found 
out that this process might be greatly affected by the delivery vector selected. We could 
indeed observe a different reaction of the environment to the viral vectors used to deliver the 
transcription factors, which can potentially affect the reprogrammed neurons engraftment and 
survival. A broader reactive gliosis and immune cells infiltration were observed with 
lentivirus or retrovirus, compared to AAV. Notably, the latter was associated with higher 
transduction rates and neuronal reprogramming efficiency.  
Thus, combining techniques to reduce the potentially harmful immune reaction and glial 
activation, which increase inflammation, with buffering of ROS, potentially further induced 
by a malfunctioning metabolic shift, could greatly improve direct neuronal reprogramming. 
Another promising strategy, potentially complementary to these approaches, involves 
modulating the metabolic change by directly acting on mitochondria composition. Indeed, 
pushing an earlier mitochondrial composition shift during conversion from astrocytes to 
neurons could greatly improve the neuronal generation.  
The potential implications of these findings for the field of direct neuronal reprogramming, 
and the gaps in knowledge which must still be filled to further boost the improvement of 
converted neurons, are here discussed and analyzed. 
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Impact of viral vectors and inflammation on direct neuronal reprogramming 
The paper from Mattugini et al. shows a degree of integration, maturity and survival hardly 
reached for reprogrammed neurons so far. This is achieved injecting the reprogramming 
factors encoded in AAV flex-switch virus in the grey and white matter of the somatosensory 
cortex 3 days following stab wound injury. The recombination occurs only in reactive 
astrocytes, as the mouse model used is a GFAP-cre line, with cre mediating the expression of 
the AAV selectively in astrocytes. Combined expression of the transcription factor nuclear 
receptor related 1 protein (Nurr1) and Neurog2 is essential for high efficiency reprogramming 
of astrocytes into neurons, which express appropriate lamina-specific hallmarks and long-
distance axonal projections. Furthermore, these newly generated neurons mature with time 
and survive up to the last evaluated time point, 9 months. Interestingly reprogramming is 
successfully restricted to grey matter astrocytes, as white matter astrocytes do not convert, 
further highlighting the importance to target the correct starter cell (Heinrich et al., 2015) and 
to properly evaluate the environment in which the neurons are generated (Gascón et al., 
2017).  
My contribution to the project was evaluating a so far uninvestigated aspect of in vivo direct 
neuronal reprogramming, namely how viral vectors used to carry the transgenes can actually 
influence the environment and the reprogramming outcome. Indeed different vectors, such as 
lentivirus, retrovirus and adeno-associated virus have been widely used for reprogramming 
approaches, each of them with their own advantages and transduction rates (Gascón et al., 
2017; Mancini and Horvath, 2018), as also described in the introduction. In general, our 
paradigm of direct neuronal reprogramming consists of viral vectors injection 3 days 
following unilateral stab-wound injury performed in the somatosensory cortex, reaching the 
grey and white matter. The first evaluation for neuronal generation is usually performed 10 
days after viral injection, namely 13 days after stab wound injury. 
Interestingly, we noticed that independently on the transcription factor expressed, whether is 
Neurog2 or GFP only, a huge difference in glial reactivity is observed. This difference 
depends on the viral vector used. In particular, retrovirus and lentivirus injections elicit, 
already at 3 days post-injection (DPI), a strong reactivity of astrocytes and microglia, 
characterized by GFAP+ and Iba1+ activation respectively (data not shown). Furthermore 
microglia acquire an ameboid reactive morphology, accumulating at the injury site (Li and 
Barres, 2017), while astrocytes up-regulate GFAP reactivity but do not accumulate, in line 
with their behavior following injury (Bardehle et al., 2013). This highly reactive environment 
is also associated to massive leukocytes invasion, characterized by CD45+ reactivity, which is 
further exacerbated at 10 DPI (Mattugini et al.,), time point where first neurons are usually 
observed with retroviral-mediated reprogramming (Gascón et al., 2016). Surprisingly, this 
massive inflammation is much reduced following AAV injection, both at 10 DPI but also at 
later time points, as 24 DPI, when first neurons are actually observed with this viral vector 
(Mattugini et al.,). Furthermore, we also analyzed the immune cell infiltrate 10 DPI following 
injection by magnetic-activated cell sorting (MACS) followed by fluorescent activated cell 
sorting (FACS) analysis. Dissecting leukocytes subpopulations we confirmed massive CD45+ 
infiltration following LV and RV injection, compared to AAV, mostly characterized by 
monocytes/macrophages and activated lymphocytes, in particular T cells (data not shown). 
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Notably sham controls in which SW injury was followed by PBS injection showed almost no 
reactive gliosis and CD45+ infiltration at 10 DPI, in line with TBI recovery observed in the 
absence of viral injections 3 days after injury (Frik et al., 2018; McKee and Lukens, 2016). 
This strongly suggests that despite the generation of viral vectors stripped of most of the 
original viral components, LV and RV in particular can still elicit a very strong inflammatory 
immune response which might explain the reduced reprogramming efficiency compared to 
the one following AAV injections (Mattugini et al.,).  
Interestingly, most studies showed that the outer components of the viral vector, like capsid or 
envelope proteins, necessary to mediate selective recognition and binding to the target cells, 
are the main inducers of an adaptive immune response. RV- and LV-based vectors, for 
example, often express envelope glycoproteins from other viruses, to improve their selective 
targeting, such as from VSV-G, Mukola virus or lymphocytic choriomenengitis virus 
(LCMV). These components, also present in the vectors used for reprogramming (Gascón et 
al., 2016; Heinrich et al., 2014), are able to specifically elicit an adaptive immune response, 
which can not only be involved in the gliosis reaction (Kunitsyna et al., 2016), but also in the 
clearing and killing of transduced cells, drastically reducing the transduction rate 
(Drokhlyansky et al., 2016). The induction of microglia and astrocytes reactivity, 
monocytes/macrophages activation and recruitment of antigen-specific T lymphocytes can all 
be concomitant factors in the relative unsuccessful rate of reprogramming observed with LV 
and RV.  
Advances in generating new viral vectors devoid of antigens able to elicit immune response or 
immunization against those components, inducers of adaptive immunity, are good strategies 
to produce improved vectors with high transduction rate and low immunogenicity, as 
demonstrated in some pivotal studies on virus infectivity in the brain (Drokhlyansky et al., 
2016; Ewer et al., 2016). Despite the higher immunogenicity of RV and LV, is important to 
mention that also AAV-mediated overexpression of different transgenes can induce an 
inflammatory reaction within the brain (Lowenstein et al., 2007). Despite that, usually the 
inflammatory reaction is not linked to cell death, but rather to mild environmental 
inflammation, mostly associated to transgene-mediated recognition as foreign antigen or to 
pre-existing antibodies against the capsid proteins within the host (Chew et al., 2016; 
Mingozzi and High, 2013). A careful understanding of the viral vector and immune 
interactions is thus fundamental for the outcome of reprogramming and most importantly for 
the safety of the treatment. 
In the field of neuronal transplantation most of the studies have been performed in 
immunodeficient or immunocompetent models receiving immunosuppressive drugs 
(Anderson et al., 2011), to allow engraftment of transplanted cells and avoiding cell rejection 
from the host immune system. An underestimation of the host immune system reaction has 
indeed led to death in some clinical trials for gene therapy (Thomas et al., 2003). Nowadays, 
transplantation of neuronal cells in primates and humans is always associated to 
immunosuppressive treatments, to avoid a pathological host response to the viral vector and 
the transgene carried (Curtis et al., 2018; Morizane et al., 2017). Translating these concepts to 
in vivo studies for direct neuronal reprogramming might be the key to further improve the 
process, bringing it closer to clinical translation. Using for example immunodeficient mice or 
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co-treatment with immunosuppressive drugs may support the neuronal integration, avoiding a 
likely detrimental immune response that would recognize and kill the infected cells, further 
increasing inflammation in the already injured brain parenchyma. 
In line with the detrimental role that immune cells might exert on converting neurons, AAV-
mediated reprogramming induces higher efficiency of transduction and neuronal survival 
(Torper et al., 2015; Mattugini et al.,). Furthermore it is associated with lower inflammatory 
reactions of microglia and astrocytes and to reduced immune infiltration, compared to LV or 
RV injections (Mattugini et al.,). It would be important to confirm whether this improved 
reprogramming is linked to the lowered immune response, for example by co-administering 
immunosuppressive drugs with the RV application, or whether it is due to internal viral vector 
properties, such as viral genes still active or different transgenes expressed (e.g. Bcl2 versus 
Nurr1).  
Intrinsic viral vectors properties might also contribute to the higher success of AAV vectors in 
mediating neuronal conversion. Indeed, one of the main differences between LV/RV and 
AAV, beyond the packaging capacity, is associated with their peculiar replication mode. 
While AAVs remain episomal within the nucleus and require longer time to efficiently 
express the transgene, up to 10 days, genome-integrating RV and LV viral vectors express the 
genomic information at higher speed and rates, few days after transduction (Gascón et al., 
2016; Mancini and Horvath, 2018; Mattugini et al.).  
This could have important consequences for the timing in which we want to apply the 
reprogramming recovery strategy. Indeed, early treatments post-injury are usually linked to 
better recovery, limiting the spreading of cell death and reducing the damage. This was 
demonstrated for neural stem cells and neuronal cells transplantation following diverse types 
of injury, in which treatment in an early window following lesion, when inflammation is not 
yet at its peak and secondary cell death not yet occurred (Burda and Sofroniew, 2014), was 
associated to improved recovery (Bacigaluppi et al., 2016; Shear et al., 2011). Delaying the 
transplantation following injury could also help the engraftment of the cells, as the highly 
inflammatory reaction and immune infiltration which hampers new cells survival might be 
reduced, as demonstrated in other studies of stem cell transplantation following brain injuries 
(Karimi-Abdolrezaee et al., 2006; Péron et al., 2017). In the case of direct neuronal 
reprogramming, 3 days post-injury was selected as optimal time for retroviral injections, as 
this was the peak of glial cell proliferation (Simon et al., 2011), with the aim to target mainly 
proliferating cells for conversion. In this case, early and strong expression of the transgenes 
mediated by RV and LV might further challenge cell conversion and survival, as strong 
inflammation is still very active (Frik et al., 2018) and as we showed is further exacerbated by 
viral vectors themselves. The less immunogenic AAV vectors might further offer the 
advantage of inducing delayed expression of the transgene at a slower rate, coinciding with a 
less inflammatory environment, and being less demanding in term of energy requirements for 
the cell itself. 
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Figure 5. Effects of the in vivo environment on the process of neuronal generation and on the 
potential integration of converted neurons (Gascón et al., 2017). 
All these pieces of information also raise the attention on the actual lesion in which direct 
neuronal reprogramming is tested, which is mostly traumatic brain injury (Gascón et al., 
2017). Indeed, the discovery that the viral vectors so far used elicited a strong inflammation 
and immune cell recruitment challenges what we knew regarding the post stab-wound injury 
environment (Frik et al., 2018; Mattugini et al., 2018). In light of this high inflammatory 
activation, with adaptive immune cells further orchestrating the reaction, the pathological 
model is more coherent to one where specific viruses or pathogens infect the brain 
parenchyma (Russo and McGavern, 2015). This can have great impact on the challenges that 
our reprogrammed neurons must cope with for proper integration and survival, as the cells 
need to engraft in a much more reactive environment than the one initially considered 
following stab wound injury. 
Thus, my contribution to Mattugini et al. was to evidence an underestimated role of the 
inflammation elicited by the viral vectors used. New studies evaluating the functional effects 
of immune cells and reactive gliosis to the reprogramming process, generation of improved 
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and less immunogenic delivery vectors, as well as a comprehensive understanding of the 
impact that different pathological environments could play on the neuronal conversion, might 
all represent fundamental steps for clinical translation of direct neuronal reprogramming. 
Role of ROS and metabolism in hampering direct neuronal reprogramming 
One of the major hallmarks of inflammation is reactive oxygen species production. ROS are 
thus early mediator of damage following an injury, mostly secreted in the CNS by dying 
neurons or reactive microglia and infiltrating macrophages (Burda and Sofroniew, 2014; 
London et al., 2013). ROS also represent one of the major hurdles identified so far to 
successful direct neuronal reprogramming, in vitro as well as in vivo (Gascón et al., 2016). 
Gascon et al., identified a critical time point during fate conversion into neurons, around 3 
days after transduction or transfection, where most of the cells succumb to cell death. 
Interestingly, attempts to prevent induced neuronal death with different inhibitors identified 
ferroptosis and ROS accumulation as leading cause for the phenomenon. Indeed genetic 
manipulation, through co-expression with the neuronal transcriptions factors of pro-survival 
gene Bcl2, and chemical co-treatment with ROS scavengers or ferroptosis inhibitors 
drastically improve the neuronal generation. This drastic amelioration could also be translated 
in vivo, through co-injection of Neurog2 and Bcl2 and co-treatment with ROS scavengers, 
increasing neuronal generation from 10% up to 90% at 10 DPI. Furthermore, these neurons 
could survive up to 1 month, maturing and differentiating also in upper layer subtype.  
 
Figure 6. High oxidation levels hamper direct neuronal reprogramming (Quadrato et al., 2016. 
License Number: 4565520722239). 
  
As ROS are byproducts of the respiratory chain activity characterizing oxphos metabolism, 
typical of neurons, while astrocytes in basal condition are mostly glycolytic, we wondered 
whether an active change in metabolism from astrocytes to neurons may affect or be 
associated to direct neuronal reprogramming.  
We observed that astrocytes cultured in medium with oligomycin A, so-called glycolysis-only 
medium, blocking the generation of ATP from the ETC and allowing energy production only 
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through alternative pathways, preserved astrocytes features and almost totally interfered with 
their neuronal conversion, despite expression of the neuronal transcription factor. 
Furthermore, oligomycin treatment in astrocytes was not affecting cell survival. Interestingly, 
we recently observed an early decrease in expression levels of neuronal genes, while glial 
factors failed to be repressed, in converting astrocytes treated with oligomycin, compared to 
control cells in normal differentiation medium (data not shown). Notably, cells grown in 
glycolysis-only medium showed reduced ROS production, which we demonstrated was 
beneficial to improve reprogramming, but could not still convert. Conversely, pushing the 
metabolism toward a higher oxphos state providing only pyruvate and 2-deoxy-glucose, a 
competitive inhibitor for glucose, drove the converting astrocytes to even higher ROS 
production and total cell death. This suggests that ROS burst is just a maladaptive response of 
the converting cell to switch metabolism toward a higher oxphos state, which is somehow not 
functional and poses the cells to enormous stress. Notwithstanding, we demonstrated that the 
metabolic switch and reliance on an active ETC are necessary prerequisites for astrocyte 
conversion to neurons.  
It has been widely studied that a proper metabolic change is necessary and sufficient for cell 
fate decision in spontaneous neurogenesis and IPSCs generation, but barely investigated in 
the field of direct neuronal reprogramming.  
Indeed, understanding what happens from a metabolic point of view to astrocytes 
transitioning fate faces several technical challenges. A major limitation to reveal fine 
molecular changes at cellular level is associated to the fact that we convert with retroviruses 
only a limited numbers of astrocytes, out of the total transduced cells, producing a 
heterogeneous population of not converted astrocytes, neurons and intermediate transitioning 
cells (Gascón et al., 2016; Masserdotti et al., 2015). Furthermore, the majority of 
untransduced astrocytes still present in the culture impede the functional analysis of induced 
neurons metabolism, likely camouflaging metabolic differences between the two cell types. 
Indeed, as discussed in Russo et al., these two cell types possess a different metabolism, but 
astrocytes possess a broader and more plastic metabolism, allowing them to rely both on 
oxphos and glycolysis. Furthermore, the different response of the converting cells and 
different outcome in neuronal subtype generated could further complicate a precise 
understanding of metabolic changes, especially in vitro. Thus, improvement in the 
reprogramming techniques and the quality of neurons generated could help unraveling new 
metabolic mechanisms. Notably, translating the findings regarding metabolic changes for 
IPSCs generation and neural stem cells differentiation might provide new knowledge for the 
field of reprogramming. 
For example, in IPSCs reprogramming from fibroblasts, changes to a more glycolytic 
metabolism have been shown to occur (Panopoulos et al., 2011; Prigione et al., 2014) and also 
to be a driving force for the switch to happen, as pushing glycolytic metabolism by lowering 
O2 or up-regulating key metabolic enzymes improves IPSCs generation (Folmes et al., 2011; 
Yoshida et al., 2009). Furthermore, acting directly on oxphos function with specific ETC 
inhibitors increases the glycolytic reliance of fibroblast, improving their conversion into 
IPSCs; while glycolysis inhibitors have the contrary effect (Son et al., 2013).  
! 137 
Notably, fibroblast conversion is associated to a transitory burst of ROS, which in this case is 
actually essential to drive the IPSCs formation, even if the final metabolism is still glycolytic, 
as its blockage hampers conversion (Kida et al., 2015). This burst of ROS needs to be 
controlled and be contained within a specific threshold, as its overactivation, exactly like for 
direct neuronal reprogramming, is detrimental for the process (Zhou et al., 2016). This could 
lead to the speculation that increased ROS activity, in IPSCs generation at least, may also be 
associated to functions that go beyond pure metabolism, as ROS are also important signaling 
mediators (Rafalski and Brunet, 2011). A better understanding of ROS function in the context 
of direct neuronal reprogramming might clarify unknown aspects of the process, as their tight 
association to metabolic pathways and to transcriptional regulation render them key 
determinants for cell fate change (Teslaa and Teitell, 2015).  
 
 
Figure 7. Metabolic changes during cell reprogramming to generate neurons (Gascón et al., 2017). 
The role of ROS has also been investigated in neurogenesis, showing complicated and 
sometimes contrary mechanisms in response to their fine modulation, time of action, cellular 
specific context and dosage in which they act (Prozorovski et al., 2015). While the role of 
ROS in promoting neurogenesis is thus still a bit vague, that NSCs face a metabolic switch 
during differentiation is a consolidate knowledge. 
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Indeed, it has been shown that NSCs experience transcriptional changes from more glycolytic 
and lipid-based metabolism toward a more oxidative profile when differentiation in neurons 
occurs (Llorens-bobadilla et al., 2015; Shin et al., 2015), which is also physiologically 
coupled to an increased ROS production (Khacho et al., 2016). Interestingly, disruption of 
key proteins essential for proper mitochondrial function, as Drp1, involved in mediating 
fission of mitochondria (Steib et al., 2014), or TFAM, involved in mitochondria biogenesis 
(Beckervordersandforth et al., 2017), dramatically impairs neuronal generation, further 
confirming the necessity for neurons to have functional mitochondria to work. This was also 
demonstrated by several studies in which components of the oxphos machinery were ablated 
in different CNS cell types, proving broader metabolic adaptation for glial cells with major 
neuronal death if aerobic respiration is impaired (Diaz et al., 2012; Fünfschilling et al., 2012; 
Supplie et al., 2017).  
Direct neuronal reprogramming has interesting correlates to endogenous neurogenesis. 
Despite that, reprogramming faces hurdles that neurogenesis does not, linked to epigenetic, 
genetic, metabolic and environmental barriers (Gascón et al., 2017). 
Indeed it is fascinating that the physiological metabolic switch occurring in neurogenesis does 
not generally lead to cell death by ROS increase, as for reprogrammed neurons. This might be 
explained by different factors. First of all, we are not aware whether the ROS increase 
observed in direct conversion has a signaling function, as it is observed for NSCs 
differentiation (Le Belle et al., 2011), or is merely a side-effect of an occurring shift from 
glycolytic to oxidative metabolism. Indeed the strong transcriptional changes and protein 
synthesis induced by the transcription factors may dramatically alter the metabolism of the 
cell, causing ROS alteration (Lu and Thompson, 2012; Spinelli and Haigis, 2018).  
Another likely possibility is that the endogenous neurons may better cope with the metabolic 
switch than induced ones because they already possess the metabolic machinery required for 
oxidative phosphorylation. It is known that NSCs already express the ETC components 
necessary for the neuronal metabolism, post-transcriptionally regulated with selective 
expression of inhibitors like ATP5IF1, which mimic oligomycin function. During NSCs 
differentiation these molecules are down-regulated, the ETC is activated and ROS increase at 
controlled levels to mediate transcriptional changes essential for neuronal generation (Khacho 
et al., 2016). Notwithstanding, big differences exist in mitochondria composition between 
different cell types, even if the ETC components are amongst the most preserved ones (Calvo 
and Mootha, 2010). However, also subtle differences in ETC subunit assembly, beyond their 
relative abundance, differentiate astrocytes and neurons in terms for example of ROS 
production (Lopez-Fabuel et al., 2016). We could also show that modulating mitochondrial 
proteome composition, underlying a functional metabolism (Johnson et al., 2007b), can be a 
driven force to improve the reprogramming process (Russo et al.,).  
The specific anti-oxidant system that each cell has could also contribute to a different 
outcome in neuronal generation from astrocytes or NSCs. We discussed in the introduction 
how neurons rely functionally on astrocytes both for substrates and anti-oxidant defense 
(Fernandez-Fernandez et al., 2012; Wang and Michaelis, 2010) and these cells indeed differ 
in term of specific anti-oxidant systems (Russo et al.,). While the anti-oxidant molecules 
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typical for neurons are only late-induced during the conversion process of astrocytes, as for 
Prdx2 (Russo et al.,), involved in important neuroprotective functions (Boulos et al., 2007), 
neural stem cells might possess this machinery already from the beginning. Indeed the 
ordered and time-controlled process of physiological neurogenesis may be linked to better 
regulation of the machinery to cope and regulate oxidative stress.  
Last but not least, a huge difference between neurogenesis and reprogramming is linked to the 
environment in which the cells integrate. While the neurogenic niches offer the perfect milieu 
of factors, cells and ECM to help newly generated neurons to integrate and survive (Doetsch, 
2003; Falk and Götz, 2017), the process of reprogramming occurs in highly reactive tissue, 
filled with ROS and pro-inflammatory cytokines, which might be very hostile for the 
converted neurons to graft (Abdul-Muneer et al., 2015; Glass et al., 2010; Mattugini et al.,). 
Intriguingly reactive astrocytes, which acquire hallmarks of NSCs in the cortex following an 
injury (Sirko et al., 2013) and share some aspects of their transcriptome (Götz et al., 2015), 
require a functional ETC machinery to perform their function, as TFAM ablation prevents 
their activation (Fiebig et al., 2019). Metabolic plasticity is thus essential not only for cell fate 
decision, as we demonstrated that preventing oxphos blocks direct neuronal reprogramming, 
but also to allow different function according to the cellular context, as it happens for immune 
cells activation (Ganeshan and Chawla, 2014).  
As metabolic plasticity is mostly linked to mitochondria performance, a better understanding 
of the role that this organelle plays in the process of direct neuronal reprogramming is 
important. This is why I examined this previously uninvestigated aspect in the last part of my 
thesis. 
Mitochondria reprogramming boosts astrocytes-to-glia conversion 
If ROS generation is a major hurdle to direct conversion of somatic cells into neurons, the 
role of mitochondria per se is rather underrated in the process. Since mitochondria are the 
main inducer of ROS and central hub for most of the metabolic pathways, regulating 
macromolecules synthesis and affecting transcriptional regulation, a careful estimation of 
their role in the reprogramming process is essential. 
In Russo et al., we first observed that a change in mitochondria morphology occurs from 
astrocytes to converted neurons, underlying changes in dynamic and function. To this aim, we 
decided to first evaluate if the metabolism of cortical astrocytes and e14-derived cortical 
neurons, as model for induced neurons, also in vitro was different, as suggested in literature. 
Indeed, we could observe profound functional differences with seahorse analysis between the 
two cell types analyzed, where astrocytes have a broader metabolic potential, relying both on 
oxphos and glycolysis, while neurons being able only to rely on oxphos for energy 
production. Digging more into the molecular characterization of these mitochondria, we 
decided to isolate functional organelles from both cell types, with good degree of purity, 
highlighting also at ultrastructural level through EM morphological differences, indicative of 
different metabolic profiles. We decided to perform proteomic analysis of independent 
biological replicates, identifying hundreds of differentially regulated proteins between 
neurons and astrocytes, leading to unique gene ontology terms. In particular, astrocytes GO 
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terms confirmed their higher metabolic plasticity, compared to neurons, and underlined that 
fatty acid oxidation is a peculiar pathway to this cortical glial cell. Interestingly, both cells 
showed higher representation of molecules involved in oxidative stress defense, even if their 
enzymatic machinery was not overlapping. Thus, we decided to evaluate astrocytic or 
neuronal mitochondrial protein expression during a time-course of astrocytes undergoing 
neuronal conversion. We demonstrated that neuron-specific mitochondrial proteins indeed 
appear in reprogrammed neurons, but are induced late during the process, around 5-7 days 
post-transduction. Surprisingly, the astrocyte-specific mitochondrial proteins are only 
partially down-regulated at this stage, demonstrating that a shift in mitochondria protein 
composition occurs, but only late and partial during the reprogramming process. This 
mitochondrial shift is also functional, as key enzymes involved in specific neuronal metabolic 
pathways, as glutaminase, appear also in reprogrammed neurons. As we also know that 
oxidative stress is an important hurdle to reprogramming, we decided to overexpress specific 
neuronal mitochondrial proteins involved in defense against ROS, early during the conversion 
of neurons. Indeed, the neuronal protein Prdx2 is up-regulated in reprogrammed neurons, but 
only at late stages of conversion. We took advantage of the recently developed dCas9 
technology, where enzymatically dead dCas9 is fused with transcriptional activators, 
combined with gRNAs, targeting Sod1 and Prdx2 promoter region, to overexpress multiple 
endogenous genes. When combined with the proneural factor Ascl1, a seven-fold boost in the 
conversion of astrocytes into neurons was observed, further corroborated by time-lapse 
imaging analysis revealing increased survival and faster conversion. We thus reprogram for 
the first time mitochondria in a cell type-specific manner, proving a powerful effect on 
astrocyte-to-neuron conversion, suggesting mitochondria change to be a driving force for the 
process.  
Astrocytes and neuronal metabolic functions have been widely investigated for decades, but a 
unanimous definition of their in vivo interplay has not yet been reached. As recently 
highlighted, understanding the cell-type specific function of mitochondria, involved beyond 
metabolic regulation also in mediating epigenetic, transcriptional and signaling events (Janke 
et al., 2015; Spinelli and Haigis, 2018), might greatly help understanding the functional effect 
on cell behavior. Despite the notion that specific mitochondrial function of astrocytes and 
neurons massively affect the physiology and pathology of the CNS (Fernandez-Fernandez et 
al., 2012; Willems et al., 2015), very few papers systematically evaluated the effect of the 
mitochondrial composition in the brain and its consequences on cell-specific function 
(Graham et al., 2017; Lopez-Fabuel et al., 2016); no one did in the field of direct neuronal 
reprogramming.    
Intriguingly several papers unraveled a high degree of differences in mitochondria 
composition, with only between 50% and 70% of the mitochondrial proteins shared at similar 
levels between different organs (Mootha et al., 2003; Pagliarini et al., 2008). Obviously, 
similarly expressed mitochondrial proteins between organs and cells exist, like the proteins 
involved in the ETC machinery (Calvo and Mootha, 2010). Surprisingly, the mitochondrial 
proteome of the brain, the organ that consumes the biggest amount of energy and substrates 
within the body, has been rarely investigated, and mostly as whole tissue (Ingram and 
Chakrabarti, 2016). As we know that mitochondrial proteome composition can greatly affect 
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the organelle function as well as its response to physiological and pathological stimuli, it is 
important to clarify this also in the process of direct neuronal reprogramming. 
Most studies evaluate broader changes in mitochondrial proteome from the whole tissue in 
pathological versus healthy conditions (Chou et al., 2011; Nilsen et al., 2007), clearly missing 
out substantial differences within different cell types which might contribute to the 
pathogenesis. Excitingly, recent studies on neurons investigated even sub-cellular differences 
in term of mitochondria composition, between synaptic and non-synaptic localization, 
showing dozens of proteins differentially expressed, underlying up to 30% difference in 
enzymatic activity (Graham et al., 2017; Völgyi et al., 2015). This clearly reveals how few we 
know of cell-type specific function of mitochondria. Our study evaluates and compares for the 
first time mitochondria proteome of cultured cortical neurons and astrocytes revealing 
profound differences with several cell-type specific pathways. 
Some of the top GO terms of mitochondria from astrocytes are lipid metabolism and fatty 
acid β-oxidation, consistent with the expression of key enzymes regulating these pathways at 
transcriptomic level in adult cortical astrocytes (van Deijk et al., 2017; Hofmann et al., 2017). 
It is not fully understood why these pathways are specifically prominent in astrocytes, given 
that fatty acid oxidation requires higher oxygen levels compared to glycolysis (Schönfeld and 
Reiser, 2013), even if it produces more ATP at similar ROS rates (Darvey, 1998; Souza et al., 
2019); but its importance in the brain is undeniable. Indeed 20% of the brain energy supply 
derives from fatty acid β-oxidation (Panov et al., 2014) and our in vitro data suggest that this 
pathway contributes to 30% of the total oxygen consumption within astrocytes, as shown by 
selectively blocking it with β-etomoxir (data not shown). Astrocyte dependence on this 
pathway might also vary according to the cellular context, as in a pathological environment 
with lack of glucose striatal astrocytes switch metabolism and start relying on fatty acid 
metabolism for energy production (Polyzos et al., 2019). 
Interestingly, the role of fatty acid metabolism goes beyond regulating energy metabolism, as 
it has functional signaling effects, for example, in mediating diverse stem cell proliferative 
and quiescent state, as for NSCs and hematopoietic stem cells (Ito et al., 2012; Knobloch et 
al., 2012, 2017). It would be interesting to evaluate whether key enzymes that regulate fatty 
acid metabolism in mitochondrial astrocytes, such as Cpt1a or Acads, are actually down-
regulated in converting neurons and which consequence their early down-regulation would 
have for neuronal conversion. 
Other pathways more represented in astrocytes over neurons are linked to cellular respiration, 
mitochondria organization and respiratory electron transport chain. This is in line with the fact 
that seahorse analysis results show a broader metabolic plasticity of astrocytes compared to 
neurons. Indeed a stronger reliance on oxphos in basal condition is present, but a 
compensatory mechanism with glycolysis for energy production is possible when oxphos is 
inhibited, on the contrary to neurons that lack this possibility. This is in line with evidence 
supporting higher reliance on oxphos for neurons (Bélanger et al., 2011; Kasischke et al., 
2004), as also demonstrated by our OCR/ECAR ratio values, where neurons rely on double 
amount to oxphos compared to astrocytes already in basal condition. These data also 
underline that astrocytes in our culture have a stronger reliance on oxphos and fatty acid 
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oxidation for energy production, compared to in vivo where they seem mostly glycolytic in 
basal condition (Bélanger et al., 2011). Interestingly, region-specific heterogeneity of 
astrocytes has also been observed in term of reliance on metabolic substrates. Indeed, in a 
model of Huntington disease, astrocytes respond to neuronal vulnerability and overall reduced 
glucose level relying on different substrates for energy production, as fatty acids in the 
striatum or through amino acids metabolism in the cerebellum (Polyzos et al., 2019). This 
further supports the concept that astrocytes are more plastic in term of metabolic support than 
neurons and can use diverse metabolic substrates in challenging conditions. 
Seahorse results reveal that both our cell types use their metabolism at their maximal rate, 
mostly linked to the in vitro condition and that neurons seem to have a lower metabolic 
activity compared to astrocytes. Even if this lower energy rate in neurons might not be 
intuitive, quantitative differences in term of ETC components within mitochondria amongst 
astrocytes and neurons might justify this relative difference. Another reason to justify this fact 
is the observation that our neuronal cultures are very pure, but may lack the fundamental glial 
components essential for neurons to receive the proper trophic and anti-oxidant support 
(Bélanger et al., 2011; Schreiner et al., 2015; Weber and Barros, 2015). This might thus limit 
the functionality of in vitro neurons, as well as their maturity. Indeed, even if our culture is 
differentiated until proper electrophysiological properties and mature markers arise, neurons 
could retain some properties of the stem cells from which they derive, as those are more 
immature in term of metabolic profile compared to adult post-mitotic neurons (Khacho et al., 
2016; Llorens-bobadilla et al., 2015). 
A more comprehensive study should anyway require more sophisticated isolation techniques 
of mitochondria, to further eliminate contaminants that are present in our isolation. This could 
improve a more defined discrimination of protein abundance. Indeed, even subtle differences 
in protein composition between astrocytes and neurons, like in the case of NDUFS1 subunit 
of Complex I, can lead to the formation of supercomplexes which generate diverse amount of 
ROS, contributing to specific cellular bioenergetic differences (Lopez-Fabuel et al., 2016). To 
discriminate and unravel novel protein function within mitochondria, cas9 technology can 
provide an easy solution and readout method in different cellular system (Arroyo et al., 2016; 
Jo et al., 2015), even for in vivo application (Zhou et al., 2018). Future studies should also 
take into account consistent processing and common databases for analysis (Calvo et al., 
2016), to ease the identification of cell-specific metabolic pathways. Cell types selected for 
comparison, mitochondria from in vitro or in vivo cells, isolation techniques, statistical 
stringency and databases selected to define mitochondria proteins, should all be parameters to 
take into consideration when comparing results amongst different studies.  
A further interesting correlate supporting our extrapolation of findings from neuronal culture 
to reprogrammed neurons comes from the observation of the mitochondrial morphology. 
Indeed, induced neurons, compared to the original astrocytes, display mitochondria with a 
smaller and roundish shape, less ramified, supporting their duty to provide energy in the long 
neuronal processes (Misgeld and Schwarz, 2017). In line with this, differential expression of 
mitochondrial proteins involved in regulating dynamic is observed, with a higher level of the 
fission regulator Drp1 in neurons and a higher level of the fusion regulator mitofusin1 in 
astrocytes. This would support the idea that astrocytes and neurons need different 
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mitochondrial network organization to support their own specific metabolic requirements, as 
also observed in vivo (Motori et al., 2013; Plucinska et al., 2012). Electron microscopy further 
sustains the idea of different mitochondrial dynamics between neurons and astrocytes, as the 
first appear smaller and roundish, while the second more ramified and elongated. Despite that, 
mitochondria ultrastructure in term of cristae organization and membrane invagination is 
comparably complex, supportive of mature organelles, as stem cells on the contrary have less 
complex and more immature mitochondria structural organization (Prigione et al., 2011). 
This also implies that, beyond reorganizing mitochondrial proteome composition during 
direct neuronal conversion, the starter cell requires also the modification of its supramolecular 
structure for the functional change to occur. Thus, manipulating mitochondrial dynamic might 
greatly impact on neuronal generation. Indeed, impairment of its key molecular regulators has 
been shown to affect neurogenesis also in vivo (Ishihara et al., 2009; Oettinghaus et al., 2016; 
Steib et al., 2014). Proper mitochondrial dynamic changes can be further important for 
functional roles, properly distributing energy and molecules in all the compartments of the 
converting astrocyte into neuron, undergoing fast and drastic morphological reorganization. In 
IPSCs generation, for example, a transitory fission wave is essential for proper cell fate 
change (Martin et al., 2012; Prieto et al., 2016). Mitochondrial dynamic is also essential for 
proper cell function, as astrocytic mitochondria position next to the neuronal terminal when 
the energy demand is increased following activity or damage (Hayakawa et al., 2016; Jackson 
et al., 2014). Excitingly, some papers highlight also the possibility to modulate mitochondrial 
dynamic by the ability of mitochondria to be transferred between neighbor cells through 
nanotunnels (Wang and Gerdes, 2015). In vivo mitochondria transfer seems to occur and have 
a functional role in improving stroke recovery, as healthy mitochondria can be transferred 
from astrocytes to surrounding suffering neurons supporting their survival (Hayakawa et al., 
2016). It could also be interesting to evaluate the role of autophagy, and consequently 
mitophagy, in supporting this process, as its modulation has been demonstrated to be essential 
for IPSCs generation (Ma et al., 2015; Wang et al., 2013) and in neuronal differentiation 
(Calvo-Garrido et al., 2019). In this study the autophagic adaptor p62 was demonstrated to be 
essential to forward neuro-epithelial stem cells in neurons differentiation, by allowing a 
metabolic switch from glycolysis to oxphos.  
Thus, faster recycle of old mitochondria with a different metabolism and proteome 
composition, through increased dynamic and autophagic processes, could speed up the 
generation of mitochondria ready to support the new cell type generated. This can be 
particularly relevant for neurons, given the critical function that mitochondria play within this 
cell type to regulate multiple processes (Plucińska and Misgeld, 2016). Despite the fact that 
some of these results are difficult to reproduce, it suggests the exciting idea of modifying cell 
fate by direct modulation of mitochondria, as we also demonstrated to be functionally relevant 
for neuronal generation by overexpressing the neuronal mitochondrial proteins Prdx2 and 
Sod1.  
Interestingly, mitochondria protein composition changes spontaneously during the transition 
from astrocytes to neurons, as we demonstrated by analyzing some markers by 
immunostaining over the process. Notably, this regulation of mitochondrial proteins is only 
partial and incomplete, as neuronal-enriched mitochondrial proteins up-regulate relatively late 
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during the conversion process, while astrocytes-enriched ones get only partially down-
regulated, even at mature stages of conversion. This heterogeneous response in the switch in 
mitochondria composition may further influence the inefficient conversion process, inducing 
increased ROS production and cell death by ferroptosis (Gascón et al., 2016).  
Despite that, the neuronal mitochondria proteins analyzed increased in expression when 
neuronal morphological features appeared, suggesting a functional metabolic switch to occur. 
This is the case for glutaminase, which catalyzes the hydrolysis of glutamine to glutamate and 
ammonia and is involved in generating neurotransmitters in neurons (Albrecht et al., 2010). 
This marker indeed appears already at 3 DPI, and by 7 DPI is represented in almost all of the 
analyzed neurons, independently from the neurogenic factors used for conversion, Neurog2 or 
Ascl1, suggesting a common mitochondria reorganization for glutamatergic or gabaergic 
neuronal cells.  
On the contrary, the astrocytes-enriched mitochondria marker Sfxn5, a transporter for citrate, 
while correctly being retained in most of the non-converting astrocytes, is down-regulated in 
only 30% of the reprogrammed neurons. As we noticed that a switch in mitochondria marker 
composition increased with differentiation process, a further down-regulation of Sfxn5 at later 
stages of neuronal differentiation cannot be excluded, as we stopped our analysis at 7 DPI, 
time where usually mature neuronal features have been described (Heinrich et al., 2010; 
Masserdotti et al., 2015). Citrate is also an essential substrate to perform TCA cycle and 
oxphos, fundamental pathways within neurons. This suggests that a complete down-regulation 
of the transporter may not be an advantage for converting neurons, but the difference 
observed by proteomic analysis between neurons and astrocytes for this protein might be only 
quantitative, rather than functional. 
Compared to the early induction of neuronal genes at transcriptomic levels, within 4 hours 
after activation of the neuronal program (Masserdotti et al., 2015), mitochondria remodeling 
seems to be far delayed, suggesting a more complicated proteomic regulation of these 
fundamental metabolic proteins. Important to note is that astrocytes undergoing conversion 
seem to face an intermediate confused stage in which not only astrocytic and neuronal 
markers overlap, as GFAP and β-III-tubulin, but also mitochondrial proteomic composition is 
changed at different pace, underlying metabolic pathways to be differentially replaced over 
time. The inefficiency in this process might further complicate the cell transition and increase 
ROS production. This prompted us to question whether modifying mitochondrial proteome 
composition earlier during the conversion could actually improve the process. 
Interestingly, also Prdx2, an anti-oxidant protein enriched in neurons, involved in neuronal 
protection from oxidative stress and early expressed following injury (Boulos et al., 2007), is 
selectively increased in converting neurons only at late stages, while being absent from 
mitochondria of astrocytes. As this time-point is way beyond the peak in oxidative stress that 
induces death in converting astrocytes (Gascón et al., 2016), we asked what would happen if 
we overexpress this protein before the ROS wave occurs, together with the proneural 
transcription factor. Furthermore, resistance to oxidative stress was one of the common GO 
terms among astrocytes and neurons mito-proteome, consequent to specific expression of 
diverse anti-oxidant molecules. In particular beyond Prdx2, Sod1, a known scavenger of 
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superoxide radicals that when mutated lead to severe neurodegeneration (Bunton-Stasyshyn et 
al., 2015), was also found enriched in the mito-proteome of neurons. 
To achieve expression of these proteins, we exploited the recently developed STAgR (String 
assembly gRNA cloning) and dCas9 technology (Breunig et al., 2018b), allowing 
synchronous overexpression of multiple endogenous targets. Up-regulating Sod1 and Prdx2 
early in the reprogramming process, together with Ascl1, could greatly improve the 
generation of neurons, up to seven fold. Time-lapse experiments further revealed that these 
molecules had a dual mode of action, acting both on cell survival and neuronal maturation. In 
particular, the neuronal morphological features started to appear at the same time compared to 
control, but at a faster speed when the anti-oxidant molecules were expressed early. Control 
cells instead reached a plateau in differentiation within a few hours and were prone to death. 
It is important to mention that the very inefficient generation of neurons obtained in control 
cells, compared to other approaches previously published with retrovirus or lentivirus 
(Masserdotti et al., 2015; Rivetti di Val Cervo et al., 2017), is probably due to the triple 
transfection itself, usually associated to lower efficiency and higher mortality rate than other 
techniques.  
Cas9 technology offers great advantages for direct neuronal reprogramming, as recently 
demonstrated by in vivo (Zhou et al., 2018) and in vitro (Black et al., 2016; Rubio et al., 2016) 
studies. It will be important to understand whether the powerful increase in reprogramming 
speed and efficiency achieved here, by activating only two neuron-specific mitochondrial 
genes, is specific or also true for other neuronal mitochondria genes. Genome-wide screening 
of mitochondrial proteins via CRISPR technology, as demonstrated for the OxPhos genes 
(Arroyo et al., 2016) or for epigenetic regulators in the brain in vivo (Swiech et al., 2015), 
could help answering this question and determining the mitochondrial proteins that are more 
relevant for the reprogramming process.  
We just started to scratch the surface on understanding how manipulating the metabolism 
could affect cell fate decision and specifically neuronal generation from astrocytes. Greater 
knowledge in the function of mitochondria-related proteins in different cellular context, not 
only from a metabolic point of view, but also as signaling molecules and epigenetic 
regulators, could greatly benefit the field of neuronal reprogramming. Furthermore, it could 
also widen our knowledge on the physiological and pathological function of astrocytes and 
neurons within the in vivo environment. 
Unraveling metabolic, mitochondria and environmental hurdles to the process could thus 
finally move the field of direct neuronal reprogramming from bench to clinic, being some of 
the greater challenges, but as well as opportunities, for the generation of functional neurons 
that properly integrated and survive in the brain tissue, supporting the recovery of the patient. 
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